Siglec ligands, conjugates, and methods of use thereof
Siglec ligand conjugates address the challenge of ADA formation by enhancing drug exposure and efficacy through linker-mediated immunosuppression, improving the pharmacological profile of therapeutic proteins and gene therapies.
Patent Information
- Application Number
- PCT/US2026/028266
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Patient immune responses to therapeutic proteins and gene therapies often result in the formation of neutralizing and non-neutralizing drug-specific antibodies (ADA), leading to inhibited drug activity, accelerated clearance, compromised safety, and reduced efficacy.
Development of Siglec ligands with linkers that are covalently bonded to biologically active substances, forming conjugates that suppress immunogenicity and improve the technical qualities of the corresponding biotherapeutics.
The Siglec ligand conjugates effectively reduce the formation of ADA, enhancing drug exposure, durability of efficacy, and reducing associated toxicities, thereby improving the pharmacological profile of otherwise undruggable modalities.
Smart Images

Figure US2026028266_19112026_PF_FP_ABST
Abstract
Description
Attorney Reference: ADTH-010WOSIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOFCROSS-REFERENCE TO RELATED APPPLICATIONS
[0001] This application claims priority to U. S. Provisional Application 63 / 807,002, filed May 16, 2025, which is incorporated herein by reference.INTRODUCTION
[0002] Therapeutic proteins and gene therapies are novel and successful drug modalities for the treatment of disease. However, patient immune responses to such therapeutics often result in inhibition of drug activity, accelerated drug clearance, compromised drug safety, and loss of drug efficacy. Prevention of the formation of neutralizing and non-neutralizing drugspecific antibodies ("anti-drug antibodies" or " ADA") is a key unsolved problem in the field of biotherapeutics. Blocking ADA responses to biotherapeutics would improve drug exposure, improve durability of efficacy, reduce ADA-related toxicities, and enable favorable pharmacology for otherwise undruggable modalities (e.g., de novo designed drugs, drugs based on endogenous proteins). Biotherapeutic conjugates with linkers that incorporate optimized Siglec ligand structures could suppress immunogenicity.SUMMARY
[0003] The present disclosure provides Siglec ligands (SigLs) with linkers. Also provided are conjugates (SigL Conjugates) that include a biologically active substance that is covalently bonded to the linker of the Siglec ligand. The linkers can have advantageous properties that improve the technical qualities of the corresponding SigL Conjugates. Also provided are methods of using the conjugates to treat patients for diseases and disorders.BRIEF DESCRIPTION OF THE DRAWINGS
[0004] FIG. 1A depicts the in vitro B cell activation assays where mouse primary B cells were treated with either a B cell receptor-agonizing anti-lgD antibody or B cell receptor-agonizing anti-IgD-Siglec Ligand conjugates. The B cell stimulatory activities were compared in dose titration experiments with an activation readout of CD69 upregulation. CD69 levels on different treatment groups were evaluated through the percentage of cells that were CD69-positive and plotted as the percentage of control (Isotype control antibody with no activity). FIG. IB showsAttorney Reference: ADTH-010WO the competitive cell binding of anti-IgD-Siglec Ligand conjugates in comparison to unmodified anti-lgD antibody.
[0005] FIG. 2A depicts the in vitro B cell activation assays where human primary B cells were treated with either a B cell receptor-agonizing anti-IgM antibody or B cell receptor-agonizing anti-IgM-Siglec Ligand conjugates. The B cell stimulatory activities were compared in dose titration experiments with an activation readout of CD69 upregulation. CD69 levels on different treatment groups were evaluated through the percentage of cells that were CD69-positive and plotted as the percentage of control (Isotype control antibody with no activity). FIG. 2B shows the competitive cell binding of anti-IgM-Siglec Ligand conjugates in comparison to unmodified anti-lgD antibody.
[0006] FIGS. 3A and 3B depict the anti-drug antibodies (ADA) over time in C57BL / 6 HSA / hFcRn mice dosed with unmodified bispecific antibody (ADXP_8) or SigL-conjugated bispecific antibody (ADXC_l-6). Mice were dosed on days 0, 7, 14, and 21. Conjugates were created by lysine conjugation of antibody lysine residues, with 4 - 10 SigL per antibody for the different bispecific antibody-SigL conjugate preparations. Error bars indicate standard error of the mean (SEM).
[0007] FIGS.4A and 4B depict analysis of serum pharmacokinetics in C57BL / 6 HSA / hFcRn mice dosed with unmodified antibody (ADXP_8) or SigL-conjugated antibody (ADXC_l-6). Conjugates were created by lysine conjugation of antibody lysine residues.
[0008] FIG. 5 depicts the anti-drug antibodies (ADA) over time in C57BL / 6 hFcRn mice dosed with unmodified antibody (ADXP_10) or SigL-conjugated antibody (ADXC_10-12). Mice were dosed on days 0, 7, 14, and 21. Conjugates were created by lysine conjugation of antibody lysine residues, with 4 -12 SigL per antibody for the different bispecific antibody-SigL conjugate preparations. Error bars indicate standard error of the mean (SEM).
[0009] FIG. 6 depicts analysis of serum pharmacokinetics in C57BL / 6 hFcRn mice dosed with unmodified antibody (ADXP_10) or SigL-conjugated antibody (ADXC_10-12). Conjugates were created by lysine conjugation of antibody lysine residues.
[0010] FIGS. 7A and 7B depict inhibition of TNFot induced NF-kB activity by bispecific antibody in NF-kB luciferase reporter HEK293 cell line. FIG.7A shows equivalent activity to reference anti-TNFa antibody. FIG. 7B shows no loss in activity following conjugation with Siglec-2 binding ligands.Attorney Reference: ADTH-010WO
[0011] FIGS. 8A and 8B depict inhibition of IL-23 induced reporter activity by bispecific antibody in IL-23 responsive STAT3 luciferase reporter HEK293 cell line. FIG. 8A shows equivalent activity to reference anti-pl9 antibody. FIG.8B shows no loss in activity following conjugation with Siglec-2 binding ligands.
[0012] FIG. 9 depicts the results of a urate oxidase activity assay at a variety of uric acid (UA) concentrations. The solid line represents a Michaelis-Menten fit.
[0013] FIG. 10 depicts the results of uricase activity assays at fixed uric acid (UA) concentrations. Unmodified Uricase-VHH (NHU-P1) shows similar activity as lysine SigL-conjugated (NHU-C1).
[0014] FIG. 11 depicts the anti-drug antibodies (ADA) over time in C57BL / 6 mice dosed with unmodified Uricase-VHH (NHU-P1) or SigL-conjugated Uricase (NHU-C1, C4-8). Mice were dosed on days 0, 14, and 28. Conjugates were done by lysine conjugation of Uricase-VHH lysine residues, with approximately 14-16 SigL per Uricase tetramer. Error bars indicate standard error of the mean (SEM).
[0015] FIG. 12A and FIG. 12B depict the anti-drug antibodies (ADA) over time in C57BL / 6 mice dosed with unmodified Uricase-VHH (NHU-P2) or SigL-conjugated Uricase (NHU-C15-19). Mice were dosed on days 0, 14, and 28. Conjugates were done by lysine conjugation of Uricase-VHH lysine residues, with approximately 4-15 Uricase tetramer. Error bars indicate standard error of the mean (SEM).
[0016] FIG. 13 depicts analysis of serum pharmacokinetics in C57BL / 6 mice dosed with unmodified Uricase-VHH (NHU-P1) or SigL-conjugated Uricase (NHU-C1, C4-8). Mice were dosed on days 0, 14, and 28. Conjugates were done by lysine conjugation of Uricase-VHH lysine residues, with approximately 14-16 SigL per Uricase tetramer.
[0017] FIG. 14 shows the serum pharmacokinetics (PK) from C57BL / 6 mice dosed with EndoS mutein or EndoS VHH mutein with and without SigL conjugation at 1 mg / kg IV.
[0018] FIG. 15 shows EndoS mutein or EndoS VHH mutein with and without SigL conjugation pharmacodynamics in C57BL / 6 mice dosed at 1 mg / kg IV by modified lectin ELISA with plasma.
[0019] FIG. 16 EndoS cysteine mutein variants conjugated with SigL show mouse siglec 2 binding by SPR with LDR dependence.Attorney Reference: ADTH-010WO
[0020] FIG. 17 shows the anti-drug antibodies (ADA) after four 2 mg / kg doses of unmodified EndoS and cysteine-conjugated muteins in C57BL / 6 mice with weekly dosing at different LDRs.
[0021] FIG. 18 individual mouse titers show ADA suppression at last time point post four 1 mg / kg biweekly doses in C57BL / 6 mice for EndoS mutein and EndoS VHH mutein with and without SigL conjugation.
[0022] FIG. 19 shows the ADA after three 1 mg / kg doses of cysteine conjugated EndoS VHH muteins in C57BL / 6 mice with biweekly dosing with various SigLs at different LDRs.
[0023] FIG. 20 shows the ADA after three 1 mg / kg doses of lysine conjugated EndoS VHH in C57BL / 6 mice with biweekly dosing with various SigLs at different LDRs.
[0024] FIG. 21A depicts the ADA over time in C57BL / 6 HSA / hFcRn mice dosed four times biweekly at 1 mg / kg with cysteine conjugated EndoS VHH muteins.
[0025] FIG. 21B depicts the serum PK from C57BL / 6 HSA / hFcRn mice dosed with cysteine conjugated EndoS VHH muteins at 1 mg / kg four times biweekly after the primary dose and last dose.
[0026] FIG. 21C depicts the PD from C57BL / 6 HSA / hFcRn mice dosed with cysteine conjugated EndoS VHH muteins at 1 mg / kg four times biweekly.DETAILED DESCRIPTION
[0027] Before the present invention is described in greater detail, it is to be understood that this invention is not limited to particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0028] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where theAttorney Reference: ADTH-010WO stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and exemplary methods and materials may now be described. Any and all publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.
[0030] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any element, e.g., any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely", "only" and the like in connection with the recitation of claim elements, or the use of a "negative" limitation.
[0031] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed. To the extent the definition or usage of any term herein conflicts with a definition or usage of a term in an application or reference incorporated by reference herein, the instant application shall control.
[0032] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.Attorney Reference: ADTH-010WODEFINITIONSChemical Groups
[0033] " Alkyl" refers to a monoradical, branched or linear, non-cyclic, saturated hydrocarbon group. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, cyclopentyl, and cyclohexyl. In some cases, the alkyl group has 1 to 24 carbon atoms, e.g. 1 to 12, 1 to 6, or 1 to 3.
[0034] " Alkenyl" refers to a monoradical, branched or linear, non-cyclic hydrocarbonyl group that comprises a carbon-carbon double bond. Exemplary alkenyl groups include ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, and tetracosenyl.
[0035] " Alkynyl" refers to a monoradical, branched or linear, non-cyclic hydrocarbonyl group that comprises a carbon-carbon triple bond. Exemplary alkynyl groups include ethynyl and n-propynyl.
[0036] " Cycloalkyl" refers to a monoradical, cyclic, saturated hydrocarbon group. Similarly, "cycloalkenyl" refers to a monoradical and cyclic group having carbon-carbon double bond whereas "cycloalkynyl" refers to a monoradical and cyclic group having carbon-carbon triple bond.
[0037] " Heterocyclyl" refers to a monoradical, cyclic group that contains a heteroatom (e.g. O, S, N) as a ring atom and that is not aromatic (i.e. distinguishing heterocyclyl groups from heteroaryl groups). Exemplary heterocyclyl groups include piperidinyl, tetra hydrofuranyl, dihydrofuranyl, and thiocanyl.
[0038] " Aryl" refers to an aromatic group containing at least one aromatic ring, wherein each of the atoms in the ring are carbon atoms, i.e. none of the ring atoms are heteroatoms (e.g. O, S, N). In some cases, the aryl group has a second aromatic ring, e.g. that is fused to the first aromatic ring. Exemplary aryl groups are phenyl, naphthyl, biphenyl, diphenylether, diphenylamine, and benzophenone.
[0039] " Heteroaryl" refers to an aromatic group containing at least one aromatic ring, wherein at least one of the atoms in the aromatic ring is a heteroatom (e.g. O, S, N). Exemplary heteroaryl groups include those obtained from removing a hydrogen atom from pyridine, pyrimidine, furan, thiophene, or benzothiophene.Attorney Reference: ADTH-010WO
[0040] The term "substituted" refers the removal of one or more hydrogens from an atom (e.g. from a C or N atom) and their replacement with a different group. For instance, a hydrogen atom on a phenyl (-CeHs) group can be replaced with a methyl group to form a -C6H4CH3 group. Thus, the -C6H4CH3 group can be considered a substituted aryl group. As another example, two hydrogen atoms from the second carbon of a propyl (-CH2CH2CH3) group can be replaced with an oxygen atom to form a -CH2C(O)CH3 group, which can be considered a substituted alkyl group. However, replacement of a hydrogen atom on a propyl (-CH2CH2CH3) group with a methyl group (e.g. giving -C^CHfCHsjCHs) is not considered a "substitution" as used herein since the starting group and the ending group are both alkyl groups. However, if the propyl group was substituted with a methoxy group, thereby giving a -CH2CH(OCH3)CH3 group, the overall group can no longer be considered "alkyl", and thus is "substituted alkyl". Thus, in order to be considered a substituent, the replacement group is a different type than the original group. In addition, groups are presumed to be unsubstituted unless described as substituted. For instance, the term "alkyl" and "unsubstituted alkyl" are used interchangeably herein.
[0041] Exemplary substituents include alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof.
[0042] In some cases, the substitutions can themselves be further substituted with one or more groups. For example, the group -C6H4CH2CH3 can be considered as substituted aryl, i.e. an aryl group substituted with the ethyl, which is an alkyl group. Furthermore, the ethyl group can itself be substituted with a pyridyl group to form -C6H4CH2CH2C5H5N, wherein -C6H4CH2CH2C5H5N can also be considered as a substituted aryl group as the term is used herein. In some cases, the substituents are not substituted with any other groups.
[0043] Monoradical and multiradical groups are described herein. For example, the methyl group (-CH3) and the ethyl group (-CH2CH3) are monoradical groups. In contrast, exemplary diradical groups include diylmethane (-CH2-, which is also known as a methylene group) and 1,2-diylethane (-CH2CH2-). The term "arylene" refers to the diradical version of an aryl group, e.g. 1,4-diylbenzene refers to a C6H4 fragment wherein two hydrogens that are located para to one another are removed and replaced with single bonds to other groups. The terms "alkenylene", "alkynylene", "heteroarylene", and "heterocyclene" are also used herein. The term "diradical connector" is used interchangeably with the term "diradical group". ExemplaryAttorney Reference: ADTH-010WO diradical groups include alkyl groups, substituted alkyl groups, polyethylene glycol groups, alkoxy groups, substituted alkoxy groups, arylalkyl groups, and substituted arylalkyl groups.
[0044] " Acyl" refers to a group of formula -C(O)R wherein R is alkyl, alkenyl, alkynyl, or substituted versions thereof. For example, the acetyl group has formula -C(O)CH3. " Carbonyl" refers to a diradical group of formula -C(O)-.
[0045] " Alkoxy" refers to a group of formula -O(alkyl). Similar groups can be derived from alkenyl, alkynyl, aryl, heteroaryl, and other groups.
[0046] " Amino" refers to the group -NRXRYwherein Rxand RYare each independently H or a non-hydrogen substituent. Exemplary non-hydrogen substituents include alkyl groups (e.g. methyl, ethyl, and isopropyl) and the carbonyl group.
[0047] " Carbonyl" refers to a diradical group of formula -C(O)-.
[0048] " Carboxy" is used interchangeably with carboxyl and carboxylate to refer to the -CO2H group and salts thereof.
[0049] " Ether" refers to a diradical group of formula -O-. For instance, if the ether group is connected to an alkyl group, then the overall group is an alkoxy group (e.g. -OCH3 or methoxy). If the ether is connected to a carbonyl group, then the overall group is an ester group of formula -OC(O)-.
[0050] " Halo" and "halogen" refer to the chloro, bromo, fluoro, and iodo groups.
[0051] " Nitro" refers to the group of formula -NO2.
[0052] " Chemoselective functional group" refers to a functional group that can selectively react with another compatible functional group to form a covalent bond, in some cases, after optional activation of one of the functional groups. Chemoselective functional groups of interest include, but are not limited to, thiols and maleimide or iodoacetamide, amines and carboxylic acids or active esters thereof, as well as groups that can react with one another via Click chemistry, e.g., azide and alkyne groups (e.g., cyclooctyne groups), tetrazine, transcyclooctene, dienes and dienophiles, and azide, sulfur(VI) fluoride exchange chemistry (SuFEX), sulfonyl fluoride, as well as hydroxyl, hydrazido, hydrazino, aldehyde, ketone, azido, alkyne, phosphine, epoxide, succinimide, pentafluorophenyl (PFP) ester, and carboxylic acid (e.g. on a lysine residue). Additional examples of chemoselective functional groups of use are esters (e.g. pentafluorophenyl ester, N-hydroxysuccinimide ester, 4-nitrophenyl ester,Attorney Reference: ADTH-010WO imidoester), isocyanates, isothiocyanates, sulfonyl chlorides, aldehydes, carbodiimides, acyl azides, anhydrides, fluorobenzenes, carbonates, epoxides, hydroxymethyl phosphines, maleimides, haloacetyls, pyridyl disulfides, thiosulfonates, vinyl sulfones, or squaramates (e.g. -amino(cyclobut-3-ene-l,2-dione)oxy-).
[0053] Unless otherwise specified, reference to an atom is meant to include all isotopes of that atom. For example, reference to H includes1H,2H (i.e. D or deuterium) and3H (i.e. tritium), and reference to C includes both12C and all other isotopes of carbon (e.g.13C). Unless specified otherwise, groups include all possible stereoisomers.Treatment
[0054] The terms "individual," "host," "subject," and "patient" are used interchangeably herein, and refer to an animal, including, but not limited to, human and non-human primates, including simians and humans; rodents, including rats and mice; bovines; equines; ovines; felines; canines; and the like. " Mammal" means a member or members of any mammalian species, and includes, by way of example, canines; felines; equines; bovines; ovines; rodentia, etc. and primates, e.g., non-human primates, and humans. Non-human animal models, e.g., mammals, e.g. non-human primates, murines, lagomorpha, etc. may be used for experimental investigations.
[0055] As used herein, the terms "treatment," "treating," and the like, refer to obtaining a desired pharmacologic and / or physiologic effect, such as reduction of viral titer. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and / or may be therapeutic in terms of a partial or complete cure for a disease and / or adverse effect attributable to the disease. " Treatment," as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease or a symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g., including diseases that may be associated with or caused by a primary disease (as in liver fibrosis that can result in the context of chronic HCV infection); (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease (e.g., reduction in viral titers).
[0056] A "therapeutically effective amount", a "therapeutically effective dose" or "therapeutic dose" is an amount sufficient to effect desired clinical results (i.e., achieve therapeutic efficacy, achieve a desired therapeutic response, etc.). A therapeutically effective dose can be administered in one or more administrations. For purposes of this disclosure, a therapeuticallyAttorney Reference: ADTH-010WO effective dose of a SigL Conjugate or a pharmaceutical composition is an amount that is sufficient, when administered to the individual, to palliate, ameliorate, stabilize, reverse, prevent, slow or delay the progression of a disease state (e.g., cancer, etc.) present in the subject.
[0057] As used herein, the terms "determining," "measuring," "assessing," and "assaying" are used interchangeably and include both quantitative and qualitative determinations.
[0058] The term "unit dosage form," as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of a SigL Conjugate calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable excipient. The specifications for unit dosage forms depend on the particular SigL Conjugate employed and the effect to be achieved, and the pharmacodynamics associated with each SigL Conjugate in the host.
[0059] A "pharmaceutically acceptable excipient," "pharmaceutically acceptable diluent," "pharmaceutically acceptable carrier," and "pharmaceutically acceptable adjuvant" means an excipient, diluent, carrier, and adjuvant that are useful in preparing a pharmaceutical composition that are generally safe, non-toxic and neither biologically nor otherwise undesirable, and include an excipient, diluent, carrier, and adjuvant that are acceptable for veterinary use as well as human pharmaceutical use. " A pharmaceutically acceptable excipient, diluent, carrier and adjuvant" as used herein includes both one and more than one such excipient, diluent, carrier, and adjuvant.
[0060] As used herein, a "pharmaceutical composition" is meant to encompass a composition suitable for administration to a subject, such as a mammal, especially a human. In general a "pharmaceutical composition" is sterile, and preferably free of contaminants that are capable of eliciting an undesirable response within the subject (e.g., the compound(s) in the pharmaceutical composition is pharmaceutical grade). Pharmaceutical compositions can be designed for administration to subjects or patients in need thereof via a number of different routes of administration including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, intracheal, intramuscular, subcutaneous, and the like.SIGLEC LIGANDS AND CONJUGATES
[0061] The term " Siglec" as used herein refers to cell surface proteins that binds to a sialic acid group. Siglecs are commonly found on the surface of leukocytes.Attorney Reference: ADTH-010WO
[0062] There are 14 different mammalian Siglecs, which are expressed on different types of leukocytes and which may exert inhibitory or activating effects on the cells on which they are expressed depending on whether they comprise an inhibitory motif or activating motif. Siglecs show distinct binding preferences for different sialic acids, and the type of linkage and type of underlying sugar also affect recognition of sialic acids. (Varki, A. and Crocker, P. R. (2009) l-type lectins. In Essentials of Glycobiology (2nd edn) (Varki, A. et al., eds), pp. 459-474, Cold Spring Harbor Laboratory Press; Crocker, P. R. et al. (2007) Nat. Rev. Immunol. 7, 255-266). Together, this provides for an array of alternative Siglec ligands that may be deployed to modulate an immune response to a biotherapeutic.
[0063] Provided by the present disclosure are Sialic acid-binding immunoglobulin-type lectin ligands, optionally attached to a linker moiety, which are also referred to herein as " Siglec-Ligands" or " Siglec Ligands".Siglec Ligands
[0064] In one aspect the invention provides a compound, such as a Siglec-Ligand, according to Formula (I). In some cases, the compound of formula (I) has a particular stereochemistry, e.g. the stereochemistry of formula (II).Z is a chemoselective functional group or ZT-T-Z2, wherein Zl' is a diradical group, T is absent or a diradical group, and Z2 is a chemoselective functional group; A1is absent or alkylene; A2is alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof; R2is -COOH, -P(O)(OH)2, -OSO2OH, -C(O)NHSO2H, tetrazole, an ester, or a substituted version thereof; R3is H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, or a substituted version thereof; R4is hydroxy, alkoxy, amino, amide, or a substituted version thereof; R5is H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene-l, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof; R7is hydroxy or halo; X1is O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-; E1is absent, -(substituted or unsubstituted C1-C6alkyleneoxy)g-, -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)q-, -(substituted or unsubstituted C1-C6alkylene)gO-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)qO-, -(substituted or unsubstituted Ci-CeAttorney Reference: ADTH-010WO alkylene)gO(substituted or unsubstituted Ci-Ce alkylene)q-, benzyl, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyloxy, cycloalkyl, or a substituted version thereof, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15; Y is absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, -C C-, -CH2CEC-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -(alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as -(methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(substituted or unsubstituted C1-C6alkyleneoxy)n-, -(substituted or unsubstituted C1-C6alkylene)n-, wherein n is an integer ranging from 1 to 15; X2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m-, -(substituted or unsubstituted C1-C6alkylene)m-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkylene)mO-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)mC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)-, -(substituted or unsubstituted C1-C6alkylene)mC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)O-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-triazole-, -(substituted or unsubstituted Ci-Ce alkylene)mO(substituted orAttorney Reference: ADTH-010WO unsubstituted Ci-Ce alkylene)w-triazole, -(substituted or unsubstituted C1-C6alkylene)m-triazole, -(substituted or unsubstituted C1-C6alkylene)mOtriazole-, triazole, -(methylene)triazole-, -(methylene)triazole(methylene)-, or a substituted version thereof, wherein m is an integer ranging from 1 to 15 and w is an integer ranging from 1 to 15; E2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h-, -(substituted or unsubstituted C1-C6alkylene)h-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hO-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xO-, -(substituted or unsubstituted C1-C6alkylene)hO(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)-, -(substituted or unsubstituted C1-C6alkylene)hC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hOC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O-, -(substituted orAttorney Reference: ADTH-010WO unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, (substituted or unsubstituted C1-C6alkylene)C(O)N(substituted or unsubstituted C1-C6alkylene)-, -C=C-, or -CH2C C-, or a substituted version thereof, wherein h is an integer ranging from 1 to 15, and x is an integer ranging from 1 to 15. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted methyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted methyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted ethyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted ethyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted propyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted propyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted butyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted butyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted pentyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted pentyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted hexyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted hexyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted methylene. In an exemplary embodiment, substituted orAttorney Reference: ADTH-010WO unsubstituted Ci-Ce alkylene is substituted methylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted ethylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted ethylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted propylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted propylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted butylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted butylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted pentylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted pentylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted hexylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted hexylene. In an exemplary embodiment, E1, Y, X2, and E2do not comprise an ester moiety. In an exemplary embodiment, E1, Y, and X2do not comprise an ester moiety. In an exemplary embodiment, g is 2, 3, 4, 5, 6, 7, 8 or 9. In an exemplary embodiment, g is 4, 5, 6, 7, 8 or 9. In an exemplary embodiment, g is 2. In an exemplary embodiment, g is 6. In an exemplary embodiment, q is 1, 2, or 3. In an exemplary embodiment, q is 1. In an exemplary embodiment, q is 2. In an exemplary embodiment, g is 2 and q is 1. In an exemplary embodiment, g is 6 and q is 1. In an exemplary embodiment, g + q = 4, 5, 6, 7, 8, 9, or 10. In an exemplary embodiment, g + q = 5, 6, 7, or 8. In an exemplary embodiment, m is 1, 2, 3, or 4. In an exemplary embodiment, m is 1. In an exemplary embodiment, m is 3. In an exemplary embodiment, m is 4. In an exemplary embodiment, w is 1, 2, 3, or 4. In an exemplary embodiment, w is 1. In an exemplary embodiment, w is 3. In an exemplary embodiment, w is 4. In an exemplary embodiment, m is 1, q is 3. In an exemplary embodiment, m is 1, q is 4. In an exemplary embodiment, h is 1, 2, 3, or 4. In an exemplary embodiment, h is 1. In an exemplary embodiment, h is 3. In an exemplary embodiment, h is 4. In an exemplary embodiment, x is 1, 2, 3, or 4. In an exemplary embodiment, x is 1. In an exemplary embodiment, x is 3. In an exemplary embodiment, x is 4. In an exemplary embodiment, h is 1, x is 3. In an exemplary embodiment, h is 1, x is 4. In an exemplary embodiment, E1is -(substituted or unsubstituted C1-C6alkyleneoxy)g-, -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)q-, -(substituted or unsubstituted C1-C6alkylene)gO-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)qO-, or -(substituted or unsubstituted Ci-Ce alkylene)gO(substituted orAttorney Reference: ADTH-010WO unsubstituted Ci-Ce alkylene)q-, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15. In an exemplary embodiment, E1is -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyl-, benzyloxy, or -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyloxy, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10. In an exemplary embodiment, E1is -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkylene)gO-, or -(substituted or unsubstituted C1-C6alkylene)gO(substituted or unsubstituted C1-C6alkylene)q-, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10, wherein g is 2, 3, 4, 5, 6, 7, 8 or 9, wherein g is 4, 5, 6, 7, 8 or 9, wherein g is 2, wherein g is 6, wherein q is 1, 2, or 3, wherein q is 1, wherein q is 2, or wherein g is 2 and q is 1, or a salt thereof. In some cases, the salt is a pharmaceutically acceptable salt.
[0065] In an exemplary embodiment, the compound, such as a Siglec-Ligand, is according to Formula (III), (IV), (V), or (VI):wherein A2, A1, R2, R3, R4, X1, E1, Y, X2, E2, and Z are as described herein, R5ais substituted Ci-Ce alkyl, such as substituted methyl, substituted ethyl, or substituted propyl; unsubstituted Ci-Ce alkyl, such as methyl; Ci-Ce alkyl, substituted with -OR5bor -NR5bR5c, wherein R5band R5care each independently H or Ci-Ce alkyl; -CH2OH, or -CH2N(CH3)2.
[0066] In an exemplary embodiment, the invention provides a compound, such as a Siglec-Ligand, according to Formula (I), (II), (III), (IV), (V), or (VI): wherein A1is absent or alkylene; A2is substituted or unsubstituted aryl; R5ais substituted or unsubstituted Ci-Ce alkyl; X1is O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-; E1is absent, -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, -(CH2)gO(CH2)q-, benzyl, -(CFhCl-hOjgbenzyl-, -(OCI-hCl-hJgbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, -(OCI-hCl-hJgbenzyloxy, or cycloalkyl, wherein g is an integer ranging from1 to 10 and q is an integer ranging from 1 to 10; Y is absent, alkylene, phenylene, substitutedAttorney Reference: ADTH-010WO phenylene, -0-, -NH-, -S-, -C C-, -CH2CEC-, -C(0)-, -0P(0)0-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -(alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as -(methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(CH2CH2O)n-, -(CH2)n-, wherein n is an integer ranging from 1 to 10; X2is absent, 0, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)m-, -(CH2)m-, -(CH2CH2O)m(CH2)w-, -(OCH2CH2)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, -(OCH2CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2)mNHC(O)(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)(CH2)w-, -(OCH2CH2)m(CH2)wNHC(O)(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)(CH2)w-, -(CH2CH2O)mC(O)NH-, -(OCH2CH2)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)mC(O)NH(CH2)w-, -(OCH2CH2)mC(O)NH(CH2)w-, -(CH2)mC(O)NH(CH2)w-, -(CH2CH2O)m(CH2)wC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wC(O)NH(CH2)w-, -(CH2)w(OCH2CH2)mC(O)NH(CH2)w-, -(CH2CH2O)mC(O)-, -(CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2)mC(O)(CH2)w-, -(CH2CH2O)m(CH2)wC(O)(CH2)w-, -(OCH2CH2)m(CH2)wC(O)(CH2)w-, -(CH2)w(OCH2CH2)mC(O)(CH2)w-, -(CH2CH2O)mC(O)O(CH2)w-, -(CH2)mC(O)O-, -(CH2CH2O)m(CH2)wC(O)O-, -(OCH2CH2)m(CH2)wC(O)O-, -(CH2)w(OCH2CH2)mC(O)O-, -(CH2)mOC(O)-, -(CH2CH2O)m(CH2)wOC(O)-, -(OCH2CH2)m(CH2)wOC(O)-, -(CH2)w(OCH2CH2)mOC(O)-, -(OCH2CH2)mNHC(O)O-, -(CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mNHC(O)O(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)O(CH2)w-, -(OCH2CH2)m(CH2)wNHC(O)O(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)O(CH2)w-, -(OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH(CH2)w-, -(CH2CH2O)m(CH2)wOC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wOC(O)NH(CH2)w-, -(CH2)w(OCH2CH2)mOC(O)NH(CH2)w-, -(OCH2CH2)mNHC(O)NH-, -(CH2)mNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, -(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2)mNHC(O)NH(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wNHC(O)NH(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2CH2O)mtriazole-, -(CH2CH2O)m(CH2)wtriazole-, -(OCH2CH2)m(CH2)wtriazole, -(CH2)w(OCH2CH2)mtriazole-, -(CH2CH2O)m(CH2)wO-triazole-, -(CH2)mO(CH2)w-triazole, -(CH2)m-triazole, -(CH2)mOtriazole-, triazole, -(methylene)triazole-, or -(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10; E2is absent, 0, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, -NHC(O)-, -NHC(O)O-, -Attorney Reference: ADTH-010WOOP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)h-, -(CH2)h-, -(CH2CH2O)h(CH2)x-, -(OCH2CH2)h(CH2)x-, -(CH2)hO-, -(CH2CH2O)h(CH2)xO-, -(OCH2CH2)h(CH2)xO-, -(CH2)x(OCH2CH2)hO-, -(CH2)hO(CH2)x-, -(CH2)hNHC(O)-, -(OCH2CH2)hNHC(O)-, -(CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, -(CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(OCH2CH2)hC(O)NH-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, -(CH2CH2O)hC(O)NH(CH2)x-, -(OCH2CH2)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hC(O)NH(CH2)x-, -(CH2CH2O)hC(O)-, (CH2)hC(O)-, -(CH2CH2O)h(CH2)xC(O)-, -(OCH2CH2)h(CH2)xC(O)-, -(CH2)x(OCH2CH2)hC(O)-, -(CH2CH2O)hC(O)O-, -(CH2)hC(O)(CH2)x-, -(CH2CH2O)h(CH2)xC(O)(CH2)x-, -(OCH2CH2)h(CH2)xC(O)(CH2)x-, -(CH2)x(OCH2CH2)hC(O)(CH2)x-, -(CH2CH2O)hC(O)O(CH2)x-,-(CH2)hC(O)O-, -(CH2CH2O)h(CH2)xC(O)O-, -(OCH2CH2)h(CH2)xC(O)O-, -(CH2)x(OCH2CH2)hC(O)O-, -(CH2)hOC(O)-, -(CH2CH2O)h(CH2)xOC(O)-, -(OCH2CH2)h(CH2)xOC(O)-, -(CH2)x(OCH2CH2)hOC(O)-, -(OCH2CH2)hNHC(O)O-, -(CH2)hNHC(O)O-, -(CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)x(OCH2CH2)hNHC(O)O-, -(CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(OCH2CH2)hOC(O)NH-, -(CH2)hOC(O)NH-, -(CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-, -(CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, -(OCH2CH2)hNHC(O)NH-, -(CH2)hNHC(O)NH-, -(CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-, -(CH2)x(OCH2CH2)hNHC(O)NH-, -(OCH2CH2)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, or -(alkylene)C(O)N(substituted alkylene)2-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10. In an exemplary embodiment, E1, Y, X2, and E2do not comprise an ester moiety. In an exemplary embodiment, E1, Y, and X2do not comprise an ester moiety. In an exemplary embodiment, g is 2, 3, 4, 5, 6, 7, 8 or 9. In an exemplary embodiment, g is 4, 5, 6, 7, 8 or 9. In an exemplary embodiment, g is 2. In an exemplary embodiment, g is 6. In an exemplary embodiment, q is 1, 2, or 3. In an exemplary embodiment, q is 1. In an exemplary embodiment, q is 2. In an exemplary embodiment, g is 2 and q is 1. In an exemplary embodiment, g is 6 and q is 1. In an exemplary embodiment, m is 1, 2, 3, or 4. In an exemplary embodiment, m is 1. In an exemplary embodiment, m is 3. In an exemplary embodiment, m is 4. In an exemplary embodiment, w is 1, 2, 3, or 4. In an exemplaryAttorney Reference: ADTH-010WO embodiment, w is 1. In an exemplary embodiment, w is 3. In an exemplary embodiment, w is 4. In an exemplary embodiment, m is 1, q is 3. In an exemplary embodiment, m is 1, q is 4. In an exemplary embodiment, h is 1, 2, 3, or 4. In an exemplary embodiment, h is 1. In an exemplary embodiment, h is 3. In an exemplary embodiment, h is 4. In an exemplary embodiment, x is 1, 2, 3, or 4. In an exemplary embodiment, x is 1. In an exemplary embodiment, x is 3. In an exemplary embodiment, x is 4. In an exemplary embodiment, h is 1, x is 3. In an exemplary embodiment, h is 1, x is 4. In an exemplary embodiment, h is 1, x is 4. In an exemplary embodiment, E1is -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, or -(CH2)gO(CH2)q-, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15. In an exemplary embodiment, E1is -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, or -(OCH2CH2)gbenzyloxy, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10. In an exemplary embodiment, E1is -(CH2)g-, -(CH2)gO-, -(CH2CH2O)g(CH2)q-, or -(CH2)gO(CH2)q-, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10, wherein g is 2, 3, 4, 5, 6, 7, 8 or 9, wherein g is 4, 5, 6, 7, 8 or 9, wherein g is 2, wherein g is 6, wherein q is 1, 2, or 3, wherein q is 1, wherein q is 2, or wherein g is 2 and q is 1. In an exemplary embodiment, g + q = 4, 5, 6, 7, 8, 9, or 10. In an exemplary embodiment, g + q = 5, 6, 7, or 8. In an exemplary embodiment, the compound, such as a Siglec-Ligand, is according to Formula (III), (IV), (V), or (VI), wherein A2, A1, R2, R3, R4, X1, E1, Y, X2, E2, and Z are as described herein, R5ais substituted Ci-Ce alkyl, such as substituted methyl, substituted ethyl, or substituted propyl; unsubstituted Ci-Ce alkyl, such as methyl; Ci-Ce alkyl, substituted with -OR5bor -NR5bR5c, wherein R5band R5care each independently H or Ci-Ce alkyl; -CH2OH, or -CH2N(CH3)2.
[0067] In one aspect the invention provides a compound, such as a Siglec-Ligand, according to Formula (I), (II), (III), (IV), (V), or (VI), wherein Z is Z1 or Zl'-T-Z2, wherein Z1 is a chemoselective functional group, wherein Zl' is a diradical group, T is absent or a diradical group, and Z2 is a chemoselective functional group, A1is absent or alkylene; A2is alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof; R2is -COOH, -P(O)(OH)2, -OSO2OH, -C(O)NHSO2H, tetrazole, an ester, or a substituted version thereof; R3is H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, or a substituted version thereof; R4is hydroxy, alkoxy, amino, amide, or a substituted version thereof; R5is H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene-1, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof; R7is hydroxy or halo; X1is O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-;Attorney Reference: ADTH-010WOE1is -(substituted or unsubstituted C1-C6alkyleneoxy)g-, -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)q-, -(substituted or unsubstituted C1-C6alkylene)gO-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)qO-, -(substituted or unsubstituted C1-C6alkylene)gO(substituted or unsubstituted C1-C6alkylene)q-, benzyl, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyloxy, cycloalkyl, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10; Y is alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, -C=C-, -CH2C C-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -(alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as -(methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(substituted or unsubstituted C1-C6alkyleneoxy)n-, -(substituted or unsubstituted C1-C6alkylene)n-, wherein n is an integer ranging from 1 to 10; X2is 0, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m-, -(substituted or unsubstituted C1-C6alkylene)m-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkylene)mO-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted Ci-Ce alkylene)mNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)mC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)-, -(substituted or unsubstituted Ci-Ce alkylene)mC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)O-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -Attorney Reference: ADTH-010WO(substituted or unsubstituted Ci-Ce alkyleneoxy)mtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-triazole-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-triazole, -(substituted or unsubstituted C1-C6alkylene)m-triazole, -(substituted or unsubstituted C1-C6alkylene)mOtriazole-, triazole, -(methylene)triazole-, -(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10; E2is -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)-, -(substituted or unsubstituted C1-C6alkylene)hC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hOC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH-, -(substituted or unsubstituted Ci-CeAttorney Reference: ADTH-010WO alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xOC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkylene)hNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Ce alkylene)hNHC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, (substituted or unsubstituted C1-C6alkylene)C(O)N(substituted or unsubstituted C1-C6alkylene)-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10; or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted methyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted methyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted ethyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted ethyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted propyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted propyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted butyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted butyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted pentyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted pentyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is unsubstituted hexyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkyleneoxy is substituted hexyleneoxy. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted methylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted methylene. In an exemplary embodiment,Attorney Reference: ADTH-010WO substituted or unsubstituted Ci-Ce alkylene is unsubstituted ethylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted ethylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted propylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted propylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted butylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted butylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted pentylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted pentylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is unsubstituted hexylene. In an exemplary embodiment, substituted or unsubstituted Ci-Ce alkylene is substituted hexylene. In an exemplary embodiment, E1, Y, X2, and E2do not comprise an ester moiety. In an exemplary embodiment, E1, Y, and X2do not comprise an ester moiety. In an exemplary embodiment, g is 2, 3, 4, 5, 6, 7, 8 or 9. In an exemplary embodiment, g is 4, 5, 6, 7, 8 or 9. In an exemplary embodiment, g is 2. In an exemplary embodiment, g is 6. In an exemplary embodiment, q is 1, 2, or 3. In an exemplary embodiment, q is 1. In an exemplary embodiment, q is 2. In an exemplary embodiment, g is 2 and q is 1. In an exemplary embodiment, g is 6 and q is 1. In an exemplary embodiment, m is 1, 2, 3, or 4. In an exemplary embodiment, m is 1. In an exemplary embodiment, m is 3. In an exemplary embodiment, m is 4. In an exemplary embodiment, w is 1, 2, 3, or 4. In an exemplary embodiment, w is 1. In an exemplary embodiment, w is 3. In an exemplary embodiment, w is 4. In an exemplary embodiment, m is 1, q is 3. In an exemplary embodiment, m is 1, q is 4. In an exemplary embodiment, h is 1, 2, 3, or 4. In an exemplary embodiment, h is 1. In an exemplary embodiment, h is 3. In an exemplary embodiment, h is 4. In an exemplary embodiment, x is 1, 2, 3, or 4. In an exemplary embodiment, x is 1. In an exemplary embodiment, x is 3. In an exemplary embodiment, x is 4. In an exemplary embodiment, h is 1, x is 3. In an exemplary embodiment, h is 1, x is 4. In an exemplary embodiment, E1is -(substituted or unsubstituted C1-C6alkyleneoxy)g-, -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)q-, -(substituted or unsubstituted C1-C6alkylene)gO-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)qO-, or -(substituted or unsubstituted C1-C6alkylene)gO(substituted or unsubstituted C1-C6alkylene)q-, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15. In an exemplary embodiment, E1is -(substituted or unsubstituted Ci-CeAttorney Reference: ADTH-010WO alkyleneoxy)gbenzyl-, benzyloxy, or -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyloxy, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10. In an exemplary embodiment, E1is -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkylene)gO-, or -(substituted or unsubstituted C1-C6alkylene)gO(substituted or unsubstituted C1-C6alkylene)q-, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10, wherein g is 2, 3, 4, 5, 6, 7, 8 or 9, wherein g is 4, 5, 6, 7, 8 or 9, wherein g is 2, wherein g is 6, wherein q is 1, 2, or 3, wherein q is 1, wherein q is 2, or wherein g is 2 and q is 1. In an exemplary embodiment, E2is -(substituted or unsubstituted C1-C6alkylene)hNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hOC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkylene)hNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted orAttorney Reference: ADTH-010WO unsubstituted Ci-Ce alkylene)hNHC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10; or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, E2is -(substituted or unsubstituted C1-C6alkylene)hNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xOC(O)O-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Ce alkylene)hNHC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10; or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, E2is -(substituted or unsubstituted C1-C6alkylene)hNHC(O)- or -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, wherein h is an integer ranging from 1 to 10, and x is an integer from 1 to 10.
[0068] In an exemplary embodiment, the compound, such as a Siglec-Ligand, is according to Formula (III), (IV), (V), or (VI), wherein A2, A1, R2, R3, R4, X1, E1, Y, X2, E2, and Z are as described herein, R5ais substituted Ci-Ce alkyl, such as substituted methyl, substituted ethyl, or substituted propyl; unsubstituted Ci-Ce alkyl, such as methyl; Ci-Ce alkyl, substituted with -OR5bor -NR5bR5c, wherein R5band R5care each independently H or Ci-Ce alkyl; -CH2OH, or -CH2N(CH3)2.Attorney Reference: ADTH-010WO
[0069] In an exemplary embodiment, the invention provides a compound, such as a Siglec-Ligand, according to Formula (I), (II), (III), (IV), (V) or (VI), wherein A1is absent or alkylene; A2is substituted or unsubstituted aryl; R5ais substituted or unsubstituted Ci-Ce alkyl; X1is 0, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-; E1is absent, -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, -(CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15; Y is absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, -C C-, -CH2CEC-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -(alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as -(methylene)triazole(alkylene)- or - (methylene)triazole(methylene)-, -(CH2CH2O)n-, -(CH2)n-, wherein n is an integer ranging from 1 to 10; X2is absent, 0, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)m-, -(CH2)m-, -(CH2CH2O)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2)mO(CH2)w-, -(CH2CH2O)mNHC(O)-, -(CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, -(CH2CH2O)mtriazole-, -(CH2CH2O)m(CH2)wtriazole-, -(OCH2CH2)m(CH2)wtriazole, -(CH2)w(OCH2CH2)mtriazole-, - (CH2CH2O)m(CH2)wO-triazole-, -(CH2)mO(CH2)w-triazole, -(CH2)m-triazole, -(CH2)mOtriazole-, triazole, -(methylene)triazole-, or -(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10; E2is absent, O, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)h-, -(CH2)h-, -(CH2CH2O)h(CH2)x-, -(CH2)hO-, -(CH2CH2O)h(CH2)xO-, -(OCH2CH2)h(CH2)xO-, -(CH2)x(OCH2CH2)hO-, -(CH2)hO(CH2)x-, -(CH2CH2O)hNHC(O)-, -(CH2)hNHC(O)-, -(CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, -(CH2CH2O)hNHC(O)(CH2)x-, -(CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(CH2)hC(O)NH-, -Attorney Reference: ADTH-010WO(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, -(CH2CH2O)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hC(O)NH(CH2)x-,-(CH2)hC(O)-, -(CH2CH2O)h(CH2)xC(O)-, -(OCH2CH2)h(CH2)xC(O)-, -(CH2)x(OCH2CH2)hC(O)-, -(CH2)hC(O)(CH2)x-, -(CH2CH2O)h(CH2)xC(O)(CH2)x-, -(OCH2CH2)h(CH2)xC(O)(CH2)x-, -(CH2)x(OCH2CH2)hC(O)(CH2)x-, -(CH2CH2O)hC(O)O-, -(CH2)hNHC(O)O-, -(CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)x(OCH2CH2)hNHC(O)O-, -(CH2)hOC(O)NH-, -(CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-,-(CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)hNHC(O)NH-, -(CH2)hNHC(O)NH-, -(CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-,-(CH2)x(OCH2CH2)hNHC(O)NH-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, or -(alkylene)C(O)N(substituted alkylene)2-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10; or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, E1, Y, X2, and E2do not comprise an ester moiety. In an exemplary embodiment, E1, Y, and X2do not comprise an ester moiety. In an exemplary embodiment, g is 2, 3, 4, 5, 6, 7, 8 or 9. In an exemplary embodiment, g is 4, 5, 6, 7, 8 or 9. In an exemplary embodiment, g is 2. In an exemplary embodiment, g is 6. In an exemplary embodiment, q is 1, 2, or 3. In an exemplary embodiment, q is 1. In an exemplary embodiment, q is 2. In an exemplary embodiment, g is 2 and q is 1. In an exemplary embodiment, g is 6 and q is 1. In an exemplary embodiment, m is 1, 2, 3, or 4. In an exemplary embodiment, m is 1. In an exemplary embodiment, m is 3. In an exemplary embodiment, m is 4. In an exemplary embodiment, w is 1, 2, 3, or 4. In an exemplary embodiment, w is 1. In an exemplary embodiment, w is 3. In an exemplary embodiment, w is 4. In an exemplary embodiment, m is 1, q is 3. In an exemplary embodiment, m is 1, q is 4. In an exemplary embodiment, h is 1, 2, 3, or 4. In an exemplary embodiment, h is 1. In an exemplary embodiment, h is 3. In an exemplary embodiment, h is 4. In an exemplary embodiment, x is 1, 2, 3, or 4. In an exemplary embodiment, x is 1. In an exemplary embodiment, x is 3. In an exemplary embodiment, x is 4. In an exemplary embodiment, h is 1, x is 3. In an exemplary embodiment, h is 1, x is 4. In an exemplary embodiment, h is 1, x is 4. In an exemplary embodiment, E2is -(CH2)hNHC(O)-, -(CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -Attorney Reference: ADTH-010WO(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2CH2O)hC(O)NH(CH2)x-, -(OCH2CH2)hC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, -(CH2CH2O)hC(O)O(CH2)x-, -(CH2)hNHC(O)O-, -(CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)hOC(O)NH-, -(CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)hNHC(O)NH-, -(CH2)hNHC(O)NH-, -(CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-, -(OCH2CH2)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10; or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, E2is -(CH2)hNHC(O)-, -(CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2CH2O)h(CH2)xOC(O)O-, -(OCH2CH2)h(CH2)xOC(O)O-, -(CH2)hNHC(O)O-, -(CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)hOC(O)NH-, -(CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-, -(CH2CH2O)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10; or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, E2is -(CH2)hNHC(O)- or -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2CH2O)h(CH2)xC(O)NH-, or -(OCH2CH2)h(CH2)xC(O)NH-, wherein h is an integer ranging from 1 to 10, and x is an integer from 1 to 10. In an exemplary embodiment, E1is -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, or -(CH2)gO(CH2)q-, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15. In an exemplary embodiment, E1is -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, or -(OCH2CH2)gbenzyloxy, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10. In an exemplary embodiment, E1is -(CH2)g-, -(CH2)gO-, -(CH2CH2O)g(CH2)q-, or -(CH2)gO(CH2)q-, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10, wherein g is 2, 3, 4, 5, 6, 7, 8 or 9, wherein g is 4, 5, 6, 7, 8 or 9, wherein g is 2, wherein g is 6, wherein q is 1, 2, or 3, wherein q is 1, wherein q is 2, or wherein g is 2 and q is 1. In an exemplary embodiment, the compound, such as a Siglec-Ligand, is according to Formula (III), (IV), (V), or (VI), wherein A2, A1, R2, R3, R4, X1, E1, Y, X2, E2, and Z are as described herein, R5aisAttorney Reference: ADTH-010WO substituted Ci-Ce alkyl, such as substituted methyl, substituted ethyl, or substituted propyl; unsubstituted Ci-Ce alkyl, such as methyl; Ci-Ce alkyl, substituted with -OR5bor -NR5bR5c, wherein R5band R5care each independently H or Ci-Ce alkyl; -CH2OH, or -CH2N(CH3)2.Further Linker Embodiments
[0070] In an exemplary embodiment, the invention provides a compound, such as a SiglecLigand, according to Formula (I), (II), (III), (IV), (V), or (VI), whereinis selected from:described herein.
[0071] In an exemplary embodiment, the invention provides a compound, such as a Siglec-Ligand, according to Formula (I), (II), (III), (IV), (V), or (VI), whereinis selected from:Attorney Reference: ADTH-010WO
[0072] In an exemplary embodiment, the invention provides a compound, such as a Siglec X1— E1— Y— X2— E2-Z Ligand, according to Formula (I), (II), (III), (IV), (V), or (VI), wherein > is selected from:Attorney Reference: ADTH-010WOdescribed herein.Attorney Reference: ADTH-010WO
[0073] In an exemplary embodiment, the invention provides a compound, such as a Siglec- — X1— E1— Y— X2— E2-Z Ligand, according to Formula (I), (II), (III), (IV), (V), or (VI), wherein > is selected from:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOFurther SigL Embodiments
[0074] In an exemplary embodiment, the invention provides a compound, such as a SigL, selected from:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOa chemoselective functional group described herein.
[0075] In an exemplary embodiment, the invention provides a compound, such as a SigL, selected from:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOSiglec-Ligand Conjugates
[0076] In an exemplary embodiment, the invention provides a compound, such as a Siglec- Ligand conjugate, according to Formula (VII). In some cases, the Formula (VII) compound has a particular stereochemistry, such as Formula (VIII). In some cases, the compound has a structure of Formula (IX) or (X):Attorney Reference: ADTH-010WOwherein y is an integer from 1 to 20; BAS is a biologically active substance; Z' is a divalentgroup. In some cases, Z' is the divalent groupwherein represents covalent ***connection to E2, and represents covalent connection to BAS, and A2, A1, R2, R3, R4, R5, R5a,R7, X1, E1, Y, X2, and E2are as described herein. In some cases, BAS is a protein, a biotherapeutic, an autoantigen, an enzyme, an antibody, a nanoparticle, or a combination thereof.Further Siglec-Ligand Conjugate Embodiments
[0077] In an exemplary embodiment, the invention provides a compound, such as a Siglec- Ligand conjugate, according to Formula (VII), (VIII), (IX), or (X), wherein pX1-E1-Y-X2-E2-Z'-BAS is selected from:Attorney Reference: ADTH-010WO
[0078] In an exemplary embodiment, the invention provides a compound, such as a Siglec- Ligand conjugate, according to Formula (VII), (VIII), (IX), or (X), wherein k*1-E1-Y-X2-E2-Z'-BAS is selected from:Attorney Reference: ADTH-010WOSpecific Siglec-Ligand Conjugates
[0079] In an exemplary embodiment, the invention provides a compound, such as a Siglec-Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOFurther Embodiments:Z
[0080] In an exemplary embodiment, Z is selected from esters (e.g. pentafluorophenyl ester, N-hydroxysuccinimide ester, 4-nitrophenyl ester, imidoester), isocyanates, isothiocyanates, sulfonyl chlorides, aldehydes, carbodiimides, acyl azides, anhydrides, fluorobenzenes, carbonates, epoxides, hydroxymethyl phosphines, maleimides, haloacetyls, pyridyl disulfides, thiosulfonates, vinyl sulfones, or squaramates (e.g. -amino(cyclobut-3-ene-l,2-dione)oxy-). In an exemplary embodiment, Z is a maleimide. In an exemplary embodiment, Z is a pentafluorophenyl ester.
[0081] In an exemplary embodiment,exemplary embodiment, Z'In an exemplary embodiment, Z'In an exemplaryAttorney Reference: ADTH-010WOembodiment, Z' is,BAS
[0082] In an exemplary embodiment, BAS is a protein (such as an enzyme or an antibody) or a nanoparticle.A1
[0083] In an exemplary embodiment, A1is absent, or A1is unsubstituted alkylene, such as unsubstituted methylene, or A1is substituted alkylene, such as methylene substituted with two carbons joined together with the methylene carbon to form a 3 membered ring.A2
[0084] In an exemplary embodiment, A2is alkyl, for example, saturated, straight-chain, or branched C1-C15 alkyl. In an exemplary embodiment, A2is methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1,1-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-l-methylpropyl, l-ethyl-2-methylpropyl, heptyl, or octyl. In an exemplary embodiment, A2is an aryl, for example, C6-C14 aryl, such as A2is phenyl, 1-naphthyl, 2-naphthyl, 1-biphenylene, or 2-biphenylene, or A2is substituted aryl, such as substituted with Ci-Cs alkyl, halogen, hydroxy, amino, Ci-Cs alkyloxy, Ci-Cs haloalkyl, cyano, nitro, aryl, heteroaryl, or C3-C8 cycloalkyl.
[0085] In an exemplary embodiment, A2is phenyl, substituted or unsubstituted biphenyl, halosubstituted phenyl, phenyl substituted with Ci-Ce alkyl, phenyl substituted with substituted Ci-Ce alkyl, phenyl substituted with substituted or unsubstituted cycloalkyl. In an exemplary embodiment, A2is phenyl, substituted or unsubstituted biphenyl, halosubstituted phenyl, phenyl substituted with Ci-Ce alkyl, phenyl substituted with substituted Ci-Ce alkyl, or phenyl substituted with substituted or unsubstituted C3-C7 cycloalkyl. In an exemplary embodiment, A2is chlorosubstituted phenyl, fluorosubstituted phenyl, phenyl substituted with halosubstituted Ci-Ce alkyl (such as halosubstituted C1-C3 alkyl), or phenyl substituted with substituted or unsubstituted cyclopropyl or substituted or unsubstituted cyclopropyl. In anAttorney Reference: ADTH-010WO exemplary embodiment, A2is 4-chlorophenyl, 3-chlorophenyl, l,l'-biphenyl, 4-(difluoromethyl)phenyl, 4-(cyclopropyl)phenyl, or phenyl. In an exemplary embodiment, A2is a heteroaryl for example, 5-10 membered heteroaryl containing one or more heteroatoms selected from S, N, 0 or SO2. In some cases, A2is furyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or 4H-thieno[3,2-c]chromene. In some cases, A2is a substituted version of a heteroaryl, for example substituted with Ci-Cs alkyl, halogen, amino, Ci-Cs alkyloxy, cyano, nitro, aryl, heteroaryl, or C3-C8 cycloalkyl. In some embodiments, A2is a cycloalkyl, for example, C3-C8 cycloalkyl. In some cases, A2is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
[0086] In some cases, A1is absent, methylene, or methylene substituted with two carbons joined together with the methylene carbon to form a 3 membered ring, and A2is -CRXRYRZwherein Rxis H, F, -CF3, or -OH, RYis H, F, -OCH3, or -CH3, and Rzis selected from any one of the groups described below:Attorney Reference: ADTH-010WOIn an exemplary embodiment, A2-Axare selected from the group consisting ofis substituted or unsubstitutedAttorney Reference: ADTH-010WOCi-Ce alkyl, or A2-Axare selected from the group consisting ofis -NHC(O)CH3, -NHC(O)CH2OH or -NHC(O)CH2N(CH3)2.R2
[0087] In an exemplary embodiment, R2is -COOH.R3
[0088] In an exemplary embodiment, R3is H.R4
[0089] In an exemplary embodiment, R4is hydroxy.R5
[0090] In an exemplary embodiment, R5is substituted or unsubstituted amide. In an exemplary embodiment, R5is -NHC(O)R5aor -C(O)NHR5awherein R5ais substituted or unsubstituted Ci-Ce alkyl. In an exemplary embodiment, R5is -NHC(O)R5a, wherein R5ais unsubstituted Ci-Ce alkyl, such as methyl. In an exemplary embodiment, R5is -NHC(O)R5awherein R5ais substituted Ci-Ce alkyl. In an exemplary embodiment, R5is -NHC(O)R5a, wherein R5ais Ci-Ce alkyl, substituted with -OR5bor -NR5bR5c, wherein R5band R5care each independently H or Ci-Ce alkyl. In an exemplary embodiment, R5is -NHC(O)CH3, -NHC(O)CH2OH or -NHC(O)CH2N(CH3)2.R7
[0091] In an exemplary embodiment, R7is hydroxy.X1
[0092] In an exemplary embodiment, X1is O. In an exemplary embodiment, X1is NH. In an exemplary embodiment, X1is S. In an exemplary embodiment, X1is absent.E1
[0093] In an exemplary embodiment, E1is -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, or -(CH2)gO(CH2)q-, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15. In an exemplary embodiment, E1is -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, or -(OCH2CH2)gbenzyloxy, wherein g is an integer ranging from 1 to 15 and q is an integerAttorney Reference: ADTH-010WO ranging from 1 to 15. In an exemplary embodiment, E1is -(CH2)g-, -(CH2)gO-, or -(CH2)gO(CH2)q-, wherein g is an integer ranging from 1 to 10 and q is an integer ranging from 1 to 10, wherein g is 2, 3, 4, 5, 6, 7, 8 or 9, wherein g is 4, 5, 6, 7, 8 or 9, wherein g is 2, wherein g is 6, wherein q is 1, 2, or 3, wherein q is 1, wherein q is 2, or wherein g is 2 and q is 1. In an exemplary embodiment, g + q = 4, 5, 6, 7, 8, 9, or 10. In an exemplary embodiment, g + q = 5, 6, 7, or 8.Y
[0094] In an exemplary embodiment, Y is -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, -NHC(O)O-, -NHC(O)NH-, -OC(O)O-, or triazole. In an exemplary embodiment, Y is triazole. In an exemplary embodiment, Y is -NH-(cyclobut-3-ene-l,2-dione)-NH-. In an exemplary embodiment, Y is -NHC(O)-.X2
[0095] In an exemplary embodiment, X2is -(CH2CH2O)m-, -(CH2)m-, -(CH2CH2O)m(CH2)w, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10. In an exemplary embodiment, the Siglec ligand is according to formula (I), or a salt or stereoisomer thereof, wherein A1, A2, R2, R3, R4, R5, R7, X1, E1, Y, E2, and Z' are as described herein, and X2is -(CH2CH2O)m-, -(CH2CH2O)m(CH2)w, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, - (CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 10 and w is an integerAttorney Reference: ADTH-010WO ranging from 1 to 10. In an exemplary embodiment, X2is -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10. In an exemplary embodiment, X2is -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10. In an exemplary embodiment, X2is -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, wherein m is 1, 2, 3, 4, or 5 and w is 1, 2, 3, 4, or 5, or wherein m is 4 and w is 1 or 2.E2
[0096] In an exemplary embodiment, E2is -(CH2)h-, wherein h is an integer ranging from 1 to 10, or wherein h is 1, 2, 3, 4, 5, or 6. In an exemplary embodiment, E2is -(CH2)hO(CH2)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10, wherein h is 1, 2, 3, 4, 5 and x is 1, 2, 3, 4, or 5, wherein h is 1 and x is 1, wherein h is 2 and x is 2, wherein h is 3 and x is 3, wherein h is 4 and x is 4, or wherein h is 5 and x is 5. In an exemplary embodiment, E2is -(CH2CH2O)h(CH2)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10, wherein h is 1, 2, 3, 4, 5 and x is 1, 2, or 3, wherein h is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 and x is 2. In an exemplary embodiment, E2is -(CH2)hNHC(O)-, -(CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, -(CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, -(CH2CH2O)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hC(O)NH(CH2)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10. In an exemplary embodiment, E2is -(CH2)hNHC(O)O-, -(CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)x(OCH2CH2)hNHC(O)O-, -(CH2)hOC(O)NH-, -(CH2CH2O)h(CH2)xOC(O)NH-, -Attorney Reference: ADTH-010WO(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-,-(CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-,-(CH2)x(OCH2CH2)hNHC(O)NH-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10. In an exemplary embodiment, E2is -(CH2)x(OCH2CH2)hC(O)NH-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10. In an exemplary embodiment, E2is -(CH2)x(OCH2CH2)hC(O)NH-, wherein h is 1, and x is 2. In an exemplary embodiment, E2is -(CH2)hC(O)NH-, wherein h is 1. In an exemplary embodiment, E2is absent. In an exemplary embodiment, E2is -(CH2)x(OCH2CH2)hC(O)NH-, wherein h is 1 and x is 2.Aspects of the Siglec-Ligand Conjugates
[0097] As discussed above, the conjugates provided herein include a Siglec ligand and biologically active substance (BAS). As used herein, the term "biologically active substance" refers to a substance that causes a change in a biological system when the biological system is contacted with the substance. In some cases, the biologically active substance is a protein. In some cases, the biologically active substance is a biotherapeutic. In some cases, the biologically active substance is an autoantigen.Biotherapeutic
[0098] The term "biotherapeutic" refers to a composition that is composed of sugars, amino acids, proteins, lipids or nucleic acids or complex combinations of these substances and that is therapeutic in an individual. Examples of biotherapeutics include protein therapeutics (e.g. antibodies, fusion proteins, and enzymes), viral therapeutics (e.g. viral particle), cell therapeutics, and nucleic acid therapeutics (e.g. polypeptides and nucleic acids).
[0099] Any protein or nucleic acid biotherapeutic may serve as the biotherapeutic that is engineered to become a hypoimmunogenic biotherapeutic according to the present disclosure, including, for example, a protein, e.g. an antibody, a fusion protein, an enzyme, a viral particle, a DNA molecule or an RNA molecule. The biotherapeutic may be naturally occurring, for example a naturally occurring protein that is delivered to a patient as a therapeutic, a naturally occurring capsid, etc. The biotherapeutic may be an engineered protein, for example, anAttorney Reference: ADTH-010WO antibody therapeutic, a fusion or "chimeric" protein, i.e. a protein comprising protein domains from two or more different proteins, or an entirely non-natural protein, i.e. having 30% identity or less with any naturally occurring protein across its functional domains (see e.g. Chen et al. (2020) De novo design of protein logic gates. Science 368 (6486): 78-84; and Polizzi et al.(2020) A defined structural unit enables de novo design of small-molecule-binding proteins Science 369 (6508): 1227-1233). In some embodiments, the biotherapeutic is a variant of a naturally occurring protein or a known engineered protein. By "variant" it is meant a mutant of a protein having less than 100% sequence identity with the protein from which it is derived. For example, a variant protein may be a protein having 60% sequence identity or more with a full length native protein, e.g. 65%, 70%, 75%, or 80% or more identity, such as 85%, 90%, or 95% or more identity, for example, 98% or 99% identity with the full length native protein. Variants also include fragments of naturally occurring proteins, particularly those having comparable or improved activity over the naturally occurring protein. The biotherapeutic may be derived from any source, e.g. human, non-human, or engineered.
[0100] Of particular interest is the suppression of an immune response to a biotherapeutic, and more particularly, of a B cell response to the biotherapeutic. Accordingly, in some embodiments, the Siglec ligand is a ligand for a Siglec that is expressed on B lymphocytes, for example Siglec-2 (also called CD22), Siglec-5 (CD170), Siglec-6, Siglec-9 (CD329), or Siglec-10 (Siglec-G). In some embodiments, the Siglec is Siglec-2. In some embodiments, the Siglec is Siglec-5. In some embodiments, the Siglec is Siglec-6. In some embodiments, the Siglec is Siglec-9. In some embodiments, the Siglec is Siglec-10. In some embodiments, the hypoimmunogenic biotherapeutic has been engineered to comprise the sialic acid ligands for one Siglec. In other embodiments, the hypoimmunogenic biotherapeutic has been engineered to comprise the Siglec ligands for two or more Siglecs, e.g. for 3 Siglecs or for 4 Siglecs, in certain cases, for 5 Siglecs. In some cases there are 5, 6, 7, 8, 9, 10, 11, 12, 13, or 15 Siglecs.
[0101] In some embodiments, the protein is an antibody or fragment thereof, for example a monoclonal antibody, a bispecific antibody, a trispecific antibody, an scFv, a Fab, a camelid nanobody, etc. Nonlimiting examples of antibodies for which the engineering contemplated herein finds particular use include adalimumab and infliximab (for the treatment of autoimmune or an inflammatory disease such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, or juvenile idiopathic arthritis), cetuximab (for the treatment of cancers, including forAttorney Reference: ADTH-010WO example metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer), natalizumab (for the treatment of multiple sclerosis), Lumoxiti / moxetumomab pasudotox (for the treatment of hairy cell leukemia), Tecentriq / atezolizumab (for the treatment of various cancers), Opdivo / Nivolumab (for the treatment of various cancers), Reopro / abciximab (anti-G PI I b / l I la, for the prevention of thrombosis during and after coronary artery procedures such as angioplasty), Brentuximab (for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL)), Certolizumab pegol (for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis), Elotuzumab (for the treatment of relapsed multiple myeloma), Benralizumab (for the treatment of asthma), Vedolizumab (for the treatment of ulcerative colitis and Crohn's disease), Galcanezumab (for the treatment of migraines and cluster headaches), Rituximab (for the treatment of autoimmune diseases and various cancer), Alemtuzumab (for the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis), Dupilumab (for the treatment of allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps), Golimumab (for the treatment of inflammation), Obinutuzumab (for the treatment of lymphomas, e.g. chronic lymphocytic leukemia, follicular lymphoma), Tildrakizumab (for the treatment of immunologically mediated inflammatory disorders), Erenumab (for the prevention of migraine), Mepolizumab (for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES)), Ramucirumab (for the treatment of solid tumors), Ranibizumab (for the treatment of "wet" age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema), Ustekinumab (for the treatment of psoriasis, Crohn's disease, and ulcerative colitis), Reslizumab (for the treatment of asthma), Ipilimumab (for the treatment of various cancers), Alirocumab (for the treatment of high cholesterol), Belimumab (for the treatment of systemic lupus erythematosus (SLE)), Panitumumab (for the treatment of various cancers), Avelumab (for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma), Necitumumab (for the treatment of metastatic squamous non-small-cell lung carcinoma (NSCLC)), Mogamulizumab (for the treatment of relapsed or refractory mycosis fungoides and Sezary disease, relapsed or refractory CCR4+ adult T-cell leukemia / lymphoma (ATCLL), and relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL)), Olaratumab (for the treatment of solid tumors), Brodalumab (for the treatment of inflammatory diseases), Eculizumab (for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica), Pertuzumab (for the treatmentAttorney Reference: ADTH-010WO of metastatic HER2-positive breast cancer), Pembrolizumab (for the treatment of various cancers), and Tocilizumab (for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis).
[0102] In some embodiments, biotherapeutic is an antibody that is not an antibody that is specific for a receptor selected from a B cell receptor (BCR), a receptor for the Fc region of immunoglobulin E (FcIRI), a Toll Like receptor (TLR), a T-cell receptor (TCR), or complexes thereof.
[0103] As used herein, an antibody that specifically binds to a target antigen refers to an antibody comprising a complementarity determining region (CDR) domain that specifically recognizes and binds to the target antigen. Thus, an antibody that specifically binds to a B cell receptor or complex thereof refers to an antibody comprising a CDR that specifically recognizes and binds to a B cell receptor or a complex comprising a B cell receptor, an antibody that specifically binds to a receptor for the Fc region of IgE refers to an antibody comprising a CDR that specifically recognizes and binds to a receptor for the Fc region of IgE or a complex comprising a receptor for the Fc region of IgE, an antibody that specifically binds to a Toll like receptor refers to an antibody comprising a CDR that specifically recognizes and binds to a Tolllike receptor or a complex comprising a Toll-like receptor, and an antibody that specifically binds to a T-cell receptor refers to an antibody comprising a CDR that specifically recognizes and binds to a T-cell receptor or a complex comprising a T-cell receptor.
[0104] In some embodiments, the protein is a native, or naturally occurring, protein. In other embodiments, the protein is an engineered protein. Examples of proteins for which the engineering contemplated herein finds particular use include erythropoietin (EPO, to stimulate the production of red blood cells), thrombopoietin (TPO, to stimulate the production of platelets), human growth hormone, tissue factor, I FN [3-lb (for the treatment of Multiple Sclerosis), IFN[3-la (for the treatment of Multiple Sclerosis), IL-2 or the IL-2 mimetic aldesleukin (for the treatment of melanoma and renal cell carcinoma), exenatide (for the treatment of Type 2 Diabetes), albiglutide (for the treatment of Type 2 Diabetes), alefacept (to control inflammation in moderate to severe psoriasis with plaque formation, for the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma), palifermin (to stimulate the growth of cells that line the surface of the mouth and intestinal tract following chemotherapy), belatacept (to promote graft / transplant survival), and neutral and basic amino acid transport protein rBAT or b(0,+)-type amino acid transporter 1 (for the treatment of cystinuria).Attorney Reference: ADTH-010WO
[0105] In some embodiments, biotherapeutic is a protein that is not ovalbumin or immunoglobulin E (IgE).
[0106] In some embodiments, the protein is an enzyme, for example a metabolic enzyme, a lysosomal enzyme, a protease, a peptidase, etc. Nonlimiting examples of enzymes for which the engineering contemplated herein finds particular use include asparaginase from Erwinia chrysanthemi (for the treatment of leukemia), bacterial IdeS (for immunosuppression following tissue transplantation or in the administration of a therapy, e.g. a gene therapy, for which the patient had preexisting immunity; for treatment of IgG antibody-driven diseases, such as Systemic lupus erythematosus, Pemphigus vulgaris or IgA Nephropathy), bacterial mucinase (for the treatment of MUC+ cancers, e.g. MUC1+ cancers), Factor VIII (for the treatment of Hemophilia A), Factor IX (for the treatment of Hemophilia B), Factor Xa (to promote clotting), a complement degrading protease, e.g. from a pathogen such as a bacterial pathogen or fungal pathogen (e.g. Pseudomonas Elastase (PaE), Pseudomonas Alkaline protease (PaAP), Streptococcal pyrogenic Exotoxin B (SpeB), a gingipain from Porphyromonas gingivalis, Aspergillus Alkaline protease 1 (Alpl), C. albicans Secreted aspartyl proteinases 1 (Sapl), 2 (Sap2), and 3 (Sap3) for the treatment of complement-mediated disease, such as IgA nephropathy), phenylalanine ammonia-lyase or the mimetic pegvaliase (for the treatment of PKU), alpha-galactosidase A (for the treatment of Fabry Disease), acid ot-glucosidase or the mimetic Alglucosidase alfa (GAA, for the treatment of Pompe Disease), glucocerebrosidase (GCase, for the treatment of Gaucher), aspartylglucosaminidase (AGA, for the treatment of Aspartylglucosaminuria), asfotase (for treatment of hypophosphatasia (HPP)), alpha-L-iduronidase (for the treatment of MPS I), iduronate sulfatase or the iduronate sulfatase mimetic idursulfase (for the treatment of MPS II), sulfaminase (for the treatment of MPS Illa), a-N-acetylglucosaminidase (NAGLU, for the treatment of MPS 111 B), heparin acetyle CoA: a-glucosaminide N-acetyltransferase (HGSNAT, for the treatment of MPS NIC), N-acetylglucosamine 6-sulfatase (GNS, for the treatment of MPS HID), N-glucosamine 3-0-sulfatase (arylsulfatase G or ARSG, for the treatment of MPS HIE), N-acetylgalactosamine 6-sulfatase(for the treatment of MPS IVA), beta-galactosidase (for the treatment of MPS IVB), N-acetylgalactosamine 4-sulfatase (for the treatment of MPS VI), beta-glucuronidase (for the treatment of MPS VI), palmitoyl protein thioesterase (PPT1, for the treatment of Batten disease / CLNl), Tripeptidyl peptidase (TPP1, for the treatment of Batten Disease / CLN2), arginase-1 or pegzilarginase (for the treatment of arginase-1 deficiency), or cystathionine betaAttorney Reference: ADTH-010WO synthase or Aeglea product AGLE-177 (for the treatment of cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria).
[0107] In some embodiments, biotherapeutic is an enzyme that is not Factor VIII.
[0108] In some embodiments, the protein is a viral protein or a viral particle, for example, a recombinant viral particle. By a "recombinant" virus or viral particle it is meant a virus / viral particle that comprises a genome comprising a polynucleotide that is heterologous to the virus, i.e., not found in nature to be associated with the capsid / envelope of the virus, wherein the polynucleotide encodes a gene product (RNA or protein). Recombinant viral particles find use in the delivery of polynucleotides that encode a therapeutic gene product for the purpose of gene therapy or oncolytic virus therapy. Gene therapy is a well-established art. Also well-established is the fact that gene therapy is severely hampered by the inability to readminister the same viral therapeutic more than once or a few times, owing to the fact that the viral particle will induce an immune response in an individual. As such, the ordinarily skilled artisan will appreciate that any viral particle used in gene therapy would benefit from engineering as contemplated herein. Nonlimiting examples of viral particles that may serve as the biotherapeutic that is engineered to become a hypoimmunogenic biotherapeutic according to the present disclosure include recombinant adeno-associated virus (rAAV) particles, e.g. an rAAV particle comprising a capsid VP1 protein from the group consisting of an AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO, AAV11, AAV12, or AAV13 VP1 protein or a variant or pseudotyped virus thereof; recombinant human adenovirus particles, e.g. an rHAdV particle comprising a capsid protein from rHAdV-A, rHAdV-B, rHAdV-C, rHAdV-D, rHAdV-E, rHAdV-F, or rHAdV-G or a variant thereof; recombinant Herpes Simplex Virus (rHSV) particles, e.g. a rHSVl or rHSV2 or variant or pseudotyped virus thereof; recombinant papillomavirus (PV) particles; recombinant polyomavirus particles; recombinant vaccinia virus particles; a recombinant cytomegalovirus (CMV) particle; a recombinant baculovirus particle; a recombinant human papillomavirus (HPV) particle; ora recombinant retrovirus particle, e.g. a recombinant lentivirus, recombinant human immunodeficiency virus (HIV) particle, Simian immunodeficiency virus (SIV) particle, Feline immunodeficiency virus (FIV) particle, Puma lentivirus (PLV) particle, Equine infectious anemia virus (EIAV) particle, Bovine immunodeficiency virus (BIV) particle, Caprine arthritis encephalitis virus particle, gammaretrovirus particle, and murine leukemia virus (MLV) particle, or variant or pseudotyped virus thereof.Attorney Reference: ADTH-010WO
[0109] In some embodiments, biotherapeutic is not a toxin. Generally, toxins are compounds that are harmful to cells in generally non-specific manner, i.e. a toxin will cause a similar amount of harm to different cells, even if such cells are from significantly different categories. In contrast, selectively damaging compounds will harm certain cells to a significantly greater degree than the harm inflicted on other types of cells. For instance, the selectively damaging compound can cause harm based on a biochemical process that is common in a lung cell but rare in a kidney cell, whereas a toxin can cause harm based on a biochemical process common to both lung and kidney cells. In some cases, the harm is cell death. In some cases, the toxin is Pseudomonas exotoxin A. In some embodiments, biotherapeutic is not a B cell modulator. Y does not increase or decrease the immune action of a B cell. Examples of modulation of the B cell include differentiation of the B cell into a biotherapeutic-specific mature B cell, e.g. plasma cells or memory cells, preventing B cells from producing antigen-specific antibodies, preventing the upregulation of activation markers such as CD69, promoting a decrease in viability of a biotherapeutic-specific B cell population. In some embodiments, B cell activation is inhibited only for those B cells with a B cell receptor that recognizes Y (in contrast to the entire B cell population recognizing X).Autoantigen
[0110] The term "autoantigen" (abbreviated as " AutoAg") refers to an endogenous molecule present in a subject which the subject's immune system does not recognize as an endogenous molecule (i.e., as a self-antigen) and thus mounts an immune response to the self-antigen. Such an immune response is referred to as an autoimmune response. The autoantigen is encoded by an endogenous gene present in a subject and may be a polypeptide, e.g., a soluble or membrane-localized polypeptide, a lipidated, glycosylated, or otherwise post-translationally modified polypeptide; a nucleic acid (e.g., DNA, RNA); or a complex thereof. In some embodiments, the autoantigen is any autoantigen that elicits a B-cell driven immune response in an individual, where the individual produces B cells that bind to the autoantigen via B-cell receptors (BCRs) and upon binding to the autoantigen differentiate into plasma cells that produce autoantibodies that bind to the autoantigen.
[0111] In contrast to a biotherapeutic, an autoantigen is a molecule that is endogenously produced by the subject, whereas a biotherapeutic is a molecule that the subject does not produce and is exogenously supplied to the person, e.g., as a polypeptide or a gene encoding the polypeptide. Thus, an immune response to a biotherapeutic is not considered anAttorney Reference: ADTH-010WO autoimmune response. Rather, an immune response to a biotherapeutic is a normal immune response. A biotherapeutic may be composed of sugars, amino acids, proteins, lipids or nucleic acids or complex combinations of these substances. Unlike an engineered autoantigen, a biotherapeutic is not intended as an autoimmune-suppressive mimic of a non-suppressive and endogenous disease-driving antigen. Nonlimiting examples of biotherapeutics include protein therapeutics, e.g., antibody therapeutics, fusion protein therapeutics, enzyme therapeutics, viral therapeutics, cell therapeutics, and nucleic acid therapeutics.
[0112] Specific examples of biotherapeutics include a monoclonal antibody, a bispecific antibody, an scFv, a Fab, a camelid, ora nanobody, e.g., adalimumab, infliximab, cetuximab, natalizumab, moxetumomab pasudotox, atezolizumab, nivolumab, abciximab, Brentuximab, Certolizumab pegol, elotuzumab, benralizumab, vedolizumab, galcanezumab, rituximab, alemtuzumab, dupilumab, golimumab, obinutuzumab, tildrakizumab, erenumab, mepolizumab, tamucirumab, ranibizumab, ustekinumab, reslizumab, ipilimumab, alirocumab, belimumab, panitumumab, avelumab, necitumumab, mogamulizumab, olaratumab, brodalumab, eculizumab, pertuzumab, pembrolizumab, or tocilizumab. In certain embodiments, the biotherapeutic is erythropoietin, thrombopoietin, human growth hormone, tissue factor, IFN[3-lb, IFN[3-la, IL-2 or the IL-2 mimetic aldesleukin, exenatide, a I biglutide, alefacept, palifermin, or belatacept.
[0113] In certain embodiments, the biotherapeutic is an enzyme, such as, asparaginase Erwinia chrysanthemi, phenylalanine ammonia-lyase, alpha-galactosidase A, acid ot-glucosidase (GAA), glucocerebrosidase (GCase), aspartylglucosaminidase (AGA), alpha-L-iduronidase, iduronate sulfatase, sulfaminase, a-N-acetylglucosaminidase (NAGLU), heparin acetyle CoA: a-glucosaminide N-acetyltransferase (HGSNAT), N-acetylglucosamine 6-sulfatase (GNS), N-glucosamine 3-O-sulfatase (arylsulfatase G or ARSG), N-acetylgalactosamine 6-sulfatase, betagalactosidase, N-acetylgalactosamine 4-sulfatase, beta-glucuronidase, Factor VIII, Factor IX, palmitoyl protein thioesterase (PPT1), Tripeptidyl peptidase (TPP1), Pseudomonas elastase (PaE), Pseudomonas alkaline protease (PaAP), or Streptococcal pyrogenic exotoxin B (SpeB).. In certain embodiments, the biotherapeutic is not Factor VIII.
[0114] In some embodiments, an autoantigen, as provided herein, is a naturally occurring antigen in a healthy individual. Using PANTHER, (Protein ANalysis THrough Evolutionary Relationships), autoantigens can be classified into the following varieties based on function played by the antigen in-vivo that may have a role to play as, for example, an enzyme,Attorney Reference: ADTH-010WO intercellular adhesive protein, cell junction protein, cytoskeletal protein, extracellular matrix protein, cellular receptor, transcription or translational protein, gene editing protein, structural protein, or the like.
[0115] Autoantigens have been found to be associated with several autoimmune disorders. A comprehensive list of disorders and associated autoantigens can be found at the database AAgAtlas 1.0 database accessed by typing into a web browser http followedby: / / biokb. ncpsb.org / followed by aagatlas / ). Nonlimiting examples of autoantigens and their associated disorders include: p53-associated autoimmune diseases lupus and scleroderma; Desmoglein (Dsg) 1 and 3 autoantigens associated with Pemphigus vulgaris; autoantigens Gliadin and type 2 transglutaminase associated with Celiac disease; autoantigens PDC-E2 (Pyruvate dehydrogenase complex component E2) and BCOADC-E2 (Branched chain 2-oxo-acid dehydrogenase complex component E2) associated with Primary Biliary Cholangitis; autoantigens PLA2R (Phospholipase A2 Receptor) and THSD7A (thrombospondin type-1 domain containing protein 7A) associated with Membranous Nephropathy; autoantigen TSHR (Thyroid-Stimulating Hormone Receptor) associated with Graves' Disease; autoantigens AChR (Acetylcholine Receptor), MuSK (Muscle-Specific Kinase), and LRP4 ( associated with Myasthenia Gravis; and autoantigens associated with rheumatoid arthritis (RA) (e.g., citrullinated peptides and proteins, carbamylated proteins, acetylated proteins) and systemic lupus erythematosus (SLE) (e.g., anti-nuclear antibodies, anti-dsDNA antibodies, antinucleosome antibodies, and others), and the like.
[0116] In certain aspects, an engineered autoantigen that suppresses an ongoing autoimmune response to the autoantigen in a subject includes a siglec ligand. The engineered autoantigen is configured to both bind to BCRs on a B cell that recognizes the autoantigen and to bind to a siglec present on the B cell. The autoantigen portion of the engineered autoantigen provides specificity for targeting only B cells that bind to the autoantigen while the siglec ligand, while not specific to a particular B cell clone, may bind to any B cell expressing the siglec, prevents activation of the B cell. In some instances, the siglec ligand provides a therapeutic benefit to the individual by suppressing the individual's immune response to the autoantigen, where the immune response is reduced by 50% or more when the engineered autoantigen is administered to an individual relative to when the individual is administered the nonengineered version of the autoantigen. Further, in some instances, the immune reaction is reduced by 60%, 70%, 80% or more, for example 85%, 90%, 95% or more, in certain cases 98%,Attorney Reference: ADTH-010WO99%, or 100%, i.e., such that the immune response is undetectable, i.e., the autoantigen is rendered nonimmunogenic.
[0117] In some aspects of the disclosure, an engineered autoantigen is provided, wherein the engineered autoantigen (referred to interchangeably as the "clonally immunosuppressive autoantigen", "hypoimmunogenic autoantigen", "modified autoantigen" or simply "subject autoantigen") is engineered to have an altered Sialic acid-binding immunoglobulin-type lectin (Siglec) ligand (sigL) profile.
[0118] Thus, disclosed herein are engineered autoantigens which may retain the epitope(s) recognized by autoimmune antibodies, while comprising one or more modifications comprising addition of a sigL that render the autoantigen capable of suppressing an antigen-specific immune response in an individual to which it has been administered as compared to the unmodified autoantigen. In some embodiments, the immune response is a humoral immune response i.e., a B cell-driven response, e.g., an IgG response.Engineered and hypoimmunogenic
[0119] The term "engineered" refers to a biotherapeutic that has been designed and built to comprise one or more modifications relative to biotherapeutic that has not been so engineered, i.e. a parental biotherapeutic, which is also referred to herein as an unengineered biotherapeutic.
[0120] By a "hypoimmunogenic" composition, it is meant a composition that suppresses an unwanted, drug-specific immune response in an individual relative to a reference composition, e.g. a corresponding nonengineered composition, when administered to the individual; for example, reducing an immune response by 50% or more relative to a reference, e.g. a nonengineered biotherapeutic, in some instances 60%, 70%, 80% or more, for example 85%, 90%, 95% or more, in certain cases 98%, 99%, or 100%, i.e. such that the immune response is undetectable, i.e. the biotherapeutic is nonimmunogenic. Thus, disclosed herein are engineered biotherapeutics which retain pharmacologic activity while comprising one or more modifications that render the biotherapeutic capable of suppressing a drug-specific immune response in an individual to which it has been administered as compared to the unmodified biotherapeutic. In some embodiments, the immune response is a humoral immune response i.e., a B cell-driven response, e.g. an IgG response.Attorney Reference: ADTH-010WOPHARMACEUTICAL COMPOSITIONS
[0121] Provided are pharmaceutical compositions. In some embodiments, the pharmaceutical composition includes a Siglec-ligand conjugate as described herein. In some cases, the pharmaceutical composition includes an excipient, a solvent, a diluent, a binder, a disintegrant, an antioxidant, a preservative, or a combination thereof. In some cases, the pharmaceutical composition includes an excipient, e.g. a pharmaceutically acceptable excipient. In some cases, the pharmaceutical composition is predominated by a particular stereoisomer, e.g. the stereoisomerism of formula (II). In such cases, more than 75% of all molecules in the pharmaceutical composition with the desired chemical structure also have the desired stereochemistry, and wherein less than 25% of all the molecules in the pharmaceutical composition with the desired chemical structure have an alternative stereochemistry. In some cases, this ratio is more than 90% compared to less than 10%, such as more than 98% compared to less than 2%.
[0122] In methods of treating an individual with the subject hypoimmunogenic biotherapeutic, the patient will typically be administered a pharmaceutical composition comprising the subject hypoimmunogenic biotherapeutic. By a pharmaceutical composition, it is meant an engineered hypoimmunogenic biotherapeutic of the present disclosure that has been formulated in a pharmaceutically acceptable carrier. As used herein, a "pharmaceutically acceptable carrier, diluent or excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
[0123] The pharmaceutical compositions of the disclosure are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease states previously described. Administration of the compounds of the disclosure or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities. While human dosage levels have yet to be optimized for the compounds of the disclosure, these can be readily extrapolated from doses administered to a relevant animal model, e.g. mice that results in treatment of the disease or disorder in that animal model. Generally, an individual human dose is from about 0.01 to 2.0 mg / kg of body weight, preferably about 0.1 to 1.5 mg / kg of body weight, and most preferablyAttorney Reference: ADTH-010WO about 0.3 to 1.0 mg / kg of body weight. Treatment can be administered for a single day or a period of days, and can be repeated at intervals of several days, one or several weeks, or one or several months. Administration can be as a single dose (e.g., as a bolus) or as an initial bolus followed by continuous infusion of the remaining portion of a complete dose over time, e.g., 1 to 7 days. The amount of active compound administered will, of course, be dependent on any or all of the following: the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. It will also be appreciated that amounts administered will depend upon the molecular weight of the biotherapeutic, the amount of Siglec ligand covalently bound, and the size of the linker.
[0124] While all typical routes of administration are contemplated (e.g. oral, topical, transdermal, injection (intramuscular, intravenous, or intra-arterial)), it is presently preferred to provide liquid dosage forms suitable for injection. Generally, depending on the intended mode of administration, the pharmaceutically acceptable composition will contain about 0.1% to 95%, preferably about 0.5% to 50%, by weight of the subject hypoimmunogenic biotherapeutic of the disclosure, the remainder being suitable pharmaceutical excipients, carriers, etc. Dosage forms or compositions containing active ingredient in the range of 0.005% to 95% with the balance made up from non-toxic carrier can be prepared.
[0125] The subject pharmaceutical compositions can be administered either alone or in combination with other pharmaceutical agents. These compositions can include other medicinal agents, pharmaceutical agents, carriers, and the like, including, but not limited to other active agents that can act as immune-modulating agents and more specifically can have inhibitory effects on B-cells, including anti-folates, immune suppressants, cyostatics, mitotic inhibitors, and anti-metabolites, or combinations thereof.
[0126] Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active composition of the disclosure (e.g., a lyophilized powder) and optional pharmaceutical adjuvants in a carrier, such as, for example, water (water for injection), saline, aqueous dextrose, glycerol, glycols, ethanol or the like (excluding galactoses), to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, stabilizing agents, solubilizing agents, pH buffering agents and the like, for example, sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate and triethanolamine oleate, etc., osmolytes, aminoAttorney Reference: ADTH-010WO acids, sugars and carbohydrates, proteins and polymers, salts, surfactants, chelators and antioxidants, preservatives, and specific ligands. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, Pharmaceutical Press, 22nd Edition, 2012. The composition or formulation to be administered will, in any event, contain a quantity of the active compound in an amount effective to treat the symptoms of the subject being treated.METHODS OF MANUFACTURE
[0127] Also provided are methods of making the conjugates disclosed herein. Provided is a method of making a conjugate, comprising: covalently attaching a Siglec ligand as described herein to a biologically active substance, thereby making the conjugate.
[0128] In another aspect, a method of making the SigL Conjugates described herein is provided. In an exemplary embodiment, the method comprises contacting a SigL according to:with a polypeptide described herein, under conditions sufficient to produce the SigL Conjugate described herein, wherein A1, A2, R5a, L', X1, E1, Y, X2, and E2are as described herein, and Z is a chemoselective functional group which reacts with the polypeptide to produce a covalent bond. In an exemplary embodiment, Z is a chemoselective functional group which reacts with an amine (e.g. primary amine) or a thiol to produce a covalent bond.Attorney Reference: ADTH-010WO
[0129] Examples of SigLs of use in making the SigL Conjugates are found in Examples 1-27.Other SigLs of use are found in WO 2024 / 259007. Specific SigL examples from WO2024 / 259007 are compounds:Attorney Reference: ADTH-010WO
[0130] The polypeptides may be present in a solution which allows for dimers to form and for formation of tetramers from the dimers. The tetramers may be separated from any monomers and dimers via a standard method, e.g., purification based on size and / or charge.
[0131] Conditions for attaching SigLs to a N-terminus, lysine side chain, or cysteine side chain of a polypeptide are provided in the Examples. Conditions when utilizing a squaramate as a chemoselective functional group can involve using a 50 mM PBS 100 mM sodium carbonate 10% v / v DMSO, pH 9.5 at 25 °C with a reaction time of at least about 4 hours which an appropriate ratio of SigL to polypeptide to produce the desired SigL-to-polypeptide ratio in the SigL Conjugate.Attorney Reference: ADTH-010WO
[0132] Additional conditions for making SigL Conjugates are found in the Bioconjugation and Crosslinking Technical Handbook (ThermoFisher Scientific, 2025) and Bioconjugate Techniques (Greg Hermanson, 3rdEdition), each of which are herein incorporated by reference for all purposes.
[0133] Methods of covalently binding Siglec ligands to biologically active substances are well appreciated in the art, any of which may be deployed to modify a biotherapeutic of choice to become an engineered hypoimmunogenic biotherapeutic of the present disclosure. For example, the modification may be performed by engineered biosynthesis. By "biosynthesis", it is meant a synthesis process that is mediated by cells. For example, in the Golgi apparatus, a subset of the 20 known sialyltransferases attach sialic acids to underlying monosaccharides such as galactose via three different types of linkage (a2,3, a2,6, and a2,8). By engineered biosynthesis, it is meant a synthesis process that is mediated by cells that have been engineered to perform the process, in some instances de novo, in other instances, in a modified way. Thus, for example, a producer cell line may be genetically engineering to express one or more sialyl transferases, e.g. sialyltransferase (EC 2.4.99), beta-galactosamide alpha-2, 6-sialyltransferase (EC 2.4.99.1), alpha-N-acetylgalactosaminide alpha-2, 6-sialyltransferase (EC 2.4.99.3), beta-galactoside alpha-2, 3-sialyltransferase (EC 2.4.99.4), N-acetyllactosaminide alpha-2, 3-sialyltransferase (EC 2.4.99.6), alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase (EC 2.4.99.8); lactosylceramide alpha-2, 3-sialyltransferase (EC 2.4.99.9), or other enzymes in an enzymatic pathway, e.g. CMP-Neu5Ac hydroxylase, sialate-4-O-acetyl transferase, sialate-4-O-acetylesterase, sialate-7(9)-O-acetyltransferase, sialate-8-O-methyl transferase, sialate-9-)-acetyltransferase, etc. that drives the covalent binding of a specific sialic acid to the biotherapeutic or that targets specific novel amino acid residues for covalent modification with sialic acid. As another example, a producer cell line could be fed a precursor substrate that will be incorporated by the producer line into the manufactured biotherapeutic as a specific Siglec ligand. Any producer cell that finds use in the expression of proteins for use as therapeutic biotherapeutics may be used in this process, for example a mammalian cell (CHO, HEK, etc.), an insect cell (SF9, etc.), a bacterium, a protozoan (Leishmania, etc.), as disclosed in, e.g. WO2017093291, W02019002512, WO2019234021, the full disclosures of which are incorporated herein in their entirety by reference.
[0134] As another example, the modification may be performed by chemical conjugation. By "chemical conjugation", it is meant a process that occurs exogenous to a cell. Thus, forAttorney Reference: ADTH-010WO example, the Siglec ligand might be enzymatically or chemically linked to the biotherapeutic after biosynthesis from producer cell line. Nonlimiting examples of such in vitro processes are disclosed in US Patent No. 7,220,555, US Patent No. 6,376,475B, and US Patent No. 5,409,817, the full disclosures of which are incorporated herein by reference. In some such embodiments, a connector may be deployed to covalently link the sialic acid to the biotherapeutic. Many examples of connector exist in the art, any of which may be used to chemically conjugate sialic acid(s) to the biotherapeutic to arrive at hypoimmunogenic biotherapeutics of the present disclosure.
[0135] As a third example, specifically directed to embodiments in which the Siglec ligand is a peptide or polypeptide sequence, e.g. an scFv or peptide derived from epratuzumab, e.g. PVl, PV2 or PV3, the modification may be performed by genetic engineering of the biotherapeutic to comprise the peptide / polypeptide sequence within the biotherapeutic. For example, the polynucleotide used to produce the biotherapeutic may be modified by standard molecular biology cloning techniques to include a polynucleotide sequence encoding the peptide / polypeptide in the same translational reading frame (" In frame"), such that upon transcription and translation of the biotherapeutic in a producing cell, the biotherapeutic will comprise the peptide / polypeptide sequence covalently associated with amino acids that make up the biotherapeutic, resulting in a biotherapeutic that is hypoimmunogenic. Preferably, the peptide / polypeptide sequence will be genetically engineered into a domain of the biotherapeutic that is not responsible for the therapeutic effect of the biotherapeutic, e.g. the enzymatic domain of an enzyme, the Fab or more specifically CDR domains of an antibody, etc. In the instance of modifying a viral particle, the peptide / polypeptide sequence will preferably be genetically engineered into a capsid or envelop protein so as to be exposed to the exterior of the viral particle, e.g. into an exposed loop of a viral capsid protein, a surface-exposed tegument protein, etc. Such structural features are well understood by one of ordinary skill in the art of viral therapies.METHODS OF USE
[0136] Provided are methods of using the conjugates. Provided is a method of treating a patient for a condition, the method comprising: administering to the patient a pharmaceutical composition comprising a Siglec-ligand conjugate as described herein. In some cases, the subject has a disorder, a disease, or a combination thereof, wherein the administration of the Siglec-ligand conjugate treats the disorder, the disease, or the combination thereof. As usedAttorney Reference: ADTH-010WO herein, some conditions can be considered disorders, some conditions can be considered diseases, and some conditions can be considered both disorders and diseases. In some cases, the disorder, the disease, or combination thereof is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, phenylketonuria, juvenile idiopathic arthritis, leukemia, colorectal cancer, a non-small cell lung cancer, a head and neck cancer, multiple sclerosis, Type 2 Diabetes, gout, immune thrombocytopenia, organ transplantation (e.g., kidney), NMOSD / neuromyelitis optica, anti-phospholipid syndrome, membrane nephritis, myasthenia gravis, pemphigus vulgaris, and combinations thereof.
[0137] The hypoimmunogenic compositions of the present disclosure find particular use in the treatment of diseases that require repeat or chronic administration of the therapeutic to be effective. There are many instances of such conditions, of which a few nonlimiting examples are provided below and elsewhere. It is expected that the ordinarily skilled artisan will be able to extrapolate from these examples to other indications and biotherapeutics as known in the art.
[0138] For example, the individual may be suffering from a chronic autoimmune or inflammatory disease, e.g. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. In such instances, the method may comprise administering to the individual a hypoimmunogenic TNFot-specific antibody, e.g. a hypoimmunogenic adalimumab engineered from adalimumab, or a hypoimmunogenic infliximab engineered from infliximab, in an amount effective to treat the chronic immune disease.
[0139] As another example, the individual may be suffering from a leukemia, e.g. ALL. In such instances, the method may comprise administering to the individual an engineered hypoimmunogenic asparaginase from Erwinia chrysanthemi in an amount effective to treat the leukemia.
[0140] As another example, the individual may be suffering from a colorectal cancer, a non-small cell lung cancer, or a head and neck cancer. In such instances, the method may comprise administering to the individual an engineered hypoimmunogenic cetuximab in an amount effective to treat the colorectal cancer, non-small cell lung cancer, or head and neck cancer.
[0141] As another example, the individual may be suffering from multiple sclerosis. In such instances, the method may comprise administering to the individual an engineeredAttorney Reference: ADTH-010WO hypoimmunogenic natalizumab, an engineered hypoimmunogenic IFN[3-lb, or an engineered hypoimmunogenic IFN[3-la in an amount effective to treat the multiple sclerosis.
[0142] As another example, the individual may be the recipient of an organ transplant and in need of an immunosuppressive agent that protects the transplanted tissue from rejection by the individual's immune system. In such instances, the method may comprise administering to the individual an engineered hypoimmunogenic IdeS in an amount effective to prevent an antibody response to the transplanted tissue. In some embodiments, the transplanted organ is an allogeneic graft. In some embodiments, the transplanted organ is a xenogeneic graft. In some embodiments, the organ is selected from kidney, heart, lung, liver, pancreas, trachea, vascular tissue, skin, bone, cartilage, adrenal tissue, fetal thymus, and cornea.
[0143] As another example, the individual may be suffering from Type 2 Diabetes. In such instances, the method would comprise administering to the individual an engineered hypoimmunogenic exenatide or engineered hypoimmunogenic a Ibiglutide in an amount effective to treat the diabetes.
[0144] As another example, the individual may be suffering from a complement-mediated disease. In such instances, the method would comprise administering to the individual an engineered hypoimmunogenic complement degrading protease, e.g. from a pathogen such as a bacterial pathogen or fungal pathogen (e.g. Pseudomonas Elastase (PaE), Pseudomonas Alkaline protease (PaAP), Streptococcal pyrogenic Exotoxin B (SpeB), a gingipain from Porphyromonas gingivalis, Aspergillus Alkaline protease 1 (Alpl), C. albicans Secreted aspartyl proteinases 1 (Sapl), 2 (Sap2), and 3 (Sap3), in an amount effective to degrade complement and treat the disease.
[0145] As another example, the individual may be suffering from an enzyme deficiency. In such instances, the method would comprise administering to the individual an engineered hypoimmunogenic enzyme in an amount effective to treat the deficiency. Nonlimiting examples of such enzyme deficiencies would include PKU, wherein a hypoimmunogenic phenylalanine ammonia-lyase would be administered; Fabry disease, wherein a hypoimmunogenic alpha-galactosidase A would be administered; Pompe disease, wherein a hypoimmunogenic acid ot-glucosidase (GAA) would be administered; Gaucher disease, wherein a hypoimmunogenic glucocerebrosidase (GCase) would be administered;Aspartylglucosaminuria, wherein a hypoimmunogenic aspartylglucosaminidase (AGA) would be administered; Hypophosphatasia (HPP), wherein a hypoimmunogenic asfotase would beAttorney Reference: ADTH-010WO administered; MPS I, wherein a hypoimmunogenic alpha-L-iduronidase would be administered; MPS II, wherein a hypoimmunogenic iduronate sulfatase would be administered; MPS Illa, wherein a hypoimmunogenic sulfaminase would be administered; MPS II IB, wherein a hypoimmunogenic a-N-acetylglucosaminidase (NAGLU) would be administered; MPS I IIC, wherein a hypoimmunogenic heparin acetyle CoA: ot-glucosaminide N-acetyltransferase (HGSNAT) would be administered; MPS HID, wherein a hypoimmunogenic N-acetylglucosamine 6-sulfatase (GNS) would be administered; MPS HIE, wherein a hypoimmunogenic N-glucosamine 3-O-sulfatase (arylsulfatase G or ARSG) would be administered; MPS IVA, wherein a hypoimmunogenic N-acetylgalactosamine 6-sulfatase would be administered; MPS IVB, wherein a hypoimmunogenic beta-galactosidase would be administered; MPS VI, wherein a hypoimmunogenic N-acetylgalactosamine 4-sulfatase would be administered; MPS VI, wherein a hypoimmunogenic beta-glucuronidase would be administered; Hemophilia A, wherein a hypoimmunogenic Factor VIII would be administered; Hemophilia B, wherein a hypoimmunogenic Factor IX would be administered; the CLN1 form of Batten Disease, wherein a hypoimmunogenic palmitoyl protein thioesterase (PPT1) would be administered; the CLN2 form of Batten Disease, wherein a hypoimmunogenic Tripeptidyl peptidase (TPP1) would be administered; arginase-1 deficiency, wherein a hypoimmunogenic arginase-1 or pegzilarginase would be administered; and cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria, wherein a hypoimmunogenic cystathionine beta synthase or Aeglea product AGLE-177 is administered.
[0146] As another example, the individual may be suffering from disease that would benefit from a gene therapy, e.g. a genetic disease, or a complex disease (i.e. not restricted to being associated with a specific genetic etiology) in which chronic expression of a therapeutic RNA or protein would treat the condition. In such instances, the method would comprise administering to the individual an engineered hypoimmunogenic viral particle comprising a polynucleotide sequence (a "transgene") encoding the therapeutic gene product of interest, in an amount effective to treat the disease. Nonlimiting examples of suitable transgenes / gene products that one might deliver via the subject hypoimmunogenic viral particle include those associated with muscular dystrophy, cystic fibrosis, familial hypercholesterolemia, and rare or orphan diseases. Examples of such rare disease may include spinal muscular atrophy (SMA), Huntingdon's Disease, Rett Syndrome (e.g., methyl-CpG-binding protein 2 (MeCP2); UniProtKB - P51608), Amyotrophic Lateral Sclerosis (ALS), Duchenne Type Muscular dystrophy, Friedrichs Ataxia (e.g., frataxin), ATXN2 associated with spinocerebellar ataxia type 2 (SCA2) / ALS; TDP-43Attorney Reference: ADTH-010WO associated with ALS, progranulin (PRGN) (associated with non- Alzheimer's cerebral degenerations, including, frontotemporal dementia (FTD), progressive non-fluent aphasia (PNFA) and semantic dementia), among others. See, e.g., www.orpha.net / consor / cgi-bin / Disease_Search_List.php; rarediseases.info.nih.gov / diseases.
[0147] Other useful therapeutic gene products that could be encoded by the transgene also include hormones and growth and differentiation factors including, without limitation, insulin, glucagon, glucagon-like peptide 1 (GLP-1), growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiopoietins, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), transforming growth factor a (TGFa), platelet-derived growth factor (PDGF), insulin growth factors I and II (IGF-I and IGF-II), any one of the transforming growth factor b superfamily, including TGF b, activins, inhibins, or any of the bone morphogenic proteins (BMP) BMPs 1-15, any one of the heregluin / neuregulin / ARIA / neu differentiation factor (NDF) family of growth factors, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophins NT-3 and NT-4 / 5, ciliary neurotrophic factor (CNTF), glial cell line derived neurotrophic factor (GDNF), neurturin, agrin, any one of the family of semaphorins / collapsins, netrin-1 and netrin-2, hepatocyte growth factor (HGF), ephrins, noggin, sonic hedgehog and tyrosine hydroxylase.
[0148] Other useful transgenes include those that encode proteins that regulate the immune system including, without limitation, cytokines and lymphokines such as thrombopoietin (TPO), interleukins (IL) IL-1 through IL-25 (including, IL-2, IL-4, IL-12, and IL-18), monocyte chemoattractant protein, leukemia inhibitory factor, granulocyte-macrophage colony stimulating factor, Fas ligand, tumor necrosis factors a and b, interferons a, b, and g, stem cell factor, Hk-2 / flt3 ligand. Gene products produced by the immune system are also useful in the invention. These include, without limitations, immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II MHC molecules, as well as engineered immunoglobulins and MHC molecules. Useful gene products also include complement regulatory proteins such as complement regulatory proteins, membrane cofactor protein (MCP), decay accelerating factor (DAF), CR1, CF2 and CD59.Attorney Reference: ADTH-010WO
[0149] Still other useful transgenes include those that encode gene products for any one of the receptors for the hormones, growth factors, cytokines, lymphokines, regulatory proteins and immune system proteins.
[0150] Still other useful transgenes include those encoding receptors for cholesterol regulation, including the low density lipoprotein (LDL) receptor, high density lipoprotein (HDL) receptor, the very low density lipoprotein (VLDL) receptor, and the scavenger receptor. The invention also encompasses gene products such as members of the steroid hormone receptor superfamily including glucocorticoid receptors and estrogen receptors, Vitamin D receptors and other nuclear receptors. In addition, useful gene products include transcription factors such as jun,fos, max, mad, serum response factor (SRF), AP-1, AP2, myb, MyoD and myogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C / EBP, SP1, CCAAT-box binding proteins, interferon regulation factor (IRF-1), Wilms tumor protein, ETS-binding protein, STAT, GATA-box binding proteins, e.g., GATA-3, and the forkhead family of winged helix proteins.
[0151] Other useful gene products include, carbamoyl synthetase I, ornithine transcarbamylase, arginosuccinate synthetase, arginosuccinate lyase, arginase, fumarylacetacetate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, glucose-e-phosphatase, porphobilinogen deaminase, Factor VIII, Factor IX, cystathione beta-synthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-coA dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin, betaglucosidase, pyruvate carboxylate, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein, T-protein, a cystic fibrosis transmembrane regulator (CFTR) sequence, and a dystrophin sequence or functional fragment thereof. Still other useful gene products include enzymes such as may be useful in enzyme replacement therapy, which is useful in a variety of conditions resulting from deficient activity of enzyme. For example, enzymes that contain mannose-6-phosphate may be utilized in therapies for lysosomal storage diseases (e.g., a suitable gene includes that encodes b-glucuronidase (GUSB)). In another example, the gene product is ubiquitin protein ligase E3A (UBE3A). Still useful gene products include UDP Glucuronosyltransferase Family 1 Member Al (UGT1A1).
[0152] In some embodiment, the gene product is not Factor VIII.
[0153] Other useful gene products include non-naturally occurring polypeptides, such as chimeric or hybrid polypeptides having a non-naturally occurring amino acid sequenceAttorney Reference: ADTH-010WO containing insertions, deletions or amino acid substitutions. For example, single-chain engineered immunoglobulins could be useful in certain immunocompromised patients. Other types of non-naturally occurring gene sequences include antisense molecules and catalytic nucleic acids, such as ribozymes, which could be used to reduce overexpression of a target.
[0154] Reduction and / or modulation of expression of a gene is particularly desirable for treatment of hyperproliferative conditions characterized by hyperproliferating cells, as are cancers and psoriasis. Target polypeptides include those polypeptides which are produced exclusively or at higher levels in hyperproliferative cells as compared to normal cells. Target antigens include polypeptides encoded by oncogenes such as myb, myc, fyn, and the translocation gene bcr / abl, ras, src, P53, neu, trk and EGRF. In addition to oncogene products as target antigens, target polypeptides for anti-cancer treatments and protective regimens include variable regions of antibodies made by B cell lymphomas and variable regions of T cell receptors of T cell lymphomas which, in some embodiments, are also used as target antigens for autoimmune disease. Other tumor-associated polypeptides can be used as target polypeptides such as polypeptides which are found at higher levels in tumor cells including the polypeptide recognized by monoclonal antibody 17-1A and folate binding polypeptides.
[0155] Other suitable transgenes include those which encode therapeutics that may be useful for treating individuals suffering from autoimmune diseases and disorders by conferring a broad based protective immune response against targets that are associated with autoimmunity including cell receptors and cells which produce self-directed antibodies. T cell mediated autoimmune diseases include Rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome, sarcoidosis, insulin dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease and ulcerative colitis. Each of these diseases is characterized by T cell receptors (TCRs) that bind to endogenous antigens and initiate the inflammatory cascade associated with autoimmune diseases.
[0156] Still other useful gene products include those used for treatment of hemophilia, including hemophilia B (including Factor IX) and hemophilia A (including Factor VIII and its variants, such as the light chain and heavy chain of the heterodimer and the B-deleted domain; US Patent No. 6,200,560 and US Patent No. 6,221,349). In some embodiments, the minigene comprises first 57 base pairs of the Factor VIII heavy chain which encodes the 10 amino acidAttorney Reference: ADTH-010WO signal sequence, as well as the human growth hormone (hGH) polyadenylation sequence. In alternative embodiments, the minigene further comprises the Al and A2 domains, as well as 5 amino acids from the N-terminus of the B domain, and / or 85 amino acids of the C-terminus of the B domain, as well as the A3, Cl and C2 domains. In yet other embodiments, the nucleic acids encoding Factor VIII heavy chain and light chain are provided in a single mini gene separated by 42 nucleic acids coding for 14 amino acids of the B domain [US Patent No.6,200,560],
[0157] Further illustrative genes which may be delivered via the hypoimmunogenic viral particle include, without limitation, glucose-6-phosphatase, associated with glycogen storage disease or deficiency type 1A (GSD1), phosphoenolpyruvate-carboxy kinase (PEPCK), associated with PEPCK deficiency; cyclin-dependent kinase-like 5 (CDKL5), also known as serine / threonine kinase 9 (STK9) associated with seizures and severe neurodevelopmental impairment; galactose-1 phosphate uridyl transferase, associated with galactosemia; phenylalanine hydroxylase (PAH), associated with phenylketonuria (PKU); gene products associated with Primary Hyperoxaluria Type 1 including Hydroxy acid Oxidase 1 (GO / HAOI) and AGXT, branched chain alpha-ketoacid dehydrogenase, including BCKDH, BCKDH-E2, BAKDH-Ela, and BAKDH-Elb, associated with Maple syrup urine disease; fumarylacetoacetate hydrolase, associated with tyrosinemia type 1; methylmalonyl-CoA mutase, associated with methylmalonic acidemia; medium chain acyl CoA dehydrogenase, associated with medium chain acetyl CoA deficiency; ornithine transcarbamylase (OTC), associated with ornithine transcarbamylase deficiency; argininosuccinic acid synthetase (ASS1), associated with citrullinemia; lecithin-cholesterol acyltransferase (LCAT) deficiency; amethylmalonic acidemia (MMA); NPC1 associated with Niemann-Pick disease, type Cl); propionic academia (PA); TTR associated with Transthyretin (TTR)-related Hereditary Amyloidosis; low density lipoprotein receptor (LDLR) protein, associated with familial hypercholesterolemia (FH), LDLR variant, such as those described in WO 2015 / 164778; PCSK9; ApoE and ApoC proteins, associated with dementia; UDP-glucouronosyltransferase, associated with Crigler-Najjar disease; adenosine deaminase, associated with severe combined immunodeficiency disease; hypoxanthine guanine phosphoribosyl transferase, associated with Gout and Lesch-Nyan syndrome; biotimidase, associated with biotimidase deficiency; alpha-galactosidase A (a-Gal A) associated with Fabry disease); beta-galactosidase (GLB1) associated with GM1 gangliosidosis; ATP7B associated with Wilson's Disease; beta-glucocerebrosidase, associated with Gaucher disease type 2 and 3; peroxisome membrane protein 70 kDa, associated with Zellweger syndrome; arylsulfatase AAttorney Reference: ADTH-010WO(ARSA) associated with metachromatic leukodystrophy, galactocerebrosidase (GALC) enzyme associated with Krabbe disease, alpha-glucosidase (GAA) associated with Pompe disease; sphingomyelinase (SMPD1) gene associated with Nieman Pick disease type A; argininosuccsinate synthase associated with adult onset type II citrullinemia (CTLN2); carbamoyl-phosphate synthase 1 (CPS1) associated with urea cycle disorders; survival motor neuron (SMN) protein, associated with spinal muscular atrophy; ceramidase associated with Farber lipogranulomatosis; b-hexosaminidase associated with GM2 gangliosidosis and Tay-Sachs and Sandhoff diseases; aspartylglucosaminidase associated with aspartyl-glucosaminuria; a-fucosidase associated with fucosidosis; a-mannosidase associated with alpha-mannosidosis; porphobilinogen deaminase, associated with acute intermittent porphyria (AIP); alpha- 1 antitrypsin for treatment of alpha- 1 antitrypsin deficiency (emphysema); erythropoietin for treatment of anemia due to thalassemia or to renal failure; vascular endothelial growth factor, angiopoietin-1, and fibroblast growth factor for the treatment of ischemic diseases; thrombomodulin and tissue factor pathway inhibitor for the treatment of occluded blood vessels as seen in, for example, atherosclerosis, thrombosis, or embolisms; aromatic amino acid decarboxylase (AADC), and tyrosine hydroxylase (TH) for the treatment of Parkinson's disease; the beta adrenergic receptor, anti-sense to, or a mutant form of, phospholamban, the sarco(endo)plasmic reticulum adenosine triphosphatase-2 (SERCA2), and the cardiac adenylyl cyclase for the treatment of congestive heart failure; a tumor suppressor gene such as p53 for the treatment of various cancers; a cytokine such as one of the various interleukins for the treatment of inflammatory and immune disorders and cancers; dystrophin or minidystrophin and utrophin or miniutrophin for the treatment of muscular dystrophies; and, insulin or GLP-1 for the treatment of diabetes.EMBODIMENTS
[0158] Notwithstanding the appended claims, the disclosure is also defined by, but not limited to, the following clauses:1. A Siglec ligand of formula (I):wherein:Attorney Reference: ADTH-010WOZ is a chemoselective functional group or ZT-T-Z2;Z1is a diradical group;T is absent or a diradical group;Z2 is a chemoselective functional group;A1is absent or alkylene;A2is alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof;R2is -COOH, -P(O)(OH)2, -OSO2OH, -CfOjNHSChH, tetrazole, an ester, or a substituted version thereof;R3is H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, ora substituted version thereof;R4is hydroxy, alkoxy, amino, amide, or a substituted version thereof;R5is H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene-l, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof;R7is hydroxy or halo;X1is 0, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-;E1is absent, -(substituted or unsubstituted C1-C6alkyleneoxy)g-, -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)q-, -(substituted or unsubstituted C1-C6alkylene)gO-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)qO-, -(substituted or unsubstituted C1-C6alkylene)gO(substituted or unsubstituted C1-C6alkylene)q-, benzyl, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyloxy, cycloalkyl, or a substituted version thereof;g is an integer ranging from 1 to 15;q is an integer ranging from 1 to 15;Y is absent, alkylene, phenylene, substituted phenylene, -0-, -NH-, -S-, -C=C-, -CH2C= C-, -C(0)-, -0P(0)0-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -(alkylene)triazole-such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as -(methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(substituted or unsubstituted C1-C6alkyleneoxy)n-, -(substituted or unsubstituted C1-C6alkylene)n-;n is an integer ranging from 1 to 15;X2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m-, -(substituted or unsubstitutedAttorney Reference: ADTH-010WOCi-Ce alkylene)m-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkylene)mO-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)mC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)-, -(substituted or unsubstituted C1-C6alkylene)mC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)O-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-triazole-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-triazole, -(substituted or unsubstituted C1-C6alkylene)m-triazole, -(substituted or unsubstituted C1-C6alkylene)mOtriazole-, triazole, -(methylene)triazole-, -(methylene)triazole(methylene)-, ora substituted version thereof;m is an integer ranging from 1 to 15;w is an integer ranging from 1 to 15;E2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h-, -(substituted or unsubstituted C1-C6alkylene)h-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hO-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xO-, -(substituted or unsubstituted C1-C6alkylene)hO(substituted or unsubstituted C1-C6alkylene)x-, -Attorney Reference: ADTH-010WO(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)-, -(substituted or unsubstituted C1-C6alkylene)hC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hOC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted orAttorney Reference: ADTH-010WO unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, (substituted or unsubstituted C1-C6alkylene)C(O)N(substituted or unsubstituted C1-C6alkylene)-, -C=C-, or -CH2C=C-, or a substituted version thereof;h is an integer ranging from 1 to 15; andx is an integer ranging from 1 to 15,or a salt thereof.2. The Siglec ligand of clause 1, wherein the Siglec ligand has a structure of formula (l-S):3. The Siglec ligand of any one of clauses 1-2, wherein R2is -COOH.4. The Siglec ligand of any one of clauses 1-3, wherein R5is -NH-C(O)-R5a;wherein R5ais substituted Ci-Ce alkyl or unsubstituted Ci-Ce alkyl.5. The Siglec ligand of clause 4, wherein R5ais substituted Ci-Ce alkyl.6. The Siglec ligand of clause 5, wherein R5ais substituted methyl, substituted ethyl, or substituted propyl.7. The Siglec ligand of any one of clauses 5-6, wherein R5ais substituted with -OR5bor -NR5bR5c,wherein R5band R5care each independently H or Ci-Ce alkyl.8. The Siglec ligand of clause 7, wherein R5ais substituted with -OR5b.9. The Siglec ligand of clause 8, wherein R5ais -CH2OH.10. The Siglec ligand of clause 7, wherein R5ais substituted with -NR5bR5c,Attorney Reference: ADTH-010WO11. The Siglec ligand of clause 10, wherein R5ais -CH2N(CH3)2.12. The Siglec ligand of clause 4, wherein R5ais unsubstituted Ci-Ce alkyl.13. The Siglec ligand of any one of clauses 1-12, whereinis selected from the group consisting of:Attorney Reference: ADTH-010WO14. The Siglec ligand of any one of clauses 1-12, whereinis selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO15. The Siglec ligand of any one of clauses 1-14, wherein A1is absent or unsubstituted alkylene.16. The Siglec ligand of any one of clauses 1-15, wherein A2is unsubstituted aryl or substituted aryl.17. The Siglec ligand of any one of clauses 1-16, wherein R3is H.18. The Siglec ligand of any one of clauses 1-17, wherein R4is hydroxy.19. The Siglec ligand of any one of clauses 1-18, wherein R7is hydroxy.20. The Siglec ligand of any one of clauses 1-19, wherein X1is absent, -O-, -NH-, or -S-.21. The Siglec ligand of any one of clauses 1-20, wherein E1is absent, -(CH2CH2O)g-, -(CH2)g-, - (CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, -(CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl.22. The Siglec ligand of any one of clauses 1-22, wherein E1is -(CH2)g-, -(CH2)gO-, or -(CH2)gO(CH2)q-.23. The Siglec ligand of clause 22, wherein E1is a group with subscript g and g is an integer ranging from 1 to 10.Attorney Reference: ADTH-010WO24. The Siglec ligand of any one of clauses 22-23, wherein E1is a group with subscript q and q is an integer ranging from 1 to 10.25. The Siglec ligand of any one of clauses 22-24, wherein E1is a group with subscript g and q, wherein g + q = 5, 6, 7, or 8.26. The Siglec ligand of any one of clauses 1-25, wherein Y is OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, -NHC(O)O-, -NHC(O)NH-, -OC(O)O-, or triazole.27. The Siglec ligand of clause 26, wherein Y is triazole, -NH-(cyclobut-3-ene-l,2-dione)-NH-, or -NHC(O)-.28. The Siglec ligand of any one of clauses 1-27, wherein X2is -(CH2CH2O)m-, -(CH2)m-, -(CH2CH2O)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10.29. The Siglec ligand of any one of clauses 1-28, wherein E2is -(CH2)h, wherein h is an integer ranging from 1 to 10.30. The Siglec ligand of any one of clauses 1-29, wherein Z is selected from the group consisting of esters, isocyanates, isothiocyanates, sulfonyl chlorides, aldehydes, carbodiimides, acyl azides, anhydrides, fluorobenzenes, carbonates, epoxides, hydroxymethyl phosphines, maleimides, haloacetyls, pyridyl disulfides, thiosulfonates, vinyl sulfones, and squaramates.31. The Siglec ligand of clause 30, wherein Z is maleimide or a pentafluorophenyl ester.32. The Siglec ligand of any one of clauses 1-31, wherein the Siglec ligand has a structure selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO33. The Siglec ligand of any one of clauses 1-31, wherein the Siglec ligand has a structure selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO34. A Siglec-liga nd conjugate of formula (VII):wherein:y is an integer from 1 to 20;BAS is a biologically active substance;Z' is a divalent group;A1is absent or alkylene;A2is alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof;R2is -COOH, -P(O)(OH)2, -OSO2OH, -C(O)NHSO2H, tetrazole, an ester, or a substituted version thereof;R3is H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, ora substituted version thereof;R4is hydroxy, alkoxy, amino, amide, or a substituted version thereof;R5is H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene-l, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof;Attorney Reference: ADTH-010WOR7is hydroxy or halo;X1is 0, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-;E1is absent, -(substituted or unsubstituted C1-C6alkyleneoxy)g-, -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)q-, -(substituted or unsubstituted C1-C6alkylene)gO-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)qO-, -(substituted or unsubstituted C1-C6alkylene)gO(substituted or unsubstituted C1-C6alkylene)q-, benzyl, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyloxy, cycloalkyl, or a substituted version thereof;g is an integer ranging from 1 to 15;q is an integer ranging from 1 to 15;Y is absent, alkylene, phenylene, substituted phenylene, -0-, -NH-, -S-, -C=C-, -CH2C= C-, -C(0)-, -0P(0)0-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -(alkylene)triazole-such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as -(methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(substituted or unsubstituted C1-C6alkyleneoxy)n-, -(substituted or unsubstituted C1-C6alkylene)n-;n is an integer ranging from 1 to 15;X2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m-, -(substituted or unsubstituted C1-C6alkylene)m-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkylene)mO-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)mC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)-, -(substituted or unsubstituted C1-C6alkylene)mC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)O-, -(substituted or unsubstituted Ci-CeAttorney Reference: ADTH-010WO alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-triazole-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-triazole, -(substituted or unsubstituted C1-C6alkylene)m-triazole, -(substituted or unsubstituted C1-C6alkylene)mOtriazole-, triazole, -(methylene)triazole-, -(methylene)triazole(methylene)-, ora substituted version thereof;m is an integer ranging from 1 to 15;w is an integer ranging from 1 to 15;E2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h-, -(substituted or unsubstituted C1-C6alkylene)h-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hO-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xO-, -(substituted or unsubstituted C1-C6alkylene)hO(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH(substituted orAttorney Reference: ADTH-010WO unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)-, -(substituted or unsubstituted C1-C6alkylene)hC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hOC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, (substituted or unsubstituted C1-C6alkylene)C(O)N(substituted or unsubstituted C1-C6alkylene)-, -C=C-, or -CH2C=C-, or a substituted version thereof;h is an integer ranging from 1 to 15; andx is an integer ranging from 1 to 15,or a salt thereof.Attorney Reference: ADTH-010WO35. The Siglec-I iga nd conjugate of clause 34, wherein Z' is a divalent group selected from the group consisting of:wherein:*** represents covalent connection to E2;s **** represents covalent connection to BAS.36. The Siglec-I iga nd conjugate of any one of clauses 34-35, wherein BAS is a protein, a biotherapeutic, an autoantigen, an enzyme, an antibody, a nanoparticle, or a combination thereof.37. The Siglec-I iga nd conjugate of any one of clauses 34-36, wherein R2is -COOH.38. The Siglec-I iga nd conjugate of any one of clauses 34-37, wherein R5is -NH-C(O)-R5a; wherein R5ais substituted Ci-Ce alkyl or unsubstituted Ci-Ce alkyl.39. The Siglec-I iga nd conjugate of clause 38, wherein R5ais substituted Ci-Ce alkyl.40. The Siglec-I iga nd conjugate of clause 39, wherein R5ais substituted methyl, substituted ethyl, or substituted propyl.41. The Siglec-I iga nd conjugate of any one of clauses 39-40, wherein R5ais substituted with -OR5bor -NR5bR5c,wherein R5band R5care each independently H or Ci-Ce alkyl.42. The Siglec-I iga nd conjugate of clause 41, wherein R5ais substituted with -OR5b.43. The Siglec-I iga nd conjugate of clause 42, wherein R5ais -CH2OH.44. The Siglec-I iga nd conjugate of clause 41, wherein R5ais substituted with -NR5bR5c,Attorney Reference: ADTH-010WO45. The Siglec-ligand conjugate of clause 44, wherein R5ais -CH2N(CH3)2.46. The Siglec-ligand conjugate of clause 38, wherein R5ais unsubstituted Ci-Ce alkyl.47. The Siglec-ligand conjugate of any one of clauses 34-46, whereinis selected from the group consisting of:Attorney Reference: ADTH-010WO48. The Siglec-ligand conjugate of any one of clauses 34-47, wherein the Siglec-liga nd conjugate has a structure selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO49. The Siglec-I iga nd conjugate of any one of clauses 34-49, wherein A1is absent or unsubstituted alkylene.50. The Siglec-I iga nd conjugate of any one of clauses 34-49, wherein A2is unsubstituted aryl or substituted aryl or alkyl.51. The Siglec-I iga nd conjugate of any one of clauses 34-50, wherein R3is H.Attorney Reference: ADTH-010WO52. The Siglec-I iga nd conjugate of any one of clauses 34-51, wherein R4is hydroxy.53. The Siglec-I iga nd conjugate of any one of clauses 34-52, wherein R7is hydroxy.54. The Siglec-I iga nd conjugate of any one of clauses 34-53, wherein X1is absent, -0-, -NH-, or - S-.55. The Siglec-I iga nd conjugate of any one of clauses 34-54, wherein E1is absent, -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, -(CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl.56. The Siglec-I iga nd conjugate of any one of clauses 34-55, wherein E1is -(CH2)g-, -(CH2)gO-, or -(CH2)gO(CH2)q-.57. The Siglec-I iga nd conjugate of clause 56, wherein E1is a group with subscript g and g is an integer ranging from 1 to 10.58. The Siglec-I iga nd conjugate of clause 56 or 57, wherein E1is a group with subscript q and q is an integer ranging from 1 to 10.59. The Siglec-I iga nd conjugate of any one of clauses 56-58, wherein E1is a group with subscript g and q, wherein g + q = 5, 6, 7, or 8. U 6560. The Siglec-I iga nd conjugate of any one of clauses 34-59, wherein Y is OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, -NHC(O)O-, -NHC(O)NH-, -OC(O)O-, or triazole.61. The Siglec-I iga nd conjugate of clause 60, wherein Y is triazole, -NH-(cyclobut-3-ene-l,2-dione)-NH-, or -NHC(O)-.62. The Siglec-I iga nd conjugate of any one of clauses 34-61, wherein X2is -(CH2CH2O)m-, -(CH2)m-, -(CH2CH2O)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -Attorney Reference: ADTH-010WO(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10.63. The Siglec-I iga nd conjugate of any one of clauses 34-62, wherein E2is -(CH2)h, wherein h is an integer ranging from 1 to 10.64. A pharmaceutical composition comprising a Siglec-liga nd conjugate according to any one of clauses 34-63.65. The pharmaceutical composition of clause 64, further comprising an excipient, a solvent, a diluent, a binder, a disintegrant, an antioxidant, a preservative, or a combination thereof.66. The pharmaceutical composition of clause 65, wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient.67. A method of manufacturing a Siglec-I iga nd conjugate, the method comprising:covalently attaching a Siglec ligand according to any one of clauses 1-33 to a biologically active substance (BAS) to thereby generate the Siglec-ligand conjugate.68. A method of treating a subject, the method comprising:administering to the subject a pharmaceutical composition comprising a Siglec-ligand conjugate according to any one of clauses 64-66.69. The method of clause 68, wherein the subject has a disorder, a disease, or a combination thereof, wherein the administration of the Siglec-ligand conjugate treats the disorder, the disease, or the combination thereof.70. The method of clause 69, wherein the disorder, the disease, or combination thereof is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, phenylketonuria, juvenile idiopathic arthritis, leukemia, colorectal cancer, a non-small cell lung cancer, a head and neck cancer, multiple sclerosis, Type 2 Diabetes, gout, immune thrombocytopenia, organ transplantation (e.g., kidney), NMOSD / neuromyelitis optica, antiAttorney Reference: ADTH-010WO phospholipid syndrome, membrane nephritis, myasthenia gravis, pemphigus vulgaris, and combinations thereof.EXAMPLES
[0159] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for.General Synthetic Procedures
[0160] Many general references providing commonly known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds are available (see, e.g., Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-lnterscience, 2001; or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).
[0161] During any of the processes for preparation of the subject compounds, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups as described in standard works, such as J. F. W. McOmie, " Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, " Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999, in " The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in " Methoden der organischen Chemie", Houben-Weyl, 4th edition, Vol. 15 / 1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, " Aminosauren, Peptide, Proteine", Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and / or in Jochen Lehmann, " Chemie der Kohlenhydrate: Monosaccharide and Derivate", Georg Thieme Verlag, Stuttgart 1974. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
[0162] The subject compounds can be synthesized via a variety of different synthetic routes using commercially available starting materials and / or starting materials prepared byAttorney Reference: ADTH-010WO conventional synthetic methods. A variety of examples of synthetic routes that can be used to synthesize the compounds disclosed herein are described in the schemes below.
[0163] All synthetic chemistry was performed in standard laboratory glassware, under inert atmosphere and anhydrous conditions unless indicated otherwise in the examples. Commercial reagents were used as received.
[0164] Analytical LC / MS was performed either on a Shimadzu LCMS-2020 equipped with a Phenomenex Jupiter® 3 pm C18300 A, LC Column 50 x 2 mm, using LabSolutions software. Retention times were determined from the extracted 214 and / or 254 nm UV chromatogram or an Agilent 1290 Infinity RRLC attached with Agilent 6120 Mass detector and Diode array Detector and equipped with a YMC Triart C18 (150 x 4.6mm), 5 pm column. Unless specified, the LC / MS analytical method on the Shimadzu used a gradient 5-100% acetonitrile in water (+0.1% TFA) over 4.25 mins. LC / MS analytical method on the Agilent 6120 used a gradient 10-100% acetonitrile in water (+0.05% TFA) over 11 mins. HPLC was performed on an Agilent 1260 infinity series HPLC with PDA detector equipped with a YMC Triart C18 (150 x 4.6mm), 5 pm column. Analytical method on the Agilent 1260 used a gradient 10-95% acetonitrile in water (+0.1% TFA) over 10 mins. Prep HPLC was performed either on a Teledyne ISCO ACCQPrep™ HP150 system (with 200-400 nm - UV PDA and ELSD detector) equipped with a Phenomenex Gemini® 10 pm NX-C18 110 A, LC column 250 x 50 mm, AXIA, a Gilson system using a 215 liquid handler, 333 and 334 pumps, UV / VIS-155 detector equipped with the same type of column and Trilution Ic software, or a Shimadzu LC 20 AP with SPD 20 A UV Detector equipped with a Waters™ Sunfire C18 (250 x 30mm), 5 pm column. Unless specified, prep HPLC purification used a gradient acetonitrile in water (+0.1% TFA).TH NMR was performed either on a Bruker 400 MHz Advance, a Bruker 500 MHz or a Bruker Fourier 300 MHz using Topspin software.Analytical thin layer chromatography was performed on silica (Sigma Aldrich TLC Silica gel 60 F254 aluminum or glass TLC plate, silica gel coated with fluorescent indicator F254) and was visualized under UV light then stained with either potassium permanganate or phosphomolybdic acid stain solutions. Silica gel chromatography was performed with Teledyne ISCO CombiFlash Rf+ automated chromatography for gradient elution. Removal of aqueous and high boiling point solvents was usually performed by lyophilization using a Labconco Freezone® 4.5 Plus -84 °C connected to a Labconco Rotary Vane Vacuum Pump, 195 LPM.Attorney Reference: ADTH-010WOEXAMPLE 1: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 1).Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (3)
[0165] To a stirred solution (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(p-tolylthio)tetrahyd ro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l, 2-diyl diacetate (1) (3 g, 3.92 mmol), 2-(2-(prop-2-yn-l-yloxy)ethoxy)ethan-l-ol (2) (0.68 g, 4.7 mmol) and Silver (1+) trifluoro methane sulfonate (AgOTf) (2.51 g, 9.80 mmol) in anhydrous dichloromethane (36 mL) and anhydrous acetonitrile (54 mL) was added activated 4 A powdered molecular sieves (5 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen. The reaction mixture was cooled to -78 °C, iodine monobromide (1.22 g, 5.88 mmol) dissolved in dichloromethane (4 mL) was added dropwise, and the resulting mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched by addition of triethylamine (1.3 mL) and allowed to stir at room temperature for 1 h. The reaction mixture was filtered, the filtrate was washed with aqueous sodium thiosulfate solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to affordAttorney Reference: ADTH-010WOthe desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (3) as off-white solid, Yield: 1.3 g, 43%.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid (4)
[0166] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (3) (1.3 g, 1.66 mmol) in methanol (16 mL) and water (4 mL) was added 25% sodium methoxide in methanol (2.27 mL, 9.96 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 6 h. After completion the reaction mixture was treated with an acidic resin (Dowex 50, H+) until pH~6, the suspension was filtered and the filtrate was concentrated to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid (4) as off-white solid, Yield: 700 mg, 70%. LCMS (ESI±) m / z 603.5 [M+H]+.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid CMPD ID 1)
[0167] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (4) (300 mg, 0.49 mmol) and perfluorophenyl l-azido-3,6,9,12-tetraoxapentadecan-15-oate (5) (224 mg, 0.49 mmol) in N-Methyl-2-Pyrrilidone (3 mL) was added Tetrakis (acetonitrile) copper (I) hexafluoro phosphate (278mg, 0.75 mmol) and the reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 1 as an off-white solid. Yield: 67 mg, 12.7%. LCMS (ESI+) m / z 1060.6 [M+H]+.XH NMR (400 MHz, MeOD) 68.06 (s, 1H), 7.31 (d, J = 1.9 Hz, 4H), 4.66 (s, 2H), 4.59 (t, J = 5.1 Hz, 2H), 4.03 (s, 2H), 3.89 (dt, J = 13.2, 5.5 Hz, 8H), 3.81 (d, J = 9.7 Hz, 1H), 3.73 (d, J = 9.5 Hz, 9H), 3.69 - 3.60 (m, 10H), 3.54 (s, 2H), 3.38 (dd, J = 8.5, 1.8 Hz, 1H), 3.25 (dd, J = 13.9, 8.1 Hz, 1H), 2.99 (t, J = 5.9 Hz, 2H), 2.78 - 2.70 (m, 1H), 1.76 (t, J = 11.8 Hz, 1H), 1.31 (s, 1H).Attorney Reference: ADTH-010WOEXAMPLE 2: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-((6-(4-(14-oxo-14-(perfluorophenoxy)-2,5,8,ll-tetraoxatetradecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 2).Synthesis of(2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-((6-(4-(14-oxo-14-(perfluorophenoxy)-2,5,8,ll-tetraoxatetradecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylicacid (CMPD ID 2)
[0168] To a stirred solution of (2R,4S,5R,6R)-2-((6-azidohexyl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihyd roxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (150 mg, 0.24 mmol), perfluorophenyl 4,7,10,13-tetraoxahexadec-15-ynoate (1) (106 mg, 0.24 mmol), and Tetrakis(acetonitrile)copper(l) hexafluorophosphate (139 mg, 0.37 mmol) in anhydrous NMP (2 mL) and the reaction mixture was stirred at room temperature for 2 h under nitrogen atmosphere. After completion, the reaction mixture was purified by prep-HPLC purification by using acetonitrile and water (+0.05%, TFA) to afford the desired product CMPD ID 2 as off white solid, Yield: 70 mg, 27%. LCMS (ESI-) m / z 1026.6 [M-H]-.1H NMR (401 MHz, MeOD) 67.99 (s, 1H), 7.30 (s, 4H), 4.65 (s, 2H), 4.40 (t, J = 7.1 Hz, 2H), 4.04 (s, 2H), 3.93 - 3.88 (m, 2H), 3.88 - 3.77 (m, 3H), 3.77 - 3.72 (m, 1H), 3.72 - 3.59 (m, 11H), 3.54 (s, 2H), 3.46 - 3.35 (m, 1H), 3.31 - 3.19 (m, 2H), 2.98 (t, J = 5.9 Hz, 2H), 2.72 (dd, J = 12.9, 4.1 Hz, 1H), 1.91 (p, J = 7.2 Hz, 2H), 1.79 - 1.68 (m, 1H), 1.55 (p, J = 6.7 Hz, 2H), 1.44 - 1.29 (m, 5H).Attorney Reference: ADTH-010WOEXAMPLE 3: (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 3).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((2, 2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1)
[0169] To a stirred solution of methyl (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-d ihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3, 8, 11, 14, 17-pentaoxa-5-aza nonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylate (3.1 g, 3.13 mmol) in MeOH (9 mL) and water (1 mL) was added LiOH. I-hO (385 mg, 9.39 mmol) at room temperature and the resulting reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was treated with an acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered. The filtrate was concentrated under reduced pressure and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1) as an off white solid, Yield: 2.4 g, 78%. LCMS (ESI+) m / z 974.1 [M-H] ’.Attorney Reference: ADTH-010WOSynthesis of(2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (2)
[0170] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-d ihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3, 8, 11, 14, 17-pentaoxa-5-aza nonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1) (2.4 g, 2.46 mmol) in anhydrous DCM (20 mL) was added TFA (0.9 mL, 7.37 mmol) at room temperature and the resulting reaction mixture was stirred at room temperature for 3 h. After completion, the reaction mixture was concentrated under reduced pressure and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-4-hyd roxy-5-(2-hyd roxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (2) as an off white solid, Yield: 1.2 g, 56%. LCMS (ESI+) m / z 876.0 [M+H] +Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 3)
[0171] To a stirred solution of (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-4-hyd roxy-5-(2-hyd roxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (2) (200 mg, 0.23 mmol) in N, N-dimethyl formamide (10 mL) was added bis(perfluorophenyl) 3,3'-oxydipropionate (564 mg, 1.14 mmol) at -20 °C then added DIEA (0.12 mL, 0.92 mmol) at same temperature. The resulting reaction mixture was stirred at -20 °C for 1.5 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 3 as an off-white solid. Yield: 121 mg, 45%; LCMS (ESI-) m / z 1184.0 [M-H] ’.1H NMR (400 MHz, MeOD): 67.87 (t, J = 1.6 Hz, 1H), 7.77 (dt, J = 7.6 Hz, 1.6 Hz, 1H), 7.56-7.53 (m, 1H), 7.46 (t, J = 8 Hz, 1H), 4.04 (s, 3H), 3.87-3.81 (m, 6H), 3.80-3.75 (m, 5H), 3.66-3.59 (m, 15H), 3.54 (t, J = 5.6 Hz, 3H), 3.52-3.45 (m, 3H), 3.35 (t, J = 5.6 Hz, 2H), 3.98 (t, J = 6 Hz, 2H), 2.72 (dd, J = 12.7, 4.1 Hz, 1H), 2.48 (t, J = 6 Hz, 2H), 1.76 (t, J = 11.9 Hz, 1H), 1.68-1.54 (m, 4H), 1.47-1.38 (m, 4H).Attorney Reference: ADTH-010WOEXAMPLE 4: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(15,21-dioxo-21-(perfluorophenoxy)-2,5,8,ll,18-pentaoxa-14-azahenicosyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 4).Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-azidohexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (2)
[0172] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(p-tolylthio) tetra hydro-2H-pyran-2-yl)-3-(2-(4-ch loro phenyl) acetamido) propane-1, 2-diyl diacetate (5 g, 6.53 mmol) and 6-azidohexan-l-ol (1) (1.12 g, 7.84 mmol) in anhydrous acetonitrile (90 mL) and anhydrous dichloromethane (60 mL) were added 4 A powdered molecular sieves (10 g) and Ag(OTf) (4.18 g, 16.32 mmol) under nitrogen. The reaction mixture was stirred for 1 h, cooled to -78 °C and a solution of iodine monobromide (2.02 g, 9.79 mmol) in dichloromethane (5 ml) was added dropwise at the same temperature. The reaction mixture was stirred at the same temperature for another 2 h. After completion, the reaction mixture was diluted with dichloromethane (30 ml), quenched with triethylamine,Attorney Reference: ADTH-010WO and filtered. The filtrate was washed with 10% aqueous of Sodium thio-sulfate solution, dried over sodium sulfate, filtered then concentrated. The crude residue obtained was purified by C-18 reverse phase column chromatography using acetonitrile and water (0.05%, TFA) as eluents to afford (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-azidohexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (2) as yellow solid, Yield-2.9 g, 57%; LCMS (ESI±) m / z 783.9 [M+H]+.Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (4)
[0173] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-azidohexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (2) (2.9 g, 3.69 mmol), and tert-butyl (3,6,9,12-tetraoxapentadec-14-yn-l-yl)carbamate (3) (1.22 g, 3.69 mmol) in anhydrous NMP (3 mL) was added Tetra kis(acetonitrile)copper(l) hexafluorophosphate (2.06 g, 5.53 mmol) at room temperature and the reaction mixture was stirred at room temperature for 1 h under nitrogen. After completion the reaction mixture was concentrated under reduced pressure. The crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (1R,2R)-1-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (4) as a pale yellow solid, Yield: 2.5 g, 61%;Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5)
[0174] To a stirred solution (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (4) (2.5 g, 2.24 mmol) in methanol (10 mL) and water (1 mL) was added NaOMe (25% in MeOH) (2.38 mL, 11.21 mmol) dropwise at 0 °C. The resulting reaction mixture was stirred at room temperature for 6 h. After completion, the reaction mixture was treated with an acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered. The filtrate was concentrated under reduced pressure and the crude residue obtained was purifiedAttorney Reference: ADTH-010WOby C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihyd roxypropyl)-2-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (5) as an off white solid, Yield: 1.6 g, 76%; LCMS (ESI-) m / z 931.1 [M-H]’.Synthesis of (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (6)
[0175] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH- 1.2.3-triazol-l-yl) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5) (1.6 g, 1.7 mmol) in anhydrous dichloromethane (9 mL) was added trifluoroacetic acid (1 mL) dropwise at 0 °C and the resulting reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by prep-HPLC (15-80% acetonitrile in water, +0.05 % TFA) as eluents to afford the desired product (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetra hydro-2H-pyran-2-carboxylic acid (6) as an off white solid, Yield: 800 mg, 56%; LCMS (ESI-) m / z 831.1 [M-H] ’.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-!., 2-dihydroxypropyl)-2-((6-(4-(15,21-dioxo-21-(perfluorophenoxy)-2,5,8,ll,18-pentaoxa-14-azahenicosyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (CMPDID4)
[0176] To a stirred solution of (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH- 1.2.3-triazol-l-yl)hexyl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (6) (200 mg, 0.24 mmol) in N, N-dimethyl formamide (10 mL) was added bis(perfluoro phenyl) 3,3'-oxydipropionate (593 mg, 1.2 mmol) at -20 °C then DIEA (0.12 mL, 0.96 mmol) at same temperature. The resulting reaction mixture was stirred at -20 °C for 1.5 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 4 as an off-white solid, Yield: 141 mg, 51%; LCMS (ESI+) m / z 1142.9 [M+H]+H NMR (400 MHz, MeOD) 68.01 (s, 1H), 7.30 (s, 4H), 4.66 (s, 2H), 4.41 (t, J = 7.1 Hz, 2H), 4.04 (s, 2H), 3.92 -Attorney Reference: ADTH-010WO3.83 (m, 5H), 3.77 (td, J = 5.5, 2.1 Hz, 3H), 3.72 - 3.59 (m, 14H), 3.56 - 3.51 (m, 4H), 3.44 - 3.34 (m, 4H), 3.28 - 3.18 (m, 1H), 2.99 (t, J = 5.9 Hz, 2H), 2.72 (dd, J = 12.8, 4.3 Hz, 1H), 2.48 (t, J = 6.2 Hz, 2H), 2.02 - 1.85 (m, 2H), 1.74 (dd, J = 12.7, 11.4 Hz, 1H), 1.55 (p, J = 6.7 Hz, 2H), 1.40 (td, J = 10.6, 4.3 Hz, 2H), 1.32 (dd, J = 10.3, 4.7 Hz, 2H).EXAMPLE 5: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 5).Synthesis of bis(perfluorophenyl) 3,3'-oxydipropionate (2)
[0177] To a stirred solution of 3,3'-oxydipropionic acid (1) (1 g, 6.16 mmol) in EtOAc (20 mL) was added 2,3,4,5,6-pentafluorophenol (2.83 g, 15.41 mmol), followed by dropwise addition of N, N'-Di-isopropyl carbodiimide (2.33 g, 18.50 mmol) at 0 °C. The resulting reaction mixture was stirred for 1 hour at the room temperature. After completion, the reaction mixture was filtered, the filtrate was concentrated and the residue obtained was purified by silica gel column chromatography to afford the desired product bis(perfluorophenyl) 3,3'-oxydipropionate (2), as white solid Yield: 1.5 g, 49%.1H NMR (400 MHz, CDCl3): δ3.91 (t, J = 12.4 Hz, 4H), 2.97 (t, J = 12 Hz, 4H).Attorney Reference: ADTH-010WOSynthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 5)
[0178] To a stirred solution of (2R,4S,5R,6R)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihyd roxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (200 mg, 0.23 mmol) in N, N-dimethyl formamide (10 mL) were successively added bis(perfluorophenyl) 3,3'-oxydipropionate (2) (569 mg, 1.16 mmol) then DIEA (0.16 mL, 0.92 mmol) at -20 °C. The resulting reaction mixture was stirred at -20 °C for 1.5 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by C18 reverse phase column chromatography using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 5 as an off-white solid. Yield: 152 mg, 56%; LCMS (ESI-) m / z 1172.9 [M-H]’.1H NMR (400 MHz, MeOD): δ8.07 (s, 1H), 7.33-7.28 (m, 4H), 4.66 (s, 2H), 4.60 (t, J = 4.8 Hz, 2H), 4.03 (s, 2H), 3.90 (t, J = 5.2 Hz, 4H), 3.87-3.82 (m, 4H), 3.71-3.65 (m, 4H), 3.64-3.59 (m, 15H), 3.55-3.52 (m, 4H), 3.40-3.33 (m, 3H), 3.29-3.22 (m, 1H), 3.00 (t, J = 6 Hz, 2H), 2.74 (dd, J = 12.7, 4.1 Hz, 1H), 2.47 (t, J = 6 Hz, 2H), 1.76 (t, J = 11.9 Hz, 1H).EXAMPLE 6: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-5-(2-(dimethylamino)acetamido)-4-hydroxy-2-((6-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 6).Attorney Reference: ADTH-010WOSynthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-5-(2-(dimethylamino)acetamido)-4-hydroxy-2-((6-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 6)
[0179] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-5-(2-(dimethylamino)acetamido)-4-hydroxy-2-((6-(prop-2-yn-l-yloxy)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (22.9 mg, 35.7 umol), perfluorophenyl l-azido-3,6,9,12-tetraoxapentadecan-15-oate (1) (17.9 mg, 39.2 umol) in anhydrous NMP (475 uL) was added Tetrakis(acetonitrile) copper (I) hexafluorophosphate (33.2 mg, 89.2 umol) and the reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 6 as a white solid, Yield: 24.9 mg, 64%. LCMS (ESI+) m / z 1099.40 [M+H]+.1H NMR (500 MHz, MeOD) δ8.01 (s, 1H), 7.30 - 7.28 (m, 4H), 4.57 (t, J = 5.0 Hz, 2H), 4.56 (s, 2H), 3.95 - 3.80 (m, 8H), 3.76 - 3.71 (m, 1H), 3.70 - 3.67 (m, 1H), 3.65 - 3.57 (m, 14H), 3.52 (s, 2H), 3.50 (t, J = 7.5 Hz, 2H), 3.45 - 3.41 (m, 1H), 3.33 - 3.31 (m, 1H), 3.25 -3.21 (m, 1H), 2.97 (t, J = 6.0 Hz, 1H), 2.89 (s, 6H), 2.78 (dd, J = 12.0 Hz, 4.5 Hz, 1H), 1.64 (t, J = 12.0 Hz, 1H), 1.61 - 1.59 (m, 2H), 1.54 - 1.51 (m, 2H), 1.35 - 1.34 (m, 4H).EXAMPLE 7: (2R,4S,5R,6R)-6-((lR,2R)-l,2-dihydroxy-3-(l-phenylcyclopropane-l-carboxamido)propyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-((4-(2-(l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)ethoxy)benzyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 7).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-l,2-dihydroxy-3-(l-phenylcyclopropane-l-carboxamido)propyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-((4-(2-(l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)ethoxy)benzyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 7)
[0180] To a stirred solution of (2R,4S,5R,6R)-2-((4-(but-3-yn-l-yloxy)benzyl)oxy)-6-((lR,2R)-l,2-dihydroxy-3-(l-phenylcyclopropane-l-carboxamido)propyl)-4-hydroxy-5-(2-Attorney Reference: ADTH-010WO hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (50.2 mg, 80.1 umol), perfluorophenyl l-azido-3,6,9,12-tetraoxapentadecan-15-oate (1) (40.3 mg, 88.1 umol) in anhydrous NMP (1.07 mL) was added Tetrakis(acetonitrile) copper (I) hexafluorophosphate (74.6 mg, 0.200 mmol) and the reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 7 as a white solid, Yield: 56.7 mg, 65%. LCMS (ESI+) m / z 1084.40 [M+H]+.1H NMR (500 MHz, MeOD) δ7.91 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.41 - 7.40 (m, 2H), 7.38 - 7.36 (m, 2H), 7.31 - 7.28 (m, 1H), 7.23 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 4.68 (d, J = 11.0 Hz, 1H), 4.55 (t, J = 5.0 Hz, 2H), 4.38 (d, J = 11.0 Hz, 1H), 4.24 (t, J = 6.0 Hz, 2H), 4.04 (s, 2H), 3.87 - 3.81 (m, 5H), 3.80 - 3.75 (m, 2H), 3.69 - 3.67 (m, 1H), 3.63 - 3.59 (m, 4H), 3.59 - 3.50 (m, 9H), 3.31 - 3.26 (m, 2H), 3.17 (t, J = 6.5 Hz, 2H), 2.94 (t, J = 6.0 Hz, 2H), 2.73 (dd, J = 12.0 Hz, 4.5 Hz, 1H), 1.75 (t, J = 12.0 Hz, 1H), 1.51 - 1.49 (m, 2H), 1.07 - 1.05 (m, 2H).EXAMPLE 8: (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 8).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID8)
[0181] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (200 mg, 0.340 mmol), perfluorophenyl l-azido-3,6,9,12-tetraoxapentadecan-15-oate (1) (155 mg, 0.340 mmol) inAttorney Reference: ADTH-010WOanhydrous NMP (2 mL) was added Tetrakis(acetonitrile) copper (I) hexafluorophosphate (190 mg, 0.51 mmol) and the reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 8 as an off white solid, Yield: 70 mg, 20%. LCMS (ESI+) m / z 1046.6 [M+H]+.1H NMR (401 MHz, MeOD) δ8.05 (s, 1H), 7.87 (t, J = 1.9 Hz, 1H), 7.77 (dt, J = 7.7, 1.4 Hz, 1H), 7.55 (ddd, J = 8.1, 2.3, 1.2 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 4.64 (s, 2H), 4.59 (t, J = 5.0 Hz, 2H), 4.04 (s, 3H), 3.90 (d, J = 5.1 Hz, 2H), 3.93 - 3.82 (m, 7H), 3.68 - 3.56 (m, 20H), 3.52 (d, J = 7.8 Hz, 1H), 3.48 - 3.43 (m, 1H), 2.98 (t, J = 6.0 Hz, 1H), 2.80 - 2.72 (m, 1H), 1.76 (s, 1H).EXAMPLE 9: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 9).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((1-(2-(2-(2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-1-yl)acetamido)ethoxy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 9)
[0182] To a solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (22.6 mg, 26.2 umol) in DMF (655 uL) was added maleimidoacetic acid N-hydroxysuccinimide ester (6.93 mg, 27.5 umol). The mixture was cooled down to 0 °C and stirred for 10 min. DIEA (13.7 uL, 78.6 umol) was added and the mixture was stirred for lh30 at 0 °C. The reaction mixture was filtered, and the filtrate was purified C18 reverse phase column chromatography using acetonitrile and water (+0.05 % TFA) as eluents. The fractions containing the desired product were lyophilized to afford CMPD ID 9 as a white solid. Yield: 18.9 mg, 72%;Attorney Reference: ADTH-010WOLCMS (ESI) m / z 1000.40 [M+H]+.XH NMR (500 MHz, MeOD): δ8.03 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.60-7.56 (m, 5H), 7.43 - 7.37 (m, 5H), 7.31 (t, J = 7.0 Hz, 1H), 6.87 (s, 2H), 4.62 (s, 2H), 4.58 (t, J = 5.0 Hz, 2H), 4.15 (s, 2H), 4.01 (s, 2H), 3.92 - 3.87 (m, 4H), 3.85 - 3.79 (m, 2H), 3.74 -3.72 (m, 1H), 3.69 - 3.66 (m, 1H), 3.65 - 3.56 (m, 18H), 3.52 (t, J = 5.5 Hz, 2H), 3.39 - 3.37 (m, 1H), 3.36 (t, J = 5.5 Hz, 2H), 3.27-3.23 (m, 1H), 2.71 (dd, J = 12.5, 4.0 Hz, 1H), 1.75 (t, J = 12.5 Hz, 1H).EXAMPLE 10: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 10).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 10)
[0183] To a solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (89.0 mg, 98.1 umol) in DMF (2.80 mL) was added Bis-PEGl-PFP ester (242 mg, 491 umol). The mixture was cooled down to -20 °C and stirred for 10 min. DIEA (68.4 uL, 393 umol) was added and the mixture was stirred for 2 h at -20 °C. The mixture was then allowed to warm up to room temperature, filtered and purified by preparatory HPLC using acetonitrile and water (+0.05 % TFA) as eluents to afford the desired product CMPD ID 10 as a white solid.Yield: 52.0 mg, 44%; LCMS (ESI) m / z 1217.50 [M+H] +. 1H NMR (500 MHz, MeOD): δ8.02 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.60-7.56 (m, 5H), 7.43 - 7.37 (m, 5H), 7.31 (t, J = 7.0 Hz, 1H), 4.62 (s, 2H), 4.56 (t, J = 5.0 Hz, 2H), 4.01 (s, 2H), 3.90 - 3.86 (m, 4H), 3.85 - 3.79 (m, 4H), 3.74 (t, J =Attorney Reference: ADTH-010WO6.0 Hz, 2H), 3.74 - 3.72 (m, 1H), 3.69 - 3.56 (m, 22H), 3.51 (t, J = 6.0 Hz, 2H), 3.39 - 3.37 (m, 1H), 3.34 (t, J = 6.0 Hz, 2H), 3.27-3.23 (m, 1H), 3.00 (t, J = 6.0 Hz, 2H), 2.74 (dd, J = 12, 4.5 Hz, 1H), 2.45 (t, J = 6.0 Hz, 2H), 1.75 (t, J = 12 Hz, 1H).EXAMPLE 11: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(18-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 11).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(18-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 11)
[0184] To a solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15- (perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (45.8 mg, 43.2 umol) in DMF(1.08 mL) was added n-(2-aminoethyl)maleimide trifluoroacetate salt (11.5 mg, 45.4 umol). The mixture was cooled down to 0 °C and stirred for 10 min. DIEA (22.6 uL, 130 umol) was added and the mixture was stirred for 1 h at 0 °C. The reaction mixture was filtered, and the filtrate was purified by C18 reverse phase column chromatography using acetonitrile and water (+0.1% TFA) as eluents. The fractions containing the desired product were lyophilized to afford CMPD ID 11 as a white solid. Yield: 35.0 mg, 80%; LCMS (ESI) m / z 1016.40 [M+H]+.1H NMR (500 MHz, MeOD): δ8.05 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.31-7.27 (m, 4H), 6.81 (s, 2H), 4.65 (s, 2H), 4.59 (t, J = 5.0 Hz, 2H), 4.02 (s, 2H), 3.90 - 3.87 (m, 4H), 3.86 - 3.79 (m, 2H), 3.74 - 3.71 (m, 1H), 3.67 - 3.64 (m, 7H), 3.63 - 3.56 (m, 17H), 3.53 (s, 2H), 3.38 - 3.35 (m, 3H), 3.26-3.21 (m, 1H), 2.72 (dd, J = 12, 4.5 Hz, 1H), 2.36 (t, J = 6.0 Hz, 2H), 1.75 (t, J = 12 Hz, 1H).Attorney Reference: ADTH-010WOEXAMPLE 12: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-17-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 12).Synthesis of tert-butyl (14-(4-((2-(2-hydroxyethoxy) ethoxy) methyl)-lH-l,2,3-triazol-l-yl)-3,6,9,12-tetraoxatetradecyl) carbamate (1)
[0185] To a stirred solution tert-butyl (3-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-2-methoxypropyl)carbamate (10 g, 43.43 mmol), 2-(2-(prop-2-yn-l-yloxy)ethoxy)ethan-l-ol (6.2 g, 43.43 mmol), Tetrakis(acetonitrile)copper(l) hexafluorophosphate (24.2 g, 65.14 mmol) in anhydrous NMP (60 mL) and the reaction mixture was stirred at room temperature for 2 h under nitrogen. After completion, the reaction mixture was filtered, the filtrate was concentrated under reduced pressure. The crude residue was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product tert-butyl (14-(4-((2-(2-hydroxyethoxy)ethoxy)methyl)-lH-l,2,3-triazol-l-yl)-3,6,9,12-tetraoxatetradecyl)carbamate (1) as a gummy liquid, Yield: 8.0 g, 57%; LCMS (ESI+) m / z 507.4 [M+H]+.Synthesis of(lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (2)
[0186] To a stirred solution (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6- (methoxycarbonyl)-6-(p-tolylthio)tetrahyd ro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (10 g, 13.07 mmol), tert-butyl (14-(4-((2-(2-hydroxyethoxy)ethoxy)methyl)-lH-l,2,3-triazol-l-yl)-3,6,9,12-tetraoxatetradecyl)carbamate (1)Attorney Reference: ADTH-010WO(7394 g, 15.68 mmol), Silver (1+) trifluoro methane sulfonate (AgOTf) (8.39 g, 32.67 mmol) in anhydrous dichloromethane (60 mL) and anhydrous acetonitrile (120 mL) was added activated 4 A powdered molecular sieves (10 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen. The solution was cooled to -78 °C, iodine monobromide (4.0 g, 32.67 mmol) dissolved in dichloromethane (10 mL) was added dropwise and the resulting mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched with triethylamine (10 mL) and stirred at room temperature. The reaction mixture was filtered, the filtrate was washed with 10% aqueous sodium thiosulfate solution, dried over sodium sulfate, filtered then concentrated under reduced pressure. The crude residue was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-aza nonadeca n-19-yl)-lH-l, 2, 3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (2) as a pale yellow solid, Yield: 5 g, 33%; LCMS (ESI+) m / z 1148.0 [M+H]+.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (3)
[0187] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (2) (5.0 g, 4.36 mmol) in anhydrous MeOH (20 mL) and water (3 mL) was added NaOMe (5 mL, 25% in MeOH) at room temperature and the resulting reaction mixture was stirred at room temperature for 6 h. After completion, the reaction mixture was treated with an acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered. The filtrate was concentrated under reduced pressure and the crude was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihyd roxypropyl)-2-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-aza nonadeca n-19-yl)-lH-l, 2, 3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hyd roxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (3) as a off white solid, Yield: 3.7 g, 87%. LCMS (ESI+) m / z 965.6 [M+H]+.Attorney Reference: ADTH-010WOSynthesis of(2R,4S,5R,6R)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxy propyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (4)
[0188] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hyd roxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (3) (3.7 g, 3.83 mmol) in anhydrous DCM (30 mL) was added TFA (1.31 g, 11.50 mmol) at room temperature and the resulting reaction mixture was stirred at room temperature for 3 h. After completion, the reaction mixture was concentrated under reduced pressure and the crude was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (4) as a brown solid, Yield: 1.2 g, 36%. LCMS (ESI+) m / z 865.6 [M+H]+.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-17-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 12)
[0189] To a stirred solution of (2R,4S,5R,6R)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihyd roxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (4) (3.0g, 3.47 mmol), 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate 13a (874 mg, 3.47 mmol), in anhydrous DMF (10 mL) was added TEA (1.05 g, 10.40 mmol) at room temperature and the resulting reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was concentrated under reduced pressure and the crude residue obtained was purified by prep HPLC using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product CMPD ID 12 as an off white solid. Yield: 513 mg, 15 %. LCMS (ESI+) m / z 1002.5 [M+H]+.XH NMR (400 MHz, Methanol-d4) 6 8.06 (s, 1H), 7.33-7.28 (m, 4H), 6.90 (s, 2H), 4.66 (s, 2H), 4.60 (t, J = 5.2 Hz, 2H), 4.18 (s, 2H), 4.03 (s, 2H), 3.91 (t, J = 5.2 Hz, 4H), 3.87 - 3.85 (m, 2H), 3.82 (s, 1H), 3.72 (s, 5H), 3.68 - 3.60 (m, 15H), 3.56 - 3.54 (m, 4H), 3.38 - 3.36 (m, 3H), 3.33 - 3.28 (m, 1H), 2.71 (dd, J = 12.8, 4.5 Hz, 1H), 1.76 (s, 1H).Attorney Reference: ADTH-010WOEXAMPLE 13: (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-17-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 13).Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (2)
[0190] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6- (methoxycarbonyl)-6-(p-tolylthio)tetrahyd ro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane- 1,2-diyl diacetate (18 g, 23.96 mmol), tert-butyl (6-hydroxyhexyl)carbamate (1) (6.23 g, 28.75 mmol) and Silver (1+) trifluoro methane sulfonate (AgOTf) (15.33 g, 59.9 mmol) in anhydrous dichloromethane (216 mL) and anhydrous acetonitrile (324 mL) was added activated 4 A powdered molecular sieves (15 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen. The solution was cooled to -78 °C, iodine monobromide (7.1 g, 35.94 mmol) dissolved in dichloromethane (7 mL) was added dropwise, and the resulting mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched by the addition of triethylamine (7 mL) and allowed to stir at room temperature for 5 min. The reaction mixture was filtered, the filtrate was washed with aqueous sodium thiosulfate solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue obtained was purified by C18 reverse phase column chromatography using waterAttorney Reference: ADTH-010WOand acetonitrile (+0.05% TFA) as eluents to afford the desired product (1R,2R)-1-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-l,2-diyl diacetate (2) as off-white solid, Yield: 9.8 g, 48%. LCMS (ESI-) m / z 842.7 [M-H] ’.Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-aminohexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (3}
[0191] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (2) (9.8 g, 11.61 mmol) in anhydrous dichloromethane (100 mL) was added trifluoro acetic acid (4 mL) dropwise at 0 °C and the resulting reaction mixture was stirred at room temperature for 3 h. After completion, the solvent was concentrated to afford the desired product as a crude (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-aminohexyl) oxy)-6-(methoxycarbonyl) tetra hydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (3) as brown gummy solid, Yield: 7.9 g, 91%;Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-y I) amino)-3,4-dioxocyclobut-l-en-1-yl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (4)
[0192] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-aminohexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l, 2-diyl diacetate (3) (7.9 g, 10.62 mmol) in ethanol (80 mL) were added triethylamine (7.60 ml, 53.09 mmol) and tert-butyl (14-((2-ethoxy-3,4-dioxocyclobut-l-en-l-yl)amino)-3,6,9,12-tetraoxatetradecyl)carbamate (4.88 g, 10.62 mmol) and the resulting reaction mixture was stirred at 50 °C for 6 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l, 2-diyl diacetate (4) as pale yellow solid, Yield: 7.5 g, 61%.Attorney Reference: ADTH-010WOSynthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((2, 2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-yl) amino)-3,4-dioxocyclobut-1-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5)
[0193] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-diyl diacetate (4) (7.5 g, 6.47 mmol) in methanol (75 mL) and water (7.0 mL) was added 25% sodium methoxide in methanol (8.39 mL, 38.86 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 6 h. After completion the reaction mixture was treated with acidic resin (Dowex 50, H+) until pH~6, the suspension was filtered, and the filtrate was concentrated to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5) as pale yellow solid, Yield: 5.5 g, 88%; LCMS (ESI-) m / z 974.8 [M-H] ’.Synthesis of (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (6)
[0194] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-d ihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3, 8, 11, 14, 17-pentaoxa-5-aza nonadeca n-19-yl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5) (5.5 g, 5.63 mmol) in anhydrous dichloromethane (55 mL) was added trifluoro acetic acid (1.92 mL) dropwise at 0 °C and the resulting reaction mixture was stirred at room temperature for 3 h. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05% TFA) to afford the desired product (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetra hydro-2H-pyran-2-carboxylic acid (6) as pale yellow solid, Yield: 3.9 g, 77%; LCMS (ESI±) m / z 876.6 [M+H]Attorney Reference: ADTH-010WOSynthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-17-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 13)
[0195] To a stirred solution of (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-4-hyd roxy-5-(2-hyd roxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (6) (1.5 g, 1.7 mmol.), 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate (430 mg, 1.7 mmol) in anhydrous DMF (15 mL) was added TEA (0.72 mL, 5.14 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 45 min. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLC to afford the desired product CMPD ID 13 as an off white solid, Yield: 576 mg, 33%. LCMS (ESI-) m / z 1011.7 [M-H]’.1H NMR (400 MHz, MeOD): 67.87 (t, J = 3.6 Hz, 1H), 7.77 (dt, J = 7.6 Hz, 1.6 Hz, 1H), 7.57-7.54 (m, 1H), 7.46 (t, J = 15.6 Hz, 1H), 6.90 (s, 2H), 4.19 (s, 2H), 4.04 (s, 3H), 3.87-3.76 (m, 7H), 3.67-3.62 (m, 16H), 3.61-3.43 (m, 5H), 3.41-3.38 (t, 2H), 2.72 (dd, J = 12.7, 4.1 Hz, 1H),, 1.76 (t, J = 11.9 Hz, 1H), 1.68-1.54 (m, 4H), 1.47-1.38 (m, 4H).EXAMPLE 14: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(16-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-15-oxo-2,5,8,ll-tetraoxa-14-azahexadecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 14).Attorney Reference: ADTH-010WOSynthesis (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(16-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-15-oxo-2,5,8,ll-tetraoxa-14-azahexadecyl)-lH- 1.2.3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 14)
[0196] To a stirred solution of (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH- 1.2.3-triazol-l-yl)hexyl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1.5 g, 1.8 mmol.), 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate (454 mg, 1.80 mmol) in anhydrous DMF (15 mL) was added TEA (0.78 mL, 5.4 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 45 min. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLCto afford the desired product CMPD ID 14 as an off white solid, Yield: 545 mg, 31%. LCMS (ESI-) m / z 968.7 [M-H]’.1H NMR (400 MHz, MeOD): 67.99 (s, 1H), 7.31 (s, 4H), 6.89 (s, 2H), 4.66 (s, 2H), 4.41 (t, J=14 Hz, 2H), 4.18 (s, 2H), 4.04 (s, 2H), 3.89 - 3.81 (m, 3H), 3.78 - 3.72 (m, 2H), 3.71 - 3.61 (m, 14H), 3.56-3.54 (m, 4H), 3.42 - 3.36 (m, 4H), 3.27 (dt, J = 6.9, 3.4 Hz, 1H), 2.71 (dd, J = 12.7, 4.5 Hz, 1H), 1.91 (t, J = 14.4 Hz, 2H), 1.76 (t, J = 12.0 Hz, 1H), 1.55-1.32 (m, 6H).EXAMPLE 15: (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2,18-dioxo-6,9,12,15-tetraoxa-3,19-diazatetracosan-24-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 15).Attorney Reference: ADTH-010WOSynthesis of perfluorophenyl 2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azaicosan-20-oate (2)
[0197] To a stirred solution of 2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azaicosan-20-oic acid (1) (5 g, 13.6 mmol) and penta-fluoro phenol (2.5 g, 13.6 mmol) in dry Ethyl acetate (50 mL) was added di-isopropyl carbodimide (2.58 g, 20.4 mmol) dropwise at 0 °C. The reaction mixture was stirred at room temperature for next 6 h. After completion, the reaction mixture was filtered, filtrate was concentrated to get the crude material, which was purified by Silica gel column chromatography, eluting with 20% EA in Hexane, to afford perfluorophenyl 2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azaicosan-20-oate (2) as off white semi solid, Yield: 5 g, 69.4%; LCMS (ESI±) m / z 533.65 [M+2]+.Synthesis of tert-butyl (21-hydroxy-15-oxo-3, 6,9, 12-tetraoxa-16-azahenicosyl) carbamate (4)
[0198] To a stirred solution of perfluorophenyl 2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azaicosan-20-oate (2) (4 g, 7.52 mmol) N, N-dimethyl formamide were added 5-aminopentan-l-ol (3) (3.11 g, 6.77 mmol) and triethylamine (3.25 ml, 22.58 mmol) at 0 °C. The resulting reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was purified by C-18 reverse phase column chromatography by using acetonitrile and water (+0.05%, TFA) as eluents to afford tert-butyl (21-hydroxy-15-oxo-3,6,9,12-tetraoxa-16-azahenicosyl) carbamate (4) as white solid, Yield: 4 g.1H NMR (400 MHz, DMSO): 67.79 (t, J = 5.2 Hz, 1H), 6.75 (t, J = 5.6, 1H), 5.6 (s, 1H), 3.59 (t, J = 6.4 Hz, 2H), 3.50 - 3.45 (m, 12H), 3.39-3.31 (m, 4H), 3.17-2.99 (m, 4H), 2.29 (t, J = 6.4 Hz, 2H), 1.44-1.36 (m, 13H), 1.20-1.14 (m, 3H)Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (6)
[0199] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-(methoxycarbonyl)-6-(p-tolylthio)tetrahyd ro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l, 2-diyl diacetate (5) (2.0 g, 2.82 mmol) and tert-butyl (21-hydroxy-15-oxo-3,6,9,12-tetraoxa-16-azahenicosyl)carbamate (4) (1.91 g, 1.41 mmol) in anhydrous dichloromethane (12 mL) and anhydrous acetonitrile (24 mL) were added Silver (+1) trifluoro methane sulfonate Ag(OTf) (1.80 g, 7.07 mmol) and activated 4 A powdered molecular sieves (5 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen atmosphere. Then the reaction mixture was cooled to -78 °C and iodine monobromide (0.87 g, 4.24 mmol, 1.5 eq.) solution in dichloromethane (4 ml) was added dropwise. The reaction mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched with triethylamine (5 mL), filtered, filtrate was washed by 10% SodiumAttorney Reference: ADTH-010WO thiosulfate solution, dried over sodium sulfate, filtered and concentrated to get the crude material, which was purified by C-18 reverse phase column chromatography, using acetonitrile and water (+0.05%, TFA) as eluents to afford (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (6) as yellow solid. Yield: 1.2 g, 41%, LCMS (ESI±) m / z 1035.4 [M+H]+.Synthesis of (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7)
[0200] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (6) (1 g, 0.96 mmol) in tetra hydrofuran (5 mL) was added lithium hydroxide monohydrate (243 mg, 5.80 mmol) solution in water. The reaction mixture was stirred at room temperature for 16 h. After completion the reaction mixture was treated with acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered, the filtrate was concentrated, to afford (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7), Yield: 850 mg, 98%; LCMS (ESI±) m / z 895.7 [M+H]+.Synthesis of (2R,4S,5R,6R)-5-acetamido-2-((l-amino-15-oxo-3,6,9,12-tetraoxa-16-azahenicosan-21-yl) oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-!., 2-dihydroxy propyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8)
[0201] To a stirred solution of (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7) (0.85 g, 9.51 mmol) in anhydrous dichloromethane (5 mL), was added trifluoroacetic acid (0.33 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was concentrated to get crude material which was dissolved in methanol and neutralized with Tetra alkyl ammonium carbonate, the polymer-bound resin. Reaction mixture was filtered and filtrate was concentrated to get (2R,4S,5R,6R)-5-acetamido-2-((l-amino-15-oxo-3,6,9,12-tetraoxa-16-azahenicosan-21-yl) oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8) as yellow solid, Yield-650 mg, 86%; LCMS (ESI±) m / z 796.6 [M+H]+.Attorney Reference: ADTH-010WOSynthesis of (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2,18-dioxo-6,9,12,15-tetraoxa-3,19-diazatetracosan-24-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 15)
[0202] To a stirred solution of (2R,4S,5R,6R)-5-acetamido-2-((l-amino-15-oxo-3,6,9,12-tetraoxa-16-azahenicosan-21-yl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8) (250 mg, 0.31 mmol.), 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate (79 mg, 0.31 mmol) in anhydrous DMF (2.5 mL) was added TEA (13 mg, 0.94 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 1 h. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 15 as an off white solid, Yield: 103 mg, 34%. LCMS (ESI-) m / z 928.7 [M-H H NMR (400 MHz, MeOD): 67.31 (s, 4H), 6.90 (s, 2H), 4.18 (s, 2H), 3.92-3.87 (m, 1H), 3.82-3.72 (m, 5H), 3.71-3.61 (m, 14H), 3.59-3.55 (m, 4H), 3.44-3.38 (m, 3H), 3.31-3.28 (m, 1H), 3.18 (t, J = 6.8 Hz, 2H), 2.71 (dd, J = 12.8, 4.2 Hz, 1H), 2.44 (t, J = 6 Hz, 2H), 1.99 (s, 3H), 1.78 - 1.69 (m, 1H), 1.61 - 1.49 (m, 4H), 1.45 - 1.37 (m, 2H).EXAMPLE 16: (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2,19-dioxo-6,9,12,15-tetraoxa-3,18-diazapentacosan-25-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 16).Attorney Reference: ADTH-010WOSynthesis of perfluorophenyl 7-hydroxyheptanoate (2)
[0203] To a stirred solution of 7-hydroxyheptanoic acid (1) (5 g, 34 mmol) in EtOAc (50 mL) was added 2,3,4,5,6-pentafluorophenol (6.25 g, 34 mmol), followed by dropwise addition of N, N'-Di-isopropyl carbodiimide (6.43 g, 51 mmol) at 0 °C. The resulting reaction mixture was stirred for 4 h at the same temperature. After completion, the reaction mixture was filtered, residue was washed with ethyl acetate, filtrate was concentrated to afford perfluorophenyl 7-hydroxyheptanoate (2), which was used as such in the next step, Yield: 7 g, 65%.Synthesis of tert-butyl (22-hydroxy-16-oxo-3, 6,9, 12-tetraoxa-15-azadocosyl) carbamate (4)
[0204] To a stirred solution of perfluorophenyl 7-hydroxyheptanoate (2) (7 g, 22 mmol) in DMF (70 mL) were added tert-butyl (14-amino-3,6,9,12-tetraoxatetradecyl)carbamate (3) (7.5 g, 22 mmol), DIEA (6 mL, 33 mmol) at 0 °C and the reaction mixture was stirred at the same temperature for next 2 h. After completion, the reaction mixture was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford tert-butyl (22-hydroxy-16-oxo-3,6,9,12-tetraoxa-15-azadocosyl) carbamate (4) as off-white solid. Yield: 7 g, 67%; LCMS (ESI+) m / z 465.5 [M+H]+.Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-diyl diacetate (6)
[0205] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6- (methoxycarbonyl)-6-(p-tolylthio)tetrahyd ro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-1,2-diyl diacetate (5) (3.0 g, 4.33 mmol) and tert-butyl (22-hydroxy-16-oxo-3,6,9,12-tetraoxa-15-azadocosyl)carbamate (4) (2.41 g, 5.19 mmol) in anhydrous dichloromethane (36 mL) and anhydrous acetonitrile (54 mL) were added Silver (+1) trifluoro methane sulfonate (AgOTf) (2.77 g, 10.8 mmol) and activated 4A powdered molecular sieves (5 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen atmosphere. Then the solution was cooled to -78 °C and iodine monobromide (1.33 g, 6.50 mmol) solution in dichloromethane (4 mL) was added dropwise. The resulting mixture was stirred at same temperature for 2 h. After completion, the reaction mixture was quenched with triethylamine (5 mL) and stirred at room temperature for 1 h. Then the reaction mixture was filtered, the filtrate was washed by 10% Sodium thiosulfate solution, dried over sodium sulfate, filtered and concentrated to get the crude material, which was purified by C-18 reverse phase column chromatography, using acetonitrile and water (+0.05%, TFA) as eluents to afford (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-Attorney Reference: ADTH-010WO6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-d iyl diacetate (6) as off-White solid, Yield: 2.2 g, 49%; LCMS (ESI+) m / z 1033.8 [M+H]+.Synthesis of (2R,4S,5R, 6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxy propyl)-2-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7)
[0206] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-diyl diacetate (6) (1.8 g, 1.74 mmol) in methanol (15 mL) and water (3 mL) was added 25% sodium methoxide in methanol (2.09 mL, 8.71 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 16 h. After completion the reaction mixture was treated with acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered. The filtrate was concentrated and purified by C18 reverse phase using water and acetonitrile (+0.05% TFA) as eluents to afford (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7) as off-white solid, Yield: 1.3 g, 83 %; LCMS (ESI±) m / z 891.8 [M-H]’.Synthesis of (2R,4S,5R,6R)-5-acetamido-2-((l-amino-16-oxo-3,6,9,12-tetraoxa-15-azadocosan-22-yl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8)
[0207] To a stirred solution of (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7) (2 g, 2.23 mmol) in anhydrous dichloromethane (20 mL) was added trifluoro acetic acid (1.03 mL, 13.43 mmol) at 0°C. The reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was concentrated and purified by C18 reverse phase using water and acetonitrile (+0.05% TFA) as eluents to afford (2R,4S,5R,6R)-5-acetamido-2-((l-amino-16-oxo-3,6,9,12-tetraoxa-15-azadocosan-22-yl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8) as off-White solid, Yield: 1.5 g, %; LCMS (ESI+) m / z 793.6 [M+H]+.Attorney Reference: ADTH-010WOSynthesis of(2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2,19-dioxo-6,9,12,15-tetraoxa-3,18-diazapentacosan-25-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 16)
[0208] To a stirred solution of (2R,4S,5R,6R)-5-acetamido-2-((l-amino-16-oxo-3,6,9,12-tetraoxa-15-azadocosan-22-yl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8) (250 mg, 0.315 mmol) and 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate (79 mg, 0.315 mmol) in anhydrous DMF (2 mL) was added TEA (0.13 mL, 0.945 mmol) at 0°C and the resulting reaction mixture was stirred at room temperature for lh. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 16 as an off white solid, Yield: 470 mg, 40 %. LCMS (ESI+) m / z 930.4 [M+H]+.1H NMR (401 MHz, MeOD) 67.88 (t, J = 1.9 Hz, 1H), 7.78 (dt, J = 7.8, 1.4 Hz, 1H), 7.56 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 6.91 (s, 2H), 4.19 (s, 2H), 4.08 - 3.99 (m, 1H), 3.85 - 3.73 (m, 3H), 3.73 - 3.60 (m, 15H), 3.60 -3.50 (m, 6H), 3.48 - 3.44 (m, 1H), 2.72 (dd, J = 12.7, 4.5 Hz, 1H), 2.19 (t, J = 7.5 Hz, 2H), 2.01 (s, 3H), 1.74 (dd, J = 12.7, 11.6 Hz, 1H), 1.58 (dq, J = 22.5, 7.1 Hz, 4H), 1.42 - 1.29 (m, 5H).EXAMPLE 17: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 23)
[0209] Disclosed in ADAXION THERAPEUTICS - WO2024 / 15872, 2024, A2 as compound 16-2.EXAMPLE 18: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l’-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl)-lH-Attorney Reference: ADTH-010WO l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H- pyran-2-carboxylic acid (CMPD ID 24)Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2- dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl)-lH- l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H- pyran-2-carboxylic acid (CMPD ID 24)
[0210] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)- l,2-dihydroxypropyl)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4- yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2- carboxylic acid (1, 89 mg, 98.1 umol) in N, N-dimethyl formamide (2.80 mL) was added bis(perfluorophenyl) 3,3'-oxydipropionate (2, 242 mg, 0.491 mmol) at -20 °C, followed by the addition of DIPEA (0.069 mL, 0.393 mmol) at the same temperature. The reaction mixture was stirred at -20 °C for 1.5 h. After completion, the reaction mixture, containing crude intermediate (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2- dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(2-(2-(3-(3-oxo-3- (perfluorophenoxy)propoxy) propanamido)ethoxy)ethyl)-lH-l,2,3-triazol-4- yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (3), was treated with 2MAttorney Reference: ADTH-010WOEthyl amine in THF (100 uL, 200 umol) in DMF (1 mL) at 0 °C and stirred for 2 h. The reaction mixture was concentrated and purified by reverse phase purification using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihyd roxypropyl)-2-(2-(2-((l-(16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hyd roxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 24) as a white solid, Yield: 46.4 mg, 44%; LCMS (ESI+) m / z 1078.50 [M+H]+.1H NMR (400 MHz, MeOD): 68.03 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.61 - 7.56 (m, 4H), 7.42 (t, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 7.31 (t, J = 7.5 Hz, 1H), 4.63 (s, 2H), 4.57 (t, J = 5.0 Hz, 2H), 4.01 (s, 2H), 3.91 - 3.79 (m, 6H), 3.74 - 3.72 (m, 1H), 3.69-3.56 (m, 25H), 3.52 (t, J = 5.5 Hz, 2H), 3.40 - 3.37 (m, 1H), 3.35 (t, J = 5.5 Hz, 2H), 3.33 - 3.30 (m, 1H), 3.27-3.23 (m, 1H), 3.19 (q, J = 7.0 Hz, 2H), 2.72 (dd, J = 12.5, 4.0 Hz, 1H), 2.43 (t, J = 6.5 Hz, 2H), 2.40 (t, J = 6.5 Hz, 2H), 1.75 (t, J = 12.5 Hz, 1H), 1.10 (t, J = 7.0 Hz, 3H).EXAMPLE 19: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 25)
[0211] Disclosed in ADAXION THERAPEUTICS - W02024 / 259007, 2024, A2 as compound 126.EXAMPLE 20: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl)-lH-Attorney Reference: ADTH-010WO l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H- pyran-2-carboxylic acid (CMPD ID 26)Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2- (2-(2-((l-(16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 26)
[0212] To a stirred solution of (2R,4S,5R,6R)-2-(2-(2-((l-(14-amino-3,6,9,12- tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4- chlorophenyl)acetamido)-l,2-dihyd roxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro- 2H-pyran-2-carboxylic acid (1, 100 mg, 0.12 mmol) in N, N-dimethyl formamide (5 mL) was added bis(perfluorophenyl) 3,3'-oxydipropionate (2, 297 mg, 0.6 mmol) at -20 °C, followed by the addition of DIPEA (0.08 mL, 0.48 mmol) at the same temperature. The reaction mixture was stirred at -20 °C for 1.5 h. After completion, the reaction mixture, containing crude intermediate (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)- 4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(2-(2-(3-(3-oxo-3-(perfluorophenoxy) propoxy) propanamido) ethoxy) ethyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy) tetrahydro-2H- pyran-2-carboxylic acid (3), was treated with 2M Ethyl amine in THF (1 mL) at 0 °C and stirredAttorney Reference: ADTH-010WO for 2 h. The reaction mixture was concentrated and purified by reverse phase purification using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 26) as an off-white solid, Yield: 55 mg, 46.0%; LCMS (ESI-) m / z 1034.1 [M-H]’.1H NMR (400 MHz, MeOD): 6 8.06 (s, 1H), 7.33-7.28 (m, 4H), 4.66 (s, 2H), 4.60 (t, J = 4.8 Hz, 2H), 4.03 (s, 2H), 3.92-3.89 (m, 4H), 3.87-3.83 (m, 2H), 3.86-3.67 (m, 9H), 3.67-3.59 (m, 16H), 3.54 (t, J = 4.8 Hz, 4H), 3.40-3.35 (m, 3H), 3.29-3.20 (m, 3H), 2.74 (dd, J = 12.7, 4.1 Hz, 1H), 2.47-2.40 (m, 4H), 1.76 (t, J = 11.9 Hz, 1H), 1.12 (t, J = 7.2 Hz, 3H).EXAMPLE 21: (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD 27)0Attorney Reference: ADTH-010WOSynthesis of methyl (2R,4S,5R,6R)-5-(2-acetoxyacetamido)-6-((lR,2R)-3-(3-chlorobenzamido)- l,2-dihydroxypropyl)-4-hydroxy-2-(p-tolylthio)tetrahydro-2H-pyran-2-carboxylate (3)
[0213] To a stirred solution of methyl (2R,4S,5R,6R)-5-(2-acetoxyacetamido)-6-((lR,2R)-3- amino-l,2-dihydroxypropyl)-4-hydroxy-2-(p-tolylthio)tetrahydro-2H-pyran-2-carboxylate (10 g, 20.55 mmol) in DMF (100 mL) was added perfluorophenyl 2-(4-chlorophenyl)acetate (I nt-2, 7.28 g, 22.6 mmol), followed by dropwise addition of triethylamine (8.58 mL, 61.7 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 3 h. After completion, the reaction mixture was concentrated to afford crude product methyl (2R,4S,5R,6R)-5-(2- acetoxyacetamido)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-4-hydroxy-2-(p- tolylthio)tetrahydro-2H-pyran-2-carboxylate (3) which was used directly in the next step without further purification. Yield: 10.5 g (crude).Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)- 6-(p-tolylthio)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-diyl diacetate (4)
[0214] To a stirred solution of methyl (2R,4S,5R,6R)-5-(2-acetoxyacetamido)-6-((lR,2R)-3-(3- chlorobenzamido)-l,2-dihyd roxypropyl)-4-hyd roxy-2-(p-tolylthio)tetrahydro-2H-pyran-2- carboxylate (lnt-3) (10.5 g, 16.8 mmol) in DMF (100 mL) were added acetic anhydride (16.9 mL, 168.0 mmol) and 4-Dimethyl amino pyridine (2.04 g, 16.8 mmol) at 0 °C. The reaction mixture was then stirred at room temperature for 16 h. After completion, the reaction mixture was diluted with cold water, extracted with ethyl acetate and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude residue was purified by normal phase column chromatography using ethyl acetate and Hexane as eluents to affordAttorney Reference: ADTH-010WO the desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(p-tolylthio)tetrahyd ro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-1, 2-diyl diacetate (4) as an off white solid, Yield: 7.0 g, 55%, over two steps; LCMS (ESI+) m / z 751.2 [M+H]+.Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (6)
[0215] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(p-tolylthio)tetrahyd ro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-1, 2-diyl diacetate (lnt-4, 18 g, 23.96 mmol), tert-butyl (6-hydroxyhexyl)carbamate (lnt-5) (6.23 g, 28.75 mmol) and Silver trifluoro methane sulfonate (AgOTf) (15.33 g, 59.9 mmol) in anhydrous dichloromethane (216 mL) and anhydrous acetonitrile (324 mL) was added activated 4A powdered molecular sieves (15 g). The reaction mixture was stirred at room temperature for 1 h under nitrogen atmosphere. The solution was then cooled to -78 °C, and a solution of iodine monobromide (7.10 g, 35.94 mmol) in dichloromethane (7 mL) was added dropwise. The resulting mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched by the addition of triethylamine (7 mL) and stirred at room temperature for 5 min. The reaction mixture was filtered, the filtrate was washed with aqueous sodium thiosulfate solution, dried over sodium sulfate, filtered, and concentrated. The crude residue obtained was purified by C18 reverse phase column chromatography using water:acetonitrile (+0.05% TFA) as eluents to afford the desired product (1R,2R)-1-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetra hydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (6) as an off-white solid, Yield: 9.8 g, 48%; LCMS (ESI±) m / z 842.7 [M-H]’.Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-aminohexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (7)
[0216] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (6, 9.8 g, 11.61 mmol) in anhydrous dichloromethane (100 mL) was added trifluoro acetic acid (4 mL) dropwise at 0 °C. The resulting reaction mixture was stirred at room temperature for 3 h. After completion, the solvent was concentrated to get crude desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3- (2-acetoxyacetamido)-6-((6-aminohexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-Attorney Reference: ADTH-010WO3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (7) as a brown gummy solid, Yield: 7.9 g, 91%.Synthesis of(lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-y I) amino)-3,4-dioxocyclobut-l-en-1-yl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (9)
[0217] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-aminohexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l, 2-diyl diacetate (lnt-7, 7.9 g, 10.62 mmol) in ethanol (80 mL) were added triethylamine (7.60 ml, 53.09 mmol) and tert-butyl (14-((2-ethoxy-3,4-dioxocyclobut-l-en-l-yl)amino)-3,6,9,12-tetraoxatetradecyl)carbamate (lnt-8, 4.88 g, 10.62 mmol). The resulting reaction mixture was stirred at 50 °C for 6 h. After completion, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography using water:acetonitrile (0.05% TFA) as eluents to afford the desired product (1R,2R)-1-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-aza nonadeca n-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (9) as a pale yellow solid, Yield: 7.5 g, 70%.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((2, 2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-yl) amino)-3,4-dioxocyclobut-1-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (10)
[0218] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l, 2-diyl diacetate (lnt-9, 7.5 g, 6.47 mmol) in methanol (75 mL) and water (7.0 mL) was added 25% sodium methoxide in methanol (8.39 mL, 38.86 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 6 h. After completion the reaction mixture was treated with acidic Dowex 50 resin to adjust the pH to approximately 6. The suspension was filtered and filtrate was concentrated to afford (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (10) as a pale yellow solid. Yield: 5.5 g, 87%; LCMS (ESI±) m / z 974.8 [M-H] ’.Attorney Reference: ADTH-010WOSynthesis of (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (11)
[0219] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-d ihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3, 8, 11, 14, 17-pentaoxa-5-aza nonadeca n-19-yl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (lnt-10, 5.5 g, 5.63 mmol) in anhydrous dichloromethane (55 mL) was added trifluoro acetic acid (1.92 mL) dropwise at 0 °C. The resulting reaction mixture was stirred at room temperature for 3 h. After completion, the solvent was concentrated to get crude which was purified by prep-HPLC using acetonitrile and water (+0.05% TFA) as eluents to afford the desired (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetra hydro-2H-pyran-2-carboxylic acid (11) as a pale yellow solid, Yield: 3.9 g, 77%; LCMS (ESI±) m / z 876.6 [M+H]+.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (CMPD 27)
[0220] To a stirred solution of (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-4-hyd roxy-5-(2-hyd roxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (lnt-11, 100 mg, 0.11 mmol) in N, N-dimethyl formamide (5 mL) was added bis(perfluorophenyl) 3,3'-oxydipropionate (lnt-12, 297 mg, 0.6 mmol) at -20 °C, followed by the addition of DIPEA (0.08 mL, 0.48 mmol) at the same temperature. The resulting reaction mixture was stirred at -20 °C for 25 min, then 2M Ethyl amine in THF (1 mL) was added at 0 °C, and the mixture was stirred for 2 h. After completion, the reaction mixture was concentrated and purified by prep-HPLC purification using acetonitrile and water (0.05%, TFA) as eluent to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((16,22-dioxo-3,6,9,12,19-pentaoxa-15,23-diazapentacosyl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (CMPD 27) as an off-white solid, Yield: 65 mg, 54.0%; LCMS (ESI-) m / z 1045.1 [M-H]-.1H NMR (401 MHz, MeOD) 67.88 (t, J = 1.9 Hz, 1H), 7.78 (dt, J = 7.7, 1.4 Hz, 1H), 7.56 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 4.12 - 3.97 (m, 3H), 3.92 - 3.75Attorney Reference: ADTH-010WO(m, 7H), 3.75 - 3.65 (m, 10H), 3.65 - 3.61 (m, 9H), 3.57 - 3.44 (m, 4H), 3.38 (t, J = 5.6 Hz, 2H), 3.22 (q, J = 7.3 Hz, 2H), 2.73 (dd, J = 12.8, 3.7 Hz, 1H), 2.45 (dt, J = 13.6, 6.1 Hz, 4H), 1.81 - 1.70(m, 1H), 1.60 (dt, J = 13.7, 6.1 Hz, 4H), 1.41 (d, J = 5.7 Hz, 4H), 1.13 (t, J = 7.3 Hz, 3H).EXAMPLE 22: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2- dihydroxypropyl)-2-((6-(4-(15,21-dioxo-2,5,8,ll,18-pentaoxa-14,22-diazatetracosyl)-lH-l,2,3- triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 28)Synthesis of(2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2- ((6-(4-(15,21-dioxo-2,5,8,ll,18-pentaoxa-14,22-diazatetracosyl)-lH-l,2,3-triazol-l- yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 28)
[0221] To a stirred solution of (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH- l,2,3-triazol-l-yl)hexyl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)- 4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1, 100 mg, 0.12 mmol) in N, N-dimethyl formamide (5 mL) was added bis(perfluorophenyl) 3,3'-oxydipropionate (2, 297 mg, 0.6 mmol) at -20 °C, followed by the addition of DIPEA (0.06 mL, 0.48 mmol) at the same temperature. The reaction mixture was stirred at -20 °C for 1.5 h. After completion, theAttorney Reference: ADTH-010WO reaction mixture, containing crude intermediate (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihyd roxypropyl)-2-((6-(4-(15,21-dioxo-21-(perfluorophenoxy)-2,5,8,ll,18-pentaoxa-14-azahenicosyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (3) was treated with 2M Ethyl amine in THF (1 mL) at 0 °C and stirred for 2 h. The reaction mixture was then concentrated and purified by prep-HPLC purification by using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(15,21-dioxo-2,5,8,ll,18-pentaoxa-14,22-diazatetracosyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 28) as an off-white solid, Yield: 60 mg, 50.0%; LCMS (ESI-) m / z 1002.1 [M-H]’.XH NMR (400 MHz, MeOD) 68.00 (s, 1H), 7.31 (s, 4H), 4.66 (s, 2H), 4.41 (t, J = 7.1 Hz, 2H), 4.04 (s, 2H), 3.92 - 3.74 (m, 5H), 3.73 - 3.58 (m, 19H), 3.58 - 3.52 (m, 4H), 3.44 - 3.34 (m, 4H), 3.23 (dq, J = 11.7, 7.7 Hz, 3H), 2.76 - 2.67 (m, 1H), 2.44 (dt, J = 12.2, 6.1 Hz, 4H), 1.91 (p, J = 7.2 Hz, 2H), 1.79 - 1.69 (m, 1H), 1.55 (p, J = 6.6 Hz, 2H), 1.43 - 1.29 (m, 5H), 1.13 (t, J = 7.3 Hz, 3H).EXAMPLE 23: (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((2,18-dioxo-6,9,12,15-tetraoxa-3,19-diazatetracosan-24-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 29)
[0222] Disclosed in ADAXION THERAPEUTICS - W02024 / 259007, 2024, A2 as compound 249.Attorney Reference: ADTH-010WOEXAMPLE 24: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-5-(2-(dimethylamino)acetamido)-4-hydroxy-2-((6-(prop-2-yn-l-yloxy)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 30)
[0223] Disclosed in ADAXION THERAPEUTICS - W02024 / 259007, 2024, A2 as compound 25.EXAMPLE 25: (2R,4S,5R,6R)-2-((4-(but-3-yn-l-yloxy)benzyl)oxy)-6-((lR,2R)-l,2-dihydroxy-3- (l-phenylcyclopropane-l-carboxamido)propyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 31)
[0224] Disclosed in ADAXION THERAPEUTICS - W02024 / 259007, 2024, A2 as compound 173.EXAMPLE 26: (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-3,6,9,12-tetraoxa-16-azaoctadecyl)-lH-Attorney Reference: ADTH-010WO l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD IDSynthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)- 6-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-yl)-3-(3chlorobenzamido) propane-1, 2-diyl diacetate (2)
[0225] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6- (methoxycarbonyl)-6-(p-tolylthio)tetrahyd ro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane- 1, 2-diyl diacetate (1, 3 g, 3.99 mmol), 2-(2-(prop-2-yn-l-yloxy)ethoxy)ethan-l-ol (690 mg, 4.79 mmol), and silver (1+) trifluoromethanesulfonate (AgOTf) (1.54 g, 5.99 mmol) in anhydrous dichloromethane (18 mL) and anhydrous acetonitrile (36 mL) was added activated 4 A powdered molecular sieves (3 g). The reaction mixture was stirred at room temperature for 1 h under a nitrogen atmosphere. The solution was then cooled to -78 °C, and a solution of iodine monobromide (1.24 g, 5.99 mmol) in dichloromethane (4 mL) was added dropwise. The resulting mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched with triethylamine (5 mL) and stirred at room temperature. The mixture was filteredhe filtrate was washed with 10% aqueous sodium thiosulfate solution, dried over sodium sulfate, filtered, and concentrated. The crude residue was purified by C18 reverse phase column chromatography using water:acetonitrile (+0.05% TFA) as eluents to afford theAttorney Reference: ADTH-010WO desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-yl)-3-(3chlorobenzamido)propane-l,2-diyl diacetate (2) as a pale yellow solid, Yield: 2.5 g, 81%; LCMS (ESI+) m / z 771.7 [M+H]+.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid (3)
[0226] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-yl)-3-(3chlorobenzamido)propane-l,2-diyl diacetate (2) (2.5 g, 3.24 mmol) in anhydrous THF (10 mL) and water (1 mL) was added LiOH. H2O (816 mg, 19.45 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 16h. After completion, the reaction mixture was treated with acidic Dowex 50 resin to adjust the pH to approximately 6, and the suspension was filtered. The filtrate was concentrated and the crude was purified by C-18 reverse phase column chromatography using water:acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (3) as a off white solid, Yield: 800 mg, 42%. LCMS (ESI+) m / z 589.9 [M+H]+.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-3,6,9,12-tetraoxa-16-azaoctadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 32)
[0227] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (3) (800 mg, 1.36 mmol) and 1-azido-N-ethyl-3,6,9,12-tetraoxapentadecan-15-amide (432 mg, 1.36 mmol) in anhydrous NMP (5 mL) was added Tetrakis(acetonitrile)copper(l)hexafluorophosphate (159 mg, 2.04 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was concentrated and the crude was purified by prep HPLC chromatography using water:acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-3,6,9,12-tetraoxa-16-azaoctadecyl)-lH-l,2,3-triazol-4yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 32) as a off white solid. Yield: 32 mg, 21%. LCMS (ESI-) m / z 905.8 [M-H]’.1H NMR (401 MHz, MeOD) 68.05 (s,Attorney Reference: ADTH-010WO1H), 7.88 (t, J = 1.9 Hz, 1H), 7.78 (dt, J = 7.8, 1.4 Hz, 1H), 7.56 (ddd, J = 8.0, 2.1, 1.1 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 4.65 (s, 2H), 4.60 (t, J = 5.1 Hz, 2H), 4.04 (s, 2H), 4.00 - 3.77 (m, 7H), 3.72 (t, J = 6.2 Hz, 2H), 3.67 (s, 4H), 3.61 (tt, J = 5.2, 2.7 Hz, 21H), 3.53 (d, J = 7.8 Hz, 1H), 3.51 - 3.43 (m, 2H), 3.38 (q, J = 1.7 Hz, 2H), 3.28 (q, J = 1.7 Hz, 2H), 3.21 (q, J = 7.2 Hz, 2H), 2.79 - 2.71 (m, 1H), 2.43 (t, J = 6.2 Hz, 2H), 1.78 (s, 1H), 1.31 (s, 1H), 1.12 (t, J = 7.3 Hz, 3H).EXAMPLE 27: (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((2,19-dioxo-6,9,12,15-tetraoxa-3,18-diazapentacosan-25-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 33)
[0228] Disclosed in ADAXION THERAPEUTICS - W02024 / 259007, 2024, A2 as compound 270.Example 28: Binding Properties of SigLsPurpose
[0229] To characterize SigL binding affinities by surface plasmon resonance (SPR).Materials and methods
[0230] The following proteins were used for SigL binding: biotinylated human Siglec-2 / CD22 protein-His-Avitag (Aero Biosystems, Cat# SI2-H82E3), biotinylated mouse Siglec-2-Fc-Avi (inhouse production), and recombinant cynomolgus Siglec-2 / CD22 His-tag (R& D systems, Cat# 9864-SL-050). Prior to immobilization, CD22 proteins were treated with SialoExo (Genovis, Cat# G1-SM1-020) for 4 hours at 37 °C to remove native sialic acid residues.
[0231] Capture of biotinylated CD22 constructs was performed using a Cytiva SA chip (BR100398) on a Biacore 8K instrument. Human Siglec 2 was immobilized on channels 1-4 and mouse Siglec 2 on channels 5-8 on the active flow cell (2) and the reference flow cell (1) was immobilized with biotinylated human FGFR2-Fc-Avi, an unrelated protein, to account for any nonspecific binding. Human Siglec 2 and Mouse Siglec 2 were diluted in running buffer to 20Attorney Reference: ADTH-010WO ug / mL and injected on the active flow cell (2) for 300 seconds at 5 pL / min, yielding about 3500 RU of captured constructs.
[0232] Surface preparation for cyno CD22 protein consisted of amine coupling to Cytiva CM5 chip (Cytiva, Cat# BR100530) using the Cytiva amine coupling kit Type 2 (Cytiva, Cat #BR100633). Following the standard amine coupling protocols, EDC and NHS from the kit were mixed 1:1 and injected over flow cells 1 and 2. Cyno CD22 was then immobilized by injecting 10 ug / mL in Sodium Acetate, pH 5.5 onto flow cell (2) for 420 seconds at 10 uL / min, yielding approximately 2500 RU of captured protein. Any active carboxy groups were then capped with IM Ethanolamine, pH 8.5 for 420s on flow cells 1 and 2.
[0233] Binding experiments of Siglec-I iga nd conjugated proteins or Siglec ligand compounds were performed on the surfaces prepared above in 10 mM HEPES, 150 mM NaCI, 0.05% Tween-20, pH 7.5, 1% DMSO as the running buffer. Compounds were serially diluted in running buffer from 50 pM to 97.6 nM and injected over both the reference and active flow cells for 90 seconds at 30 pL / min. The compounds were then allowed to dissociate from the surface for 120 seconds. No regeneration was required as the compounds completely dissociated from the surface after 30 seconds. Solvent correction was performed using 0.5, 1, 1.5, and 2% DMSO spike into running buffer without DMSO. Siglec-liga nd conjugated proteins were injected in a similar manner from 2 pM to 31.25 nM and the surface was regenerated with 4 M MgC. Data was analyzed using steady-state analysis in Biacore Insight Evaluation Software, version 3.0 for Siglec ligand compounds.Results and conclusions
[0234] The biochemical binding properties of the compounds were measured, as shown in the table below.Table 1. Affinities of SigL molecules.Attorney Reference: ADTH-010WOKD > 10 u M was “ + ”, 1 u M < KD< 10 u M was “++”, and KD < 1 pM was +++. Siglec compounds show a range of affinities to human, mouse, and cyno CD22.Example 29: Production of Protein ConjugatesPurpose
[0235] The purpose of this example is to demonstrate the expression, purification, and conjugation of various antibodies with various Siglec ligands (SigLs) that are used in the patent examples.Materials and Methods— Mammalian Protein expression and purification
[0236] Mammalian expression of anti-mouse IgD antibody, anti-human IgM antibody, bispecific antibodies, and Uricase was carried out using Expi293F (Life Technologies, A14527) or ExpiCHO-S cells (Life Technologies, A29127). For antibody and bispecific production, two pTT5 plasmids encoding the heavy and light chains were mixed at a 1:1 ratio. Uricase constructs were also cloned into a single pTT5 vector. Transfections were performed using the ExpiFectamine 293 Transfection Kit (Life Technologies, A14524). Culture media was collected 3-6 days post-transfection, clarified by centrifugation, and filtered through a 0.2 pm PES vacuum sterile single-use filter unit (ThermoScientific, 5670020).
[0237] Purification was performed with 1.5 mL MabSelect Sure resin (Cytiva / GE Cat #: 17-5438-03) for each 250 mL culture supernatant. Briefly, each column was equilibrated with PBS pH 7.2 and loaded with culture supernatant. After the loading step, the column was washed with PBS pH 7.2 and eluted with 10 mL IgG Elution buffer (Thermo Scientific, Cat. No. 21004). The pH of the elution pool was adjusted with 1 mL 1 M Sodium Phosphate pH 6.5 for each 10 mL elution pool. Finally, buffer exchange was performed with PBS pH 7.2 using a 30 kDa Amicon Ultra-15 Centrifugal Filter Unit.Bacterial protein expression and purification
[0238] For EndoS expressions, the DNA sequences were cloned into pET plasmid and transformed into chemically competent BL21(DE3) or Shuffle T7 cells. E. coli was grown overnight in Miller's Luria Broth (LB) or 2XYT media containing 100 pg / mL of ampicillin andAttorney Reference: ADTH-010WO diluted 1:50 in fresh media containing 100 |ig / mL of ampicillin the following day. Cultures were grown to OD6000.5-0.8 at 37 °C then induced with 1 mM Isopropyl [3-D-l-thiogalactopyranoside (IPTG) for 18-24 hours at 18 °C. Expression cultures were then centrifuged at 4000 rpm for 20 minutes at 4 °C to pellet the cells for extraction.
[0239] Cell pellets were resuspended in 20 mL of Tris lysis buffer with or without reducing conditions (20 mM Tris, 300 mM NaCI, 10 mM Imidazole, ±_4 mM [3-mercaptoethanol, pH 8.0, EDTA-free protease inhibitor cocktail tablet) and subject to a freeze-thaw cycle. An additional 20 mL of Tris lysis buffer was added then sonicated using a Qsonica sonicator pulse ON 1 sec and pulse OFF 2 sec for a total of 2 minutes at 40 % amplitude. Lysates were centrifuged at 14,000 rpm for 20 minutes to pellet cell residue. Clarified supernatants were incubated with Ni-NTA resin for 1 hour at 4 °C with rocker mixing. Mixture was transferred to a 25 mL column for gravity flow chromatography and washed with Tris wash buffer (20 mM Tris, 300 mM NaCI, 20 mM Imidazole, ±_4 mM [3-mercaptoethanol, pH 8). Protein was eluted with Tris elution buffer (20 mM Tris, 300 mM NaCI, 250 mM Imidazole, ±_4 mM [3-mercaptoethanol, pH 8) and buffer exchanged into PBS ±_4mM TCEP, pH 7.4 using a 30 kDa Amicon ultra-15 Centrifugal Filter Unit. Aggregate removal was achieved by size exclusion chromatography on an Akta Pure 2 with a Superdex Hiload 16 / 600200 Increase column. Endotoxin was removed by performing a Ni-NTA purification with 0.2% Triton-X-114 wash.Analytics for protein production
[0240] Analysis of endotoxin content was performed using the Charles River Endosafe PTS 0.01-1 EU / ml detection. Size exclusion chromatography was performed on an Agilent Chemstation HPLC-SEC with a Sepax-Zenix SEC-300, 200mm x 7.8mm ID, 3uM column. Capillary gel electrophoresis (cGE) was performed on a Caliper LabChip GXII Protein 200 with the Perkin Elmer Chip (Cat. No. 760499). LC-MS analysis was performed on Agilent 6545XT (G6549A), HPLC: Agilent AdvanceBio Desalting-RP, Column, 2.1mm X 12mm (PL612-1102).Protein-Siglec Ligand Conjugation
[0241] Conjugation of Siglec Ligands to protein lysine amino acids can be done using Siglec ligands with Pentafluorophenyl (PFP), carbamate, or N-Hydroxysuccinimide (NHS) conjugation handles. Briefly, SigLs comprising PFP were added to reaction mixtures at a molar ratio of 4-30 times above protein based on desired degree of labeling in the presence of 10% v / v of 50 mM Sodium Tetraborate pH 8.5 and 10% v / v DMSO. Reactions were incubated for 3 hours at 25 °C.Attorney Reference: ADTH-010WOAfter the 3 h incubation period, 10% v / v of 1 M Tris-HCI pH 8.0 was added to quench the unreacted SigL. Neutralized reactions were then allowed to incubate at 25 °C for 15 min.
[0242] The lysine groups can be coupled to carbamates and NHS through any suitable methods, such as the experimental conditions described in Morpurgo et al. (" N-hydroxysuccinimide carbonates and carbamates are useful reactive reagents for coupling ligands to lysines on proteins", Journal of Biochemical and Biophysical Methods, Volume 38, Issue 1, 1999, Pages 17-28, ISSN 0165-022X, doi:10.1016 / S0165-022X(98)00027-X.).Additionally, conjugations to lysine with urea groups and 3, 4-diaminocyclobut-3-ene-l, 2-dione groups can also be performed, e.g. with the methods described in Brun, MP., Gauzy-Lazo, L. (2013). Protocols for Lysine Conjugation. In: Ducry, L. (eds) Antibody-Drug Conjugates. Methods in Molecular Biology, vol 1045. Humana Press, Totowa, NJ. https: / / doi.org / 10.1007 / 978-l-62703-541-5_10.Protein-Siglec Ligand Conjugation to site-specific cysteines
[0243] Site specific conjugations to protein cysteine amino acids requires cysteine side changes to be in their reduced state. Reduction of cysteines were carried out using conventional techniques such as addition of molar excess of tris(2-carboxyethyl)phosphine) (TCEP) or Dithiothreitol (DTT) to the protein solutions. In some instances, reducing agent was removed prior to conjugation. In other cases, it was preferable to keep reducing reagent present to prevent unwanted cysteine oxidation or protein aggregation. Conjugatable cysteines were either native to the protein sequence or introduced via protein engineering.
[0244] For site-specific cysteine conjugation, Siglec Ligands with maleimide conjugation handles were added to the reaction mixtures at a molar ratio of 10 - 60 times above protein, based on the desired degree of labeling. Reactions were incubated at range of temperatures such as 4, 25 or 37 °C, for 1-24 h. After the incubation period, 4-fold excess N-Ethylmaleimide (NEM) was added to quench any unreacted SigLs. The neutralized reactions were incubated at 25 °C for an additional 15 min.Protein Siglec-Ligand Conjugate Purification
[0245] Quenched conjugation reactions were purified by conventional purification techniques such as preparative size exclusion chromatography.Attorney Reference: ADTH-010WOAnalysis of Protein-Siglec Ligands
[0246] The " LDR", or Ligand-to-Drug ratio, was measured for each conjugate preparation by LC / MS, by evaluating the relative abundances of species varying in the degree of conjugation, as described here. Such a series of molecular species can be represented as:
[0247] In this statement, each biotherapeutic, Y (adalimumab, in this case), is covalently bound to a Siglec Ligand as defined by XnL, where X is a sialic acid species of valency, n, with a Siglec Ligand-to-biotherapeutic ratio that varies between 1 and m. All species have the same Sialic Acid valency, n (monovalent, bivalent, or trivalent).
[0248] As a total measure of the degree of conjugation in such an ensemble of species with varying degrees of conjugation, the LDR can be defined as follows: LDR is a weighted average of the individual Siglec ligand-to-biotherapeutic ratios (integer value m) in a mixture of species varying in said ratio, and Pi (0 < Pj < 1, with t=1Pi = 1) representing the fractional abundance of each species in the mixture:
[0249] Protein-siglec ligands are analyzed using the following parameters: LC-MS: Mass spectrometer: Agilent 6545XT (G6549A); HPLC: Agilent AdvanceBio Desalting-RP, Column, 2.1mm X 12mm (PL612-1102); 2.1 mm x 12.5 mm, flow rate 400 ul / min, Sample load: 5ug;Buffer A: Water + 0.1% Formic Acid; Buffer B: Acetonitrile + 0.1% Formic Acid. Analytical SEC:Superose 6 Increase 10 / 300 GL; Injection Volume: 25uL at 1 mg / mL of sample; Buffer: PBS, pH 7.2; Flow rate: 0.75 mL / min. SDS-PAGE: 4-12% Bis-Tris 10-well gel in MES; Samples boiled 5 minutes at 90 degrees C in loading solution. Endotoxin Measurement: Charles River Endosafe PTS Cartridge 0.05-5 EU / ml, at 1:50 ml / ml dilution of the original sample concentration.Results and conclusionsTable 2. Summary of conjugates described in examplesAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO
[0250] All conjugates are purified to homogeneity for oligomeric species, with the intended oligomeric structure (e.g., monomer, dimer, trimer) being purified by preparative size exclusion chromatography.Example 30: Suppression of B cell receptor-mediated activation of mouse primary B cells by Siglec Ligand-anti-lgD antibody conjugates.Purpose
[0251] The purpose of this example was to assess the suppressive effects of IgG-Siglec ligand conjugates on mouse B cell activation via B cell receptor (BCR) stimulation. Studying BCR agonism in vitro using a single, well-defined BCR antigen is challenging due to the vast diversity of primary B cell populations and BCR sequences— up to 1012unique clones in humans. To overcome this, pan-BCR activators such as anti-lgD or anti-IgM antibodies are commonly used, as they can bind, crosslink, and activate BCRs regardless of clonal variability. In this study, an anti-mouse IgD monoclonal antibody was used either in its parental IgG form or conjugated to Siglec ligands, allowing evaluation of how co-engagement of Siglec-2 and the BCR influences B cell activation.
[0252] To ensure that any observed suppressive effects were specifically due to coengagement of Siglec-2 and the BCR, and not a result of impaired BCR binding from antibody conjugation, competition binding assays were performed. These assays evaluated the binding activity of the anti-IgD-Siglec ligand conjugates to confirm that their ability to bind the BCR was not compromised after conjugation.Attorney Reference: ADTH-010WOMaterials & Methods - In Vitro Murine B-cell Activation
[0253] Anti-lgD and Anti-IgD-Siglec Ligand test articles were prepared as described in Example29. The anti-lgD constructs were conjugated at lysine using a SigL comprising PFP.
[0254] Splenocytes from C57BL / 6 mice were harvested into single cell suspension, subjected to red cell lysis using ACK buffer, and plated at a concentration of 200,000 cells per well in round bottom 96 well plates in complete RPMI media. Cells were stimulated by the addition of increasing concentration of anti-mouse IgD or Siglec ligand-conjugated anti-mouse IgD and incubated for 3 hours at 37 °C, 5 % CO2. Cell activation was assessed by flow cytometry.
[0255] To measure B cell activation following the described stimulation, cells were washed twice by centrifugation at 350 g for 5 minutes and adding staining buffer (1% bovine serum albumin / 0.1% sodium azide / 1 x phosphate buffered saline). Cells were then resuspended in staining buffer and incubated with Fc-block (Biolegend) for five minutes before the addition of anti-CD45, anti-CD19, anti-CD69, and anti-CD86 antibodies (BD Biosciences, Biolegend, Fisher). Cells were then incubated in the dark for 30 minutes at room temperature. Cells were then washed three times with staining buffer and analyzed on ZE5 (BioRad). Data analysis was performed using FlowJo (vl0.8.0) software.Surface IgD Competition Binding Assays
[0256] Competition binding analysis of Siglec ligand-conjugated anti-mouse IgD and antimouse IgD binding was performed on splenocytes that were harvested as described above. Cells were prepared at a concentration of 4 x 106cells / mL in staining buffer and then incubated with mouse Fc-block (BD Biosciences) for five minutes. Following this incubation, anti-CD19 and anti-CD45 antibodies were added. Cells were plated at 50 pL per well (200,000 cells / well) in round bottom 96 well plates in staining buffer. Anti-mouse-lgD-AlexaFluor647 at a fixed concentration of 2.88 nM and an increasing titration (0 - 40 nM) of non-fluorescently labeled Siglec ligand-conjugated anti-mouse IgD was added to the cells simultaneously. Cells were placed on ice for 30 minutes in the dark. Afterwards, cells were washed twice by centrifugation with staining buffer and antibody binding was analyzed using flow cytometry (ZE5, BioRad) and measuring the AlexaFluor647 mean fluorescence intensity (MFI) of at least 10,000 cells.Results and Conclusions
[0257] FIG. 1A shows an in vitro assay evaluating the role of CD22 engagement in the suppression of B cell receptor (BCR) activation by Siglec ligand-conjugated antibodies. Primary mouse B cells were stimulated with either a BCR-activating anti-lgD antibody or various anti-Attorney Reference: ADTH-010WOIgD— Siglec ligand conjugates. Where parental anti-lgD antibody induces a strong, concentration-dependent increase in % CD69-positive cells, a nti-IgD-SigL conjugates show varying degrees of suppression. As shown in FIG. IB, no significant changes in binding affinity were observed with the anti-lgD conjugates with the high degree of labeling, indicating that any suppression observed was not due to inhibition of IgD binding. Overall, these results support that Siglec Ligands generally increased suppression of BCR activation through Siglec-2 co-engagement activity.Example 31: Suppression of B cell receptor-mediated activation of human primary B cells by Siglec Ligand-anti-IgM antibody conjugates.Purpose
[0258] This example evaluated the suppressive effects on human B cell activation with B cell receptor agonist anti-IgM-Siglec Ligand conjugates. This experiment is analogous to Example 30, with the focus here on primary human, PBMC-derived B cells, rather than primary mouse splenocytes.Materials and Methods- In Vitro human B-cell Activation
[0259] Anti-IgM and Anti-IgM-Siglec Ligand test articles were prepared as described in Example 29. The anti-IgM constructs were conjugated at lysine using a SigL comprising PFP.
[0260] Human PBMCs (StemExpress) were plated at a concentration of 200,000 cells per well in round bottom 96 well plates in complete RPMI media. Cells were stimulated for 18 hours by the addition of increasing concentration of anti-human IgM or Siglec ligand-conjugated antihuman IgM. B cell activation was assessed by flow cytometry.
[0261] To measure B cell activation following the described stimulation, cells were washed twice by spinning cells at 1200 rpm for 5 minutes and rinsing with PBS. Cells were resuspended in staining buffer (1% bovine serum albumin / 0.1% sodium azide / 1 x phosphate buffered saline) and incubated with Fc-block (BD Biosciences) for five minutes before the addition of anti-CD45, anti-CD19, anti-CD69, and anti-CD86 antibodies (BD Biosciences, Biolegend, Fisher). Cells were incubated in the dark for an additional 30 minutes at room temperature, then washed three times with staining buffer and then analyzed on ZE5 (BioRad). Data analysis was performed using FlowJo (vl0.8.0) software.Surface IgM Competition Binding Assays
[0262] Competition of Siglec ligand-conjugated anti-human IgM binding was carried out on human PBMCs from the same donors used in assays described above. For this assay, cells wereAttorney Reference: ADTH-010WO seeded at a concentration of 200,000 cells per well in round bottom 96 well plates in complete RPMI media. Cells were subsequently incubated with human Fc-block (BD Biosciences) for five minutes. Following this incubation period, 2.4 nM anti-human-lgM-AlexaFluor647 was added to the cells along with RPMI alone or an increasing titration of non-fluorescently labeled Siglec ligand-conjugated anti-human IgM and anti-CD19. Cells were incubated at 4 °C for 30 minutes in the dark. After incubation, cells were washed twice by centrifugation with staining buffer (1% bovine serum albumin / 0.1% sodium azide / 1 x phosphate buffered saline) and antibody binding was analyzed by flow cytometry (ZE5, BioRad) by determination of the mean fluorescence intensity (MFI) of at least 5,000 cells.Results and Conclusions
[0263] FIG. 2A shows representative B cell stimulatory activities of anti-IgM and anti-IgM-CD22 ligand conjugates in dose titration experiments with an activation readout of CD69 upregulation. CD69 levels on the different treatment groups are evaluated through the percentage of cells that are CD69-positive. Similar to the anti-lgD results, the anti-IgM antibodies that were conjugated to Siglec Ligand demonstrated suppressed activation in comparison to the unmodified anti-IgM antibody. Moreover, as shown in FIG.2B, there is no interference of the conjugates with IgM binding, so the suppression is not a reflection of decreased IgM binding. Importantly, these data show translation of the suppressive effect of Siglec-2 Ligand conjugates between a primary human B cell system and those shown in a primary mouse B cell system.Example 32: In vivo suppression of anti-drug antibodies in mice treated with bispecific antibody - Siglec Ligand conjugatesPurpose
[0264] The purpose of this experiment was testing for suppression of immunogenicity in mice dosed with anti-TNFa / IL-23 bispecific antibodies conjugated to Siglec ligands. Parental anti-TNFa / IL-23 bispecific antibodies are highly immunogenic in mice, with strong immunoglobulin responses after a single dose.Materials and Methods
[0265] Anti-TNFa / IL-23 Bispecific Ab SigL Conjugates were prepared as described in Example 29.
[0266] To evaluate the production of antibodies specific to anti-TNFa / IL-23 bispecific antibodies with and without Siglec ligand conjugation, mice were immunized throughAttorney Reference: ADTH-010WO subcutaneous injections with bispecific antibodies or Bispecific Ab SigL Conjugates. Double humanized HSA-hFcRN (HSA: human serum albumin; hFcRn: human neonatal Fc receptor) in C57BL / 6 background purchased from genOway (C57BL / 6N-fcrgttml l(FCRGT)Geno; A / btml l(ALB)Geno) or hFcRn in C57BL / 6 mice from Biocytogen (C57BL / 6-Fcgrtml-FCG / ?r-, Sc9e'? / Bcgen) were used in this example. On study day -1, animals were randomized into treatment groups based on body weight. On study day 0, animals were bled for baseline serum and then injected subcutaneously with unconjugated bispecific antibodies or Bispecific Ab SigL Conjugates. The individual antigens were prepared by making antigen solution in sterile PBS pH 7.4. Animals were then injected with antigen subcutaneously weekly (days 0, 7, 14, 21) with 0.1 mL on each side of the rear flank near base of tail. The total dose based on a 25 g mouse would be 2 mg / kg. Submandibular blood collection was performed weekly (days 6, 13, 20, 27) throughout the study under inhaled isoflurane anesthesia. Whole blood was collected into Microvette EDTA capillary collection tubes (Sarstedt Inc) and then further processed following the manufacturer's instructions for serum collection. Samples were stored at -80 °C until analysis was performed.
[0267] ADA assays were performed on 96-well assay plates (Nunc Plates, Black 96-Well Immuno Plates, Thermo Scientific, Cat. No. 437111) coated with antigen, as follows. A mixture of bispecific antibodies and Bispecific Ab SigL Conjugates was generated containing an equal concentration of antigens, with final mixture concentration of 5 pg / ml, and plates were coated with 100 pL / well of the mixture. All coated antigens were diluted in PBS pH 7.2 and incubated overnight at 4 °C. The following day, plate coating solution was removed, and plates were blocked with 200 pL / well of 3% BSA, 20 pM EDTA, 0.1% Tween-20 in PBS for 1 hour at room temperature. Serum samples were diluted 1:185 in 3% BSA, 20 pM EDTA, 0.1% Tween-20 in PBS and added in three-fold serial dilutions. Plates were incubated 1 hour at room temperature, then washed with PBS buffer with 0.05% Tween-20. After washing, 100 pL of 1:2500 diluted Donkey Anti-Mouse lgG(H+L)-HRP (Southe...
Claims
Attorney Reference: ADTH-010WOCLAIMS:
1. A Siglec ligand of formula (I):wherein:Z is a chemoselective functional group or ZT-T-Z2;Z1is a diradical group;T is absent or a diradical group;Z2 is a chemoselective functional group;A1is absent or alkylene;A2is alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof;R2is -COOH, -P(O)(OH)2, -OSO2OH, -CfOjNHSChH, tetrazole, an ester, or a substituted version thereof;R3is H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, ora substituted version thereof;R4is hydroxy, alkoxy, amino, amide, or a substituted version thereof;R5is H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene-l, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof;R7is hydroxy or halo;X1is 0, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-;E1is absent, -(substituted or unsubstituted C1-C6alkyleneoxy)g-, -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)q-, -(substituted or unsubstituted C1-C6alkylene)gO-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)qO-, -(substituted or unsubstituted C1-C6alkylene)gO(substituted or unsubstituted C1-C6alkylene)q-, benzyl, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyloxy, cycloalkyl, or a substituted version thereof;g is an integer ranging from 1 to 15;q is an integer ranging from 1 to 15;Attorney Reference: ADTH-010WOY is absent, alkylene, phenylene, substituted phenylene, -0-, -NH-, -S-, -C=C-, -CH2C= C-, -C(0)-, -0P(0)0-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -(alkylene)triazole-such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as -(methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(substituted or unsubstituted C1-C6alkyleneoxy)n-, -(substituted or unsubstituted C1-C6alkylene)n-;n is an integer ranging from 1 to 15;X2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m-, -(substituted or unsubstituted C1-C6alkylene)m-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkylene)mO-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)mC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)-, -(substituted or unsubstituted C1-C6alkylene)mC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)O-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-triazole-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-triazole, -(substituted or unsubstituted C1-C6alkylene)m-triazole, -(substituted or unsubstituted C1-C6alkylene)mOtriazole-, triazole, -(methylene)triazole-, -(methylene)triazole(methylene)-, ora substituted version thereof;Attorney Reference: ADTH-010WO m is an integer ranging from 1 to 15;w is an integer ranging from 1 to 15;E2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, - NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h-, -(substituted or unsubstituted C1-C6alkylene)h-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hO-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xO-, -(substituted or unsubstituted C1-C6alkylene)hO(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)-, -(substituted or unsubstituted C1-C6alkylene)hC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hOC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O-, -(substituted orAttorney Reference: ADTH-010WO unsubstituted Ci-Ce alkylene)hOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, (substituted or unsubstituted C1-C6alkylene)C(O)N(substituted or unsubstituted C1-C6alkylene)-, -C=C-, or -CH2C=C-, or a substituted version thereof;h is an integer ranging from 1 to 15; andx is an integer ranging from 1 to 15,or a salt thereof.
2. The Siglec ligand of claim 1, wherein the Siglec ligand has a structure of formula (l-S):(ID-3. The Siglec ligand of any one of claims 1-2, wherein R2is -COOH.
4. The Siglec ligand of any one of claims 1-3, wherein R5is -NH-C(O)-R5a;wherein R5ais substituted Ci-Ce alkyl or unsubstituted Ci-Ce alkyl.
5. The Siglec ligand of claim 4, wherein R5ais substituted Ci-Ce alkyl.
6. The Siglec ligand of claim 5, wherein R5ais substituted methyl, substituted ethyl, or substituted propyl.Attorney Reference: ADTH-010WO7. The Siglec ligand of any one of claims 5-6, wherein R5ais substituted with -0R5bor -NR5bR5c, wherein R5band R5care each independently H or Ci-Ce alkyl.
8. The Siglec ligand of claim 7, wherein R5ais substituted with -0R5b.
9. The Siglec ligand of claim 8, wherein R5ais -CH2OH.
10. The Siglec ligand of claim 7, wherein R5ais substituted with -NR5bR5c,11. The Siglec ligand of claim 10, wherein R5ais -Q-hNfCHsh-12. The Siglec ligand of claim 4, wherein R5ais unsubstituted Ci-Ce alkyl.X1- E1— Y- X2- E2-Z13. The Siglec ligand of any one of claims 1-12, wherein ’ is selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOX1- E1— Y- X2- E2-Z14. The Siglec ligand of any one of claims 1-12, wherein? is selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO15. The Siglec ligand of any one of claims 1-14, wherein A1is absent or unsubstituted alkylene.
16. The Siglec ligand of any one of claims 1-15, wherein A2is unsubstituted aryl or substituted aryl.
17. The Siglec ligand of any one of claims 1-16, wherein R3is H.
18. The Siglec ligand of any one of claims 1-17, wherein R4is hydroxy.
19. The Siglec ligand of any one of claims 1-18, wherein R7is hydroxy.
20. The Siglec ligand of any one of claims 1-19, wherein X1is absent, -O-, -NH-, or -S-.Attorney Reference: ADTH-010WO21. The Siglec ligand of any one of claims 1-20, wherein E1is absent, -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, -(CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl.
22. The Siglec ligand of any one of claims 1-22, wherein E1is -(CH2)g-, -(CH2)gO-, or -(CH2)gO(CH2)q-.
23. The Siglec ligand of claim 22, wherein E1is a group with subscript g and g is an integer ranging from 1 to 10.
24. The Siglec ligand of any one of claims 22-23, wherein E1is a group with subscript q and q is an integer ranging from 1 to 10.
25. The Siglec ligand of any one of claims 22-24, wherein E1is a group with subscript g and q, wherein g + q = 5, 6, 7, or 8.
26. The Siglec ligand of any one of claims 1-25, wherein Y is OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, -NHC(O)O-, -NHC(O)NH-, -OC(O)O-, or triazole.
27. The Siglec ligand of claim 26, wherein Y is triazole, -NH-(cyclobut-3-ene-l,2-dione)-NH-, or -NHC(O)-.
28. The Siglec ligand of any one of claims 1-27, wherein X2is -(CH2CH2O)m-, -(CH2)m-, -(CH2CH2O)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10.Attorney Reference: ADTH-010WO29. The Siglec ligand of any one of claims 1-28, wherein E2is -(CH2)h, wherein h is an integer ranging from 1 to 10.
30. The Siglec ligand of any one of claims 1-29, wherein Z is selected from the group consisting of esters, isocyanates, isothiocyanates, sulfonyl chlorides, aldehydes, carbodiimides, acyl azides, anhydrides, fluorobenzenes, carbonates, epoxides, hydroxymethyl phosphines, maleimides, haloacetyls, pyridyl disulfides, thiosulfonates, vinyl sulfones, and squaramates.
31. The Siglec ligand of claim 30, wherein Z is maleimide or a pentafluorophenyl ester.
32. The Siglec ligand of any one of claims 1-31, wherein the Siglec ligand has a structure selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO33. The Siglec ligand of any one of claims 1-31, wherein the Siglec ligand has a structure selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO34. A Siglec-liga nd conjugate of formula (VII):wherein:y is an integer from 1 to 20;BAS is a biologically active substance;Z' is a divalent group;Attorney Reference: ADTH-010WOA1is absent or alkylene;A2is alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof;R2is -COOH, -P(O)(OH)2, -OSO2OH, -CfOjNHSChH, tetrazole, an ester, or a substituted version thereof;R3is H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, ora substituted version thereof;R4is hydroxy, alkoxy, amino, amide, or a substituted version thereof;R5is H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene-l, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof;R7is hydroxy or halo;X1is 0, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-;E1is absent, -(substituted or unsubstituted C1-C6alkyleneoxy)g-, -(substituted or unsubstituted C1-C6alkylene)g-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)q-, -(substituted or unsubstituted C1-C6alkylene)gO-, -(substituted or unsubstituted C1-C6alkyleneoxy)g(substituted or unsubstituted C1-C6alkylene)qO-, -(substituted or unsubstituted C1-C6alkylene)gO(substituted or unsubstituted C1-C6alkylene)q-, benzyl, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted C1-C6alkyleneoxy)gbenzyloxy, cycloalkyl, or a substituted version thereof;g is an integer ranging from 1 to 15;q is an integer ranging from 1 to 15;Y is absent, alkylene, phenylene, substituted phenylene, -0-, -NH-, -S-, -C=C-, -CH2C= C-, -C(0)-, -0P(0)0-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -(alkylene)triazole-such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as -(methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(substituted or unsubstituted C1-C6alkyleneoxy)n-, -(substituted or unsubstituted C1-C6alkylene)n-;n is an integer ranging from 1 to 15;X2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m-, -(substituted or unsubstituted C1-C6alkylene)m-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)w-, -(substituted or unsubstituted C1-C6alkylene)mO-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-,Attorney Reference: ADTH-010WO-(substituted or unsubstituted C1-C6alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)mC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)-, -(substituted or unsubstituted C1-C6alkylene)mC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)mC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mNHC(O)O-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)mOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)mtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wtriazole-, -(substituted or unsubstituted C1-C6alkyleneoxy)m(substituted or unsubstituted C1-C6alkylene)wO-triazole-, -(substituted or unsubstituted C1-C6alkylene)mO(substituted or unsubstituted C1-C6alkylene)w-triazole, -(substituted or unsubstituted C1-C6alkylene)m-triazole, -(substituted or unsubstituted C1-C6alkylene)mOtriazole-, triazole, -(methylene)triazole-, -(methylene)triazole(methylene)-, ora substituted version thereof;m is an integer ranging from 1 to 15;w is an integer ranging from 1 to 15;E2is absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h-, -(substituted or unsubstituted C1-C6alkylene)h-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hO-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xO-, -(substituted or unsubstituted C1-C6alkylene)hO(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted orAttorney Reference: ADTH-010WO unsubstituted Ci-Ce alkylene)hNHC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)-, -(substituted or unsubstituted C1-C6alkylene)hC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)hC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)hOC(O)(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH-, -(substituted or unsubstituted C1-C6alkylene)hNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)O(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkylene)hOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xOC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH-, -(substituted or unsubstituted C1-C6alkyleneoxy)h(substituted or unsubstituted C1-C6alkylene)xNHC(O)NH(substituted or unsubstituted C1-C6alkylene)x-, -Attorney Reference: ADTH-010WO(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, (substituted or unsubstituted C1-C6alkylene)C(O)N(substituted or unsubstituted C1-C6alkylene)-, -C=C-, or -CH2C=C-, or a substituted version thereof;h is an integer ranging from 1 to 15; andx is an integer ranging from 1 to 15,or a salt thereof.
35. The Siglec-I iga nd conjugate of claim 34, wherein Z' is a divalent group selected from the group consisting of:wherein:ft* >* represents covalent connection to E2;S ft**represents covalent connection to BAS.
36. The Siglec-I iga nd conjugate of any one of claims 34-35, wherein BAS is a protein, a biotherapeutic, an autoantigen, an enzyme, an antibody, a nanoparticle, or a combination thereof.
37. The Siglec-I iga nd conjugate of any one of claims 34-36, wherein R2is -COOH.
38. The Siglec-I iga nd conjugate of any one of claims 34-37, wherein R5is -NH-C(O)-R5a;wherein R5ais substituted Ci-Ce alkyl or unsubstituted Ci-Ce alkyl.
39. The Siglec-I iga nd conjugate of claim 38, wherein R5ais substituted Ci-Ce alkyl.
40. The Siglec-I iga nd conjugate of claim 39, wherein R5ais substituted methyl, substituted ethyl, or substituted propyl.Attorney Reference: ADTH-010WO41. The Siglec-I iga nd conjugate of any one of claims 39-40, wherein R5ais substituted with - OR5bor -NR5bR5c,wherein R5band R5care each independently H or Ci-Ce alkyl.
42. The Siglec-I iga nd conjugate of claim 41, wherein R5ais substituted with -OR5b.
43. The Siglec-I iga nd conjugate of claim 42, wherein R5ais -CH2OH.
44. The Siglec-I iga nd conjugate of claim 41, wherein R5ais substituted with -NR5bR5c,45. The Siglec-I iga nd conjugate of claim 44, wherein R5ais -CH2N(CH3)2.
46. The Siglec-I iga nd conjugate of claim 38, wherein R5ais unsubstituted Ci-Ce alkyl.
47. The Siglec-I iga nd conjugate of any one of claims 34-46, whereinisAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO48. The Siglec-I iga nd conjugate of any one of claims 34-47, wherein the Siglec-I iga nd conjugate has a structure selected from the group consisting of:Attorney Reference: ADTH-010WOAttorney Reference: ADTH-010WOAttorney Reference: ADTH-010WO49. The Siglec-I iga nd conjugate of any one of claims 34-49, wherein A1is absent or unsubstituted alkylene.
50. The Siglec-I iga nd conjugate of any one of claims 34-49, wherein A2is unsubstituted aryl or substituted aryl or alkyl.
51. The Siglec-I iga nd conjugate of any one of claims 34-50, wherein R3is H.
52. The Siglec-I iga nd conjugate of any one of claims 34-51, wherein R4is hydroxy.
53. The Siglec-I iga nd conjugate of any one of claims 34-52, wherein R7is hydroxy.
54. The Siglec-I iga nd conjugate of any one of claims 34-53, wherein X1is absent, -O-, -NH-, or - S-.
55. The Siglec-I iga nd conjugate of any one of claims 34-54, wherein E1is absent, -(CH2CH2O)g- (CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, - (CH2)q(OCH2CH2)gO-, -(CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl.Attorney Reference: ADTH-010WO56. The Siglec-I iga nd conjugate of any one of claims 34-55, wherein E1is -(CH2)g-, -(CH2)gO-, or -(CH2)gO(CH2)q-.
57. The Siglec-I iga nd conjugate of claim 56, wherein E1is a group with subscript g and g is an integer ranging from 1 to 10.
58. The Siglec-I iga nd conjugate of claim 56 or 57, wherein E1is a group with subscript q and q is an integer ranging from 1 to 10.
59. The Siglec-I iga nd conjugate of any one of claims 56-58, wherein E1is a group with subscript g and q, wherein g + q = 5, 6, 7, or 8. U 6560. The Siglec-I iga nd conjugate of any one of claims 34-59, wherein Y is OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, -NHC(O)O-, -NHC(O)NH-, -OC(O)O-, or triazole.
61. The Siglec-I iga nd conjugate of claim 60, wherein Y is triazole, -NH-(cyclobut-3-ene-l,2-dione)-NH-, or -NHC(O)-.
62. The Siglec-I iga nd conjugate of any one of claims 34-61, wherein X2is -(CH2CH2O)m-, -(CH2)m-, -(CH2CH2O)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 10 and w is an integer ranging from 1 to 10.
63. The Siglec-I iga nd conjugate of any one of claims 34-62, wherein E2is -(CH2)h, wherein h is an integer ranging from 1 to 10.
64. A pharmaceutical composition comprising a Siglec-liga nd conjugate according to any one of claims 34-63.Attorney Reference: ADTH-010WO65. The pharmaceutical composition of claim 64, further comprising an excipient, a solvent, a diluent, a binder, a disintegrant, an antioxidant, a preservative, or a combination thereof.
66. The pharmaceutical composition of claim 65, wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient.
67. A method of manufacturing a Siglec-I iga nd conjugate, the method comprising:covalently attaching a Siglec ligand according to any one of claims 1-33 to a biologically active substance (BAS) to thereby generate the Siglec-ligand conjugate.
68. A method of treating a subject, the method comprising:administering to the subject a pharmaceutical composition comprising a Siglec-ligand conjugate according to any one of claims 64-66.
69. The method of claim 68, wherein the subject has a disorder, a disease, or a combination thereof, wherein the administration of the Siglec-ligand conjugate treats the disorder, the disease, or the combination thereof.
70. The method of claim 69, wherein the disorder, the disease, or combination thereof is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, phenylketonuria, juvenile idiopathic arthritis, leukemia, colorectal cancer, a non-small cell lung cancer, a head and neck cancer, multiple sclerosis, Type 2 Diabetes, gout, immune thrombocytopenia, organ transplantation (e.g., kidney), NMOSD / neuromyelitis optica, antiphospholipid syndrome, membrane nephritis, myasthenia gravis, pemphigus vulgaris, and combinations thereof.
